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Abstract 
With a population both increasing in number and age, comes a need for new 
diagnostic tools in the healthcare system, capable of diagnosing and monitoring 
multiple disorders in a cheap and effective way to provide personalised 
healthcare. Multiplex label-free biosensors have the potential to rejuvenate the 
current system. This thesis details the assessment of an ‘in house’ built label-
free array screening technology that has potential to be a point-of-care 
diagnostic for personalised medicine – the Array Reader. 
The performance of the Array Reader platform is considered in detail and 
optimised for both antibody and protein screening arrays. A Global Fit protocol 
is developed to extract kinetic constants for all protein-protein interactions, 
assuming a Langmuir adsorption binding model. Standard operating procedures 
are developed to provide optimised dynamic range, sensitivity, reproducibility 
and limit of detection of immuno-kinetic assay. A new antibody bio-stack signal 
amplification strategy is formed, improving the detection limit 60-fold. As a 
consequence, the bio-stack resulted in a novel method for determining the 
plasmon field penetration depth, defining the assay sensing volume at the 
nanoparticle surface.  
Antibody screening arrays were investigated with an IgG quantification assay to 
determine total IgG content from serum samples. It relied on the ability of 
protein A/G to bind antibodies via the Fc region. Specific antigens were used to 
measure the binding properties of the antibody Fab region. By characterising 
both regions, we have gained insight into the overall ability of an antibody to 
trigger an immune response. Protein screening assay were investigated 
targeting C-reactive protein (CRP), a marker of inflammation. The assays 
performance characteristics compared favourably with clinically used CRP 
assays. 
Finally, an antibody screening array was developed to assess the efficacy of a 
vaccine against Yersinia pestis in a non-human primate model. The vaccine 
screening array is an excellent example of the versatility of the platform and just 
one of many possible applications for the future. 
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1 Introduction       
Modern healthcare requires a move from current treatment to a more 
personalised approach, providing a precise, predictable and powerful tool for 
medicine. To achieve a tailored treatment regimen, a profile of the patient’s 
phenotype is required and this will not be accomplished with any one marker 
but an extensive panel of markers. The first point of call is the genome, which 
given the current state of rapid sequencing technologies, will be available to 
everyone for a few thousand dollars in the near future. Thanks to the Human 
Genome Project, genetic markers of diseases could now include a panel of all 
20,300 protein coding genes [1] as a single assay. However, a better target for 
personalised medicine may be the human proteome, which consists of a far 
greater number of protein molecules, the structure and function of which vary in 
time and with patient health. Of the 20,300 protein-coding human genes 
mapped there is very little evidence on the role of 30% of these; as we discover 
the functions many of these proteins play, we unlock potentially invaluable tools 
for use in biomarker and drug discovery [2]. 
A biomarker, or biological marker, is defined by the World Health Organisation 
as “any substance, structure, or process that can be measured in the body or its 
products and influence or predict the incidence of outcome or disease” [3]. The 
use of biomarkers has become essential to clinical practice, playing a critical 
role in the monitoring and diagnosis of infections and disease. Personalised 
medicine uses biomarkers to make patient-specific diagnosis and consequent 
treatment, taking into account all co-morbidities, phenotype and genotype, 
prescribing the right drug to patients at the right time, with the right dose [4]. 
The cutting edge of personalised medicine is the diagnosis of diseases or 
disease susceptibility on the basis of target genes in a person’s genome. 
However, there are no protein biomarker panels that provide a diagnosis of 
disease and a companion diagnostic for a treatment regimen with such 
accuracy. The real-time nature of the proteome is a key advantage in the 
treatment of patients and a biomarker screening panel will take personalised 
medicine to the bedside; especially important with the current aging population. 
The use of biomarkers is largely dominated by diagnosing and treating disease 
on the basis of genetic variations that have been found to contribute to human 
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illness. Companion diagnostic tests can be developed to aid the clinician, either 
from a laboratory test or at the point-of-care from a number of body fluids 
including blood, cerebral spinal fluid or urine; with the blood offering the highest 
quality data.  
Recent advances in the ‘omics’ technologies, that include metabonomics, 
transcriptomics and proteomics are accelerating the rate of biomarker discovery 
[5]. This has led to a growth in the field of biosensors, many of which are point-
of-care testing, with lab-on-a-chip technologies particularly promising for sample 
handling and assay automation. The knock-on effect of these technological 
advances and uptake to the healthcare system could be enormous in years to 
come, by reducing healthcare costs and improving patient treatment and 
outcome. For example, the American Society of Oncology estimates that routine 
testing of people with colon cancer for mutations in the K-RAS oncogene could 
save at least US $600 million a year [6]. 
Progress in biomarker research now allows panels of biomarkers rather than a 
single biomarker assay on one chip to be used as a diagnostic test taking into 
account the changes in all biomarkers simultaneously, such as metabolically-
connected proteins that form part of a biological system [7]. An example of such 
a ‘multivariate index assay’ is OVA1, an FDA-approved panel assay consisting 
of five protein biomarkers and a decision algorithm [8] to evaluate ovarian 
masses for the likelihood of cancer preoperatively. Development of such tests 
are likely to produce ‘diagnostic values’ of disease state from an algorithm 
based on a variety of data from each contributing assay and demographic, 
rather than absolute protein concentrations. A bigger assay panel, results in 
more processing that must be automated to provide a clinician-friendly 
interpretation. The design and development of measurement technologies must 
go hand-in-hand with the development of the diagnostic algorithms.  
In our laboratory, we have been making technological advances for the 
measurement of a large number of protein biomarkers simultaneously and the 
design and development of diagnostic array screening technology is the subject 
of this thesis. The choice of assays on the array and the final protein biomarker 
panels need to be designed and optimised for a specific task which requires a 
significant testing and validation process before culminating in the analysis of a 
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biomedical problem. In this thesis, I will describe the process for the validation 
of a series of assays that advance instrument optimisation leading to novel 
applications in personalised healthcare. 
This chapter will explore the concept of biomarkers and the field of biosensors, 
explaining the principles of our in-house Array Reader (AR) and comparing the 
performance with other assay technology platforms. The bio-specificity of many 
sensor platforms is obtained by the antibody-antigen interaction fundamental to 
the immune response. A brief review of the immune system and its link with 
vaccination will highlight how studying these interactions can help development 
of biosensors. Applications can then be extended to specific medical uses for 
the differential diagnosis of disease. 
1.1 Biomarker Panels and Diagnosis 
The current state of the art biomarker panel assays can be grouped into three 
categories; predictive, prognostic and pharmacodynamic [9]. Predictive 
biomarkers help assess the most likely response to a particular treatment and 
prognostic markers can monitor the progression of disease and the prescribed 
treatment [10]. While pharmacodynamic biomarkers can indicate how effective 
a drug may be and how a patient is likely to process it [9].  
The major challenge of biomarker validation is that within the human population 
there is considerable variability in biomarker levels in both range and 
concentration; this is especially true for complex samples such as blood. For 
instance, the blood proteome is continuously undergoing dynamic changes in 
the concentration of each molecule and their relative ratio. These proteins can 
also undergo modification in vivo; this is reflected by the fact that nearly 10% of 
mammalian genes encode for proteins that modify other proteins [11]. Often to 
compensate for the varying concentration of biomarkers in an individual and 
across a population, a biosensor is required containing a panel of biomarkers 
with high sensitivity and specificity for their respective target. In an ideal 
scenario, this biosensor should also have a high throughput and require a low 
sample volume providing fast diagnosis with minimum invasion. Candidate 
biomarkers in medicine include DNA, RNA and proteins [12]. These can be 
monitored from a number of bodily fluids including serum, urine, saliva and 
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bowel lavage; the source of biomarkers for the work presented here are from 
serum samples.  
DNA levels in serum can be associated with various cancers released by 
tumours and even sepsis [13]. Mutations in oncogenes and tumour-suppressor 
genes can also serve as DNA biomarkers [14]. For instance, mutations in the 
oncogene KRAS predict metastatic spread in various tumour types, and there 
are mutations in the gene that encode the tumour suppressor p53 in more than 
half of sporadic cancers [15, 16]. Other potential DNA biomarkers include 
single-nucleotide polymorphisms (SNPs) and mitochondrial DNA markers. 
Particular SNPs are associated with increased cancer risk and haplotype 
assessment can be predictive of several cancers like lung [17], prostate and 
breast [18, 19]. Similarly mutations in mitochondrial DNA occur in many cancer 
types [20, 21]. DNA markers are generally evaluated individually whereas many 
high-throughput technologies can now access RNA expression 
comprehensively [13]. In 2008, Lawrie et al. introduced miRNAs (micro RNA) as 
a new class of biomarkers for cancer [22]. Since then serum miRNA levels have 
been profiled for many conditions including autoimmune diseases [23], sepsis 
[24], and acute myocardial infarction [25]. miRNAs have been claimed to serve 
as an improved biomarker for many diseases due to their presence in many 
bodily fluids and their conserved nature from human-to-human [26, 27]. miRNAs 
have also been demonstrated to be robust against external impacts such as 
enzymatic degradation, freezing, and thawing, or intense pH conditions [28]. 
DNA levels can be a useful diagnostic tool in blood, however proteins are 
generally considered as a better target for a broader range of conditions. 
Proteins are involved in the majority of vital biological processes and about 97% 
of all current therapeutic agents target proteins [11]. Proteomic-based 
biomarker discovery is rather complex compared to DNA and RNA, owing to the 
very large range of analyte concentrations that can be detected and quantified 
[29]. However, the ease by which protein samples from serum for example, can 
be safely obtained and the fact that it comprehensively samples the human 
phenotype; the state of the body at a particular point in time. Serum and plasma 
samples are therefore more attractive than other biofluid samples such as saliva 
and urine, which will either only provide a small subset of proteins or else are 
restricted to local sampling of cellular activity [30]. 
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The blood proteome has been estimated to contain approximately 245 proteins 
with normal concentration ranges from g/L in Human serum albumin, to pg/L of 
the interleukins such as IL-6 – 12 orders of magnitude, Figure 1.1 [30]. Both the 
higher concentration proteins are as useful in diagnosis as the lower 
concentrations: HSA is used as an indicator of severe liver disease and IL-6 can 
be used as an indicator of inflammation and infection [31]. Many disease-
specific biomarkers are thought to reside at or below a level of nanograms per 
mL in blood making identifying these markers a daunting challenge. 
 
Figure 1.1. Reference intervals for 70 proteins in the human blood proteome. Reproduced with 
permission from Anderson and Anderson [30]. Abundance is plotted on a log scale spanning 12 
orders of magnitude. Where only an upper limit is quoted, the lower end of the interval line shows 
an arrowhead. 
There is currently no single biosensor capable of detecting the dynamic range 
of the blood proteome, although there are many labelled and label-free 
platforms with dynamic ranges suitable to a subset of proteins. Some may offer 
high accuracy and a low level of detection but may only be able to measure a 
single biomarker at one time, whilst others may measure multiple biomarkers 
but offer a much poorer level of detection; trading sensitivity for panel 
applicability.  
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1.2 Biosensors 
A biosensor can be defined as a specific type of chemical sensor comprising a 
biological recognition element and a physico-chemical transducer to generate a 
signal [32]. The interaction of the recognition element with a target analyte 
results in a measurable change, which is converted into a quantifiable electrical 
signal by the transducer. The mode of transduction usually results in an 
electrochemical or optical detection event that is subsequently digitised for 
analysis [33]. Biosensors can be used to detect pathogens and monitor many 
diseases and conditions including blood glucose levels in diabetics [34] and 
also diagnose and monitor cancer [35]. The military also has a strong interest in 
the development of biosensors as counter bioterrorism devices that can detect 
elements of chemical and biological warfare to avoid potential exposure or 
infection [36]. In theory, the applications for biosensors are vast, with a vision 
for the future of biosensors including chip-scale devices placed in the human 
body for monitoring vital signs and delivering drugs. 
An electrochemical sensor was the first demonstration of a biosensor, in the 
form of an “enzyme electrode” by Clark and Lyons in 1962. It coupled glucose 
oxidase to an amperometric electrode for monitoring glucose in blood [33] and 
was label-free with the bio-specificity conferred by the enzyme. More broadly, 
biosensors are grouped into one of two categories, either as a label-based or a 
label-free sensor; both of these approaches have their merits and 
disadvantages. The label-based detection methods require labelling of target 
molecules with radioisotopes, epitope tags or fluorescent dyes [37] and are 
widely used due to the common availability of reagents and simple instrument 
requirements. They can also be extremely sensitive, capable of detecting single 
molecules [38]. However, these labelling strategies may alter the target 
molecule and provide false information on the in vivo concentration – efficiency 
of the labelling process. Moreover, the labelling procedure is lengthy, laborious 
and limits the number and types of target molecules that can be studied [39]. 
Profiling the entire blood proteome would require 245 distinct labels and 
labelling processes each with their own efficiencies and a significant time 
overhead investment and sample size. 
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1.2.1 Enzyme-Linked Immuno-Sorbant Assays 
The most widely used labelled biosensor platform is enzyme-linked 
immunosorbant assays (ELISA) which are used daily throughout the world [40]. 
Generally, enzymes are used rather than fluorescent markers or isotopes, this 
method was first devised by Engvall and Pearlmann [41]. The principle is that a 
chromogenic of fluorogenic substrate could be degraded by an enzyme label, 
yielding an amplification factor by way of colour change which measured 
optically. 
There are three main variations to the general ELISA technique which will be 
detailed here:  
1. The competitive ELISA test for a target antigen. Two tests are run in 
tandem, one where a known plus an unknown antigen sample are 
labelled with an enzyme and allowed to bind to antibody immobilised in 
the solid phase. The addition of substrate allows a comparison between 
the two tests, the offset in signal being attributed to the unknown antigen 
sample.  
2. The indirect method, this involves the passive absorption of antigen onto 
the solid phase, followed by the incubation of test sera containing the 
antibody to allow antibody-antigen binding. Washing then removes any 
unreacted serum components, after which an antiglobulin-enzyme 
conjugate is added and incubated, allowing the antiglobulin to bind to the 
antibody-antigen complex. Finally, after washing, the enzyme substrate 
is added and produces a colour change which measures the quantity of 
fixed conjugate, which is proportional to the concentration of antibody in 
the test sample.  
3. The double antibody ‘sandwich’ technique. The solid phase is coated 
with antibody, which is then reacted with the test sample and binds any 
of its respective antigens present in the sample. After washing to remove 
excess sample constituents, an enzyme labelled antibody is added 
(called the reporter antibody), also specific to the target antigen. After 
further washing, the substrate is added producing a colour change 
proportional to the concentration of reporter antibody present, and 
therefore the concentration of antigen [40]. 
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The success of the ELISA platform is largely owed to its high sensitivity and 
specificity. The fact that it is so widely used means that it has a good level of 
quality assurance and control, with data easily comparable between two studies 
from either side of the world. However, as it is a labelled end-point assay, 
ELISA tests require a long incubation time and a trained operator [42]. 
In contrast, in label-free detection, target molecules are not labelled or altered 
and are detected in their natural forms. This type of detection is relatively easy 
and cheap to perform and allows for quantitative and kinetic measurement of 
molecular interaction. Some label-free detection mechanisms measure 
refractive index (RI) change induced by molecular interactions, which is related 
to the sample concentration or surface density, instead of total sample mass. As 
a result, the detection signal does not scale down with the sample volume. 
When detection volume is important label-free detection is advantageous over 
fluorescence-based detection whose signal usually depends on the total 
number of analytes in the detection volume or on the detection surface [43]. 
1.3 Label vs. Label-Free Biosensors 
Many label-free techniques such as surface plasmon resonance (SPR), carbon 
nanotubes, nanohole arrays, and interferometry are emerging rapidly as 
potential complementary technologies to labelling methods [39]. Currently label-
free based sensors can be divided into two groups: optical and non-optical 
signal transducer schemes [44, 45]. Non-optical label-free biosensor platforms 
include acoustic resonance [46], microcantilevers [47], field effect nanowires 
[48], mass spectrometry [49], surface enhanced Raman scattering microscopy 
(µSERS) [50], optical waveguides and biolayer interferometry [51, 52]. Optical 
biosensors, in general, rely on the change of the properties of light or its 
propagation such as changes in angle of refraction, spectral wavelength or 
interference patterns to measure physical changes [45]. Optical-based sensors 
dominate the label-free field with the most popular being SPR. Two variations of 
the SPR technique are considered in this thesis: surface plasmons on 
continuous metal surfaces and localised plasmons on nanoparticle surfaces. 
1.3.1 Surface Plasmon Resonance 
SPR sensors have already been demonstrated in the field of medical diagnosis 
of infectious diseases, such as AIDS and hepatitis have used the specific 
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interaction between antigens and antibodies. Usually, samples of medical 
diagnosis are urine, saliva, serum, plasma, and so on. Serum is most frequently 
used for medical diagnosis of infectious diseases. A SPR assay for prostate 
specific antigen (PSA) using a commercially available system (Biacore2000™, 
GE Healthcare) was reported that uses serum samples [53]. A detection limit of 
10 ng/mL PSA, marginally acceptable for clinical use, was obtained using this 
direct assay in serum samples. Dillon et al. [54] demonstrated the use of an 
SPR biosensor for the detection in urine of morphine-3-glucuronide, the main 
metabolite of heroin and morphine. The detection limit for morphine-3-
glucuronide in buffer and in urine (diluted 1:250) was found to be < 1 ng/mL. 
Yang et al. [55] measured levels of interleukin-8 (IL-8) protein in the saliva of 
healthy individuals and patients with oropharyngeal squamous cell carcinoma 
using the commercial SPR sensor Biacore X. The detection limit for IL-8 was 
determined to be 2.5 pM (≈ 20 pg/mL) for detection in buffer and 184 pM (≈ 1.5 
ng/mL) for detection in saliva samples. These examples, of assays based on 
SPR, are all comparable in ability to that of labelled detection systems but have 
the added advantage of being more than just an end-point assay due to 
principles behind their sensing capabilities. 
All SPR instruments rely on the same fundamental principles and comprise of a 
detector, a sensor chip, often incorporating the biosensing surface and an 
integrated liquid handling system for the exact transport of the sample to the 
adsorption and detection channels [56]. In general, the SPR platforms make 
use of the Kretschmann configuration, Figure 1.2A, which uses a p-polarised 
light source at a fixed wavelength to illuminate a metal surface in near-field. At 
the critical angle, the energy from the light is coupled into a wave in the 
conduction electrons called a plasmon. Above the critical angle there is a 
spectrum of angles of excitation with maximum coupling occurring at the 
resonance angle, which has a minimum reflectivity (θspr), Figure 1.2. The local 
conditions at the metal-dielectric interface (the refractive index (RI) of solution at 
the interface) determine the SPR angle. The RI changes with the mass of any 
molecule contributing to the local RI at the surface of the gold film, therefore any 
change in RI will cause the angle to shift, ∆θspr, Figure 1.2B.  
Chapter 1 
10 
 
 
Figure 1.2. The Kretschmann configuration for SPR excitation (A), and the resonance angle 
spectrum and shift associate with the change in local RI.  
Surface plasmons are a collection of electromagnetic modes or oscillations 
arising from the interaction of light with mobile electrons in the thin metal 
surface (typically 50 nm thick) [57]. These plasmons are transverse 
electromagnetic waves that propagate along the interface between materials 
(e.g., a metal/dielectric layer) [58]. The intensity of the electromagnetic waves 
decay exponentially with increasing distance from the metal surface [59]. The 
distance at which the intensity of the plasmon field decays to 1 ⁄  of its initial 
value at the interface is called the penetration depth, ld. The plasmon field is 
sensitive to changes in the local RI approximately 200-300 nm away from the 
continuous surface [60, 61], see discussion in Chapter 3. The plasmon typically 
propagates 60 µm along the surface but in the case of gold nanoparticles it is 
localised to the particle and has a different but characteristic penetration depth. 
1.3.2 Localised Surface Plasmon Resonance 
Localised surface plasmon resonance (LSPR) is a nanoscale phenomenon 
associated with the resonance of noble metal nanostructures. These 
resonances lead to extinction (absorption and scattering processes) with shape-
dependent electromagnetic near-field enhancements at the surfaces [62]. The 
past decade has witnessed significant improvements in the fabrication of metal 
nanostructures to tailor the enhancement effects and this has led to advances in 
several areas of LSPR [63]; notably sensitivity.  
A comparison of the two plasmon types associated with SPR and LSPR is 
presented in Figure 1.3. In the case of surface plasmons, Figure 1.3A, 
plasmons propagate in the x- and y-directions along the metal-dielectric 
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interface, for distances in the order of tens to hundreds of microns [64]; for this 
reason they are also known as propagating surface plasmons. For localised 
surface plasmons, light interacts with particles that are much smaller than the 
incident wavelength (Figure 1.3B). This leads to a plasmon that oscillates locally 
around the nanoparticle containing free electrons and induce a collective 
oscillation in the electrons termed a localised surface plasmon (LSP) [65, 66]. 
 
Figure 1.3. Schematic diagrams comparing the excitation of (A) a surface plasmon (SP) and (B) a 
localised surface plasmon (LSP). 
LSPs propagate along the outside of the particle both inside the conduction 
band and the medium immediately above the surface. The propagation of the 
plasmon depends on the metal and the RI of the medium. The plasmon electric 
field penetrates the medium above the surface exponentially [62] with the 
characterised decay of the field, like in SPR, called the penetration depth.  
Whilst, SPR currently dominates commercial instrumentation, LSPR offers 
many of the same advantages for sensing instruments, along with several 
additional benefits [67]. The first benefit from a manufacturing point of view is 
cost, LSPR platforms are simpler and smaller than SPR platform; at the stage of 
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commercialisation this is vital. Both SPR and LSPR instruments can provide 
thermodynamic and real-time kinetic data for binding processes. Moreover, 
although SPR provides much higher sensitivity to changes in the RI than LSPR 
[68], the response of the two techniques becomes similar when measuring RI 
within the penetration depth of plasmon field which is typically comparable to 
the particle radius [69, 70]. By varying the shape, size and material of the 
nanoparticles [71, 72] the properties of the biosensor can be more finely tuned. 
We have published a study on the value of the penetration depth (Appendix C) 
[69] and will be discussed in Chapter 3. 
SPR and LSPR biosensors are more sensitive than other label-free devices, 
they are still unable to achieve the direct detection of small molecules (few 
hundreds of Daltons), the low-mass limit and the lower extremes of the blood 
proteome molecules such as IL-6 concentrations (physiological concentration), 
on the surface of the biosensor [73]. Consequently, various proposals have 
been developed to enhance the sensitivity and limit of detection of biosensors 
by using different SPR detection methods [74-76].  
The localised plasmon is sensitive to any changes in the local RI but the change 
is not bio-specific. In the majority of studies using the in-house AR platform [61, 
77-80] the bio-specificity of the sensors is derived from functionalising the 
nanoparticles with antibodies or antigens. This thesis will focus on antibody – 
antigen interactions which are favoured due to their strong interaction with one 
another leading to very good bio-specificity; we will consider both protein 
screening and antibody screening arrays.  
1.4 Biospecificity: the Antibody – Antigen Interaction 
In 1987, Vo-Dinh et al. showed that antibodies could be utilised in situ for the 
detection of a chemical carcinogen in a fibre-optic immunosensor [81]. Since 
then, antibodies are increasingly being used in medical research, basic science, 
disease diagnosis and therapy [82]. SPR and LSPR play an important role in 
antibody screening and characterisation, providing a variety of useful data such 
as antibody affinity [83], epitope mapping [84], and binding specificity [85]. 
LSPR can also be used to assess antibody cross-reactivity in multiplex assays 
[86], which is an important property to confer assay specificity and a reason why 
immunoassays dominate the market.  
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Proteins, one of the largest, most versatile and complex class of biological 
molecules, include antibodies. The correct folding of every protein within the cell 
is essential for living systems to function. The initial folding into a three-
dimensional structure is determined by the sequence of amino acids monomer 
units in the protein polymer. The process of folding is determined by the 
interaction of a number of functional groups including alcohols, thiols, thio 
ethers, carboxylic acids, carboxamides, and a variety of basic groups [87]. All of 
these groups are present in the side chains of twenty amino acid structures that 
vary in size, shape, charge, hydrogen-bonding capacity, hydrophobic character, 
and chemical reactivity [88]. 
An antibody is a protein of the immune system that is raised to recognise and 
attach to target proteins called antigens and these interactions are some of the 
highest affinity interactions in the body. The interaction site on an antigen is 
called the epitope and is specific to the complementary antibody [89]. An 
epitope is typically 5-8 amino acids in length but is formally a three-dimensional 
region on the protein surface [90]; the conformational epitope. Humans can 
generate around ten billion unique antibodies based on a vast range of possible 
epitopes, each capable of binding to individual targets [91]. The vast spectrum 
however does raise the possibility of common epitopes which may result in 
cross-reactivity with other proteins. Cross-reactivity is however surprisingly rare 
but the need to characterise the epitope and antibody structure is important to 
understand its immunological role. 
1.4.1 Antibody Structure 
The classical description of an antibody is a “Y” shape which is comprised of 
four individual units: two heavy chains and two light chains, Figure 1.4. There 
are two variable antigen-specific Fab arms at the end of which is the epitope 
binding site. The stem of the antibody contains the constant region, known as 
the Fc “tail” that binds a limited number of immune cell Fc receptors. Both Fc 
and Fab domains are required for an effective immune response. 
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Figure 1.4. Structure of an antibody. (A) Schematic representation of antibody type IgG; the two 
heavy chains are shown in blue with the light chains in green. The purple represent the antigen 
binding sites situated on the Fab domain; (B) protein structure of IgG (PBD = 1IGT). 
Antibodies are generically called immunoglobulins (Ig) which are classified into 
five different classes, or isotypes, known as IgM, IgD, IgG, IgA, and IgE, which 
are distinguished by their conserved Fc regions. Human IgG is further divided 
into four subclasses (IgG1, IgG2, IgG3 and IgG4) and IgA into two (IgA1 and 
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IgA2). This diversity offers distinct functional roles in the immune system. 
Collectively the IgG subclasses are involved in opsonisation and activation of 
the Complement system; IgM is the first Ig produced in the immune response 
and is also a strong activator of the Complement system. IgA prevents bacterial 
colonisation; IgE is involved in hypersensitivity responses and IgD can activate 
B-cells, although its role is still not fully understood [92].  
IgG is the most common class in serum, constituting typically 80% of the total Ig 
and will be the primary target of analysis in this thesis. Table 1-1 presents a 
summary of selected important properties of all the Ig classes and subclasses. 
Table 1-1. Properties and biological activies of classes and subclasses of human serum 
immunoglobulins. Activity levels indicated as follows: ++ = high; + = moderate; +/- = minimal; - = 
none; ? = questionable. Adapted from [89] 
 
IgG1 IgG2 IgG3 IgG4 IgA1 IgA2 IgM IgE IgD 
Molecular weight 
(kDa) 150 150 150 150 
150-
600 
150-
600 
900 190 150 
Possible monomer 
units per Ig 
1 1 1 1 1-4 1-4 5 1 1 
Heavy chain 
component 
γ1 γ2 γ3 γ4 α1 α2 µ ε δ 
Average serum level 
(mg/mL) 9 3 1 0.5 3.0 0.5 1.5 3×10
-3
 0.03 
In vivo serum half-
life (days) 23 23 8 23 6 6 5 2.5 3 
Activates classical 
complement 
pathway 
+ +/- ++ - - - ++ - - 
Crosses placenta + +/- ++ - - - - - - 
Present on 
membrane of 
mature B cells 
- - - - - - + - + 
Binds to Fc 
receptors of 
phagocytes 
++ +/- ++ + - - ? - - 
Mucosal transport - - - - ++ ++ + - - 
Induces mast cell 
degranulation 
- - - - - - - + - 
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The Fc region of an antibody is involved in a number of innate immune 
responses which are initiated after recognition by cells expressing specific Fc-
receptors depending on the isotype [93]. Antibodies enhance the innate effector 
responses by: (a) stimulation of phagocytosis through opsonisation of antigen; 
(b) activation of the membrane attack complex by stimulating the Classical 
Complement Cascade-pathway and (c) stimulation of natural killer cells via the 
antibody-dependent cell cytotoxicity response (ADCC) [89]. The production of 
antibodies is triggered by an immune challenge and is the basis of a successful 
humoral response of an animal to the target antigen; understanding this process 
is critical to the interpretation of immunoassay, especially when screening for 
antibodies. 
1.5 The Immune System Response and the Production of 
Antibodies  
The immune system functions as surveillance against infectious organisms 
and/or their toxic products [87]. It can be categorised into two mechanisms; 
innate and adaptive immunity [94]. Innate immunity is a general non-specific 
response to foreign molecules and is the first line of defence against invading 
organism. It includes systems such as phagocytosis (macrophages), cell lysis 
(natural killer cells) and a host of chemical and physical elements [89]; these 
systems are present and ready to be mobilised early in infection. The second, 
slower response to an immune challenge is the adaptive immune system which 
requires several days to synthesis a specific antibody response to the 
challenge. It also affords protection against re-exposure to the same pathogen 
and reacts more rapidly on subsequent exposures; known as immunological 
memory. Screening serum for antibodies is one potential application for 
assessing the immunological memory post vaccination. 
Adaptive immunity is mediated by lymphocytes that are responsible for the 
secretion of antibodies [95] and can be divided into two responses, the cellular 
and humoral responses. The cellular response is carried out by T-cells which 
either help mediate the immune response or contribute by directly attacking 
infected cells [96]. Helper T-cells coordinate the immune response by 
communicating with other cells. These are generally dendritic cells which 
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process antigens into short peptides and present these on the cell surface as a 
complex with major histocompatibility complex-II peptides (MHC II). This 
complex is then presented to the helper T-cells; the helper T-cells can then 
stimulate nearby B-cells to produce antibodies [97]. A stimulated B-cell 
undergoes repeated cell divisions, enlargement and differentiation forming 
clones for antibody production and secretion. Hence, through specific antigen 
recognition of the invader, clonal expansion and B-cell differentiation, they 
acquire an effective number of plasma cells all secreting the same targeted 
antibody. Other helper T-cells present in serum can call in phagocytes and 
activate remaining T-cells. T-cells that attack infected cells are known as 
cytotoxic T lymphocytes - also called killer T-cells [89]. These cells directly 
attack other cells carrying certain foreign or abnormal molecules on their 
surfaces.  
The humoral response involves the production of B-cells which are terminally 
differentiated to give rise to memory B-cells that immediately recognise the 
antigen upon re-exposure and plasma cells, which are necessary for secretion 
of specific antibodies in response to the antigen [98, 99].  
The antibodies formed as result of an immune challenge (following infection or 
vaccination) are polyclonal, i.e. displaying heterogeneity in epitope against the 
antigen. This means there is a population of IgG with different binding sites for 
different epitopes on the surface of the target antigen. Monoclonal antibodies 
(mAbs) are specific for a precise epitope on an antigen; these are produced by 
isolating antibody-secreting lymphocytes from the animal, fusing them with a 
myeloma cell line and isolating a clone producing identical antibodies [100]. The 
use of both polyclonal and monoclonal antibodies is fundamental in research, 
e.g. in immunoassays, affinity purification and western blotting. 
The choice of monoclonal or polyclonal antibodies as capture or detection 
antibodies for biosensors affects directly the utility and performance of the 
assay. The heterogeneity of polyclonal antibody binding site distribution means 
they are more tolerant to slight changes to the antigen e.g. denaturation, 
polymorphism or differences in glycosylation state [95] and are more likely to 
remain active. The binding site distribution of monoclonal antibodies is 
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homogeneous; this ensures better reproducibility between tests when 
conditions are kept constant. 
1.6 Immunoassays 
Immuno-assays monitor the antibody – antigen interaction allowing either the 
antigen or the antibody to be the target analyte in a diagnostic test. The 
following chapters will investigate both of these approaches; however, the main 
focus will be on antibody screening assays on an array, Chapters 3, 4 and 6. 
These chapters will cumulate in a study on vaccine development but other 
applications can include autoimmune disease and therapeutic antibody 
screening. 
Autoantibodies are antibodies raised against host proteins rather than invading 
pathogens and are the cause of autoimmune disease [101]. It is generally 
accepted that autoimmune disorders are the result of a complex interaction 
between genetic and environmental factors, most of which have not been 
identified [102, 103]. Both humoral and cellular immune response contribute 
and there are roughly 70 disorders that are related to autoimmunity [104]. The 
most common autoimmune disorder is rheumatoid arthritis which affects ≈ 1% 
of the population worldwide and is 3× more likely to affect women than men 
[105]. It is caused by a precipitation of immune complexes that build up against 
citrullinated proteins in joints [106]. Autoimmune disorders are not the focus of 
the work presented here but are a promising target for future assays as more 
about the role these antibodies play is understood. 
Antibody screening for the development of humanised antibodies for 
immunotherapy and the monitoring of antibodies levels following treatment, are 
another promising application. A requirement of therapeutic antibodies is that 
they exhibit very little immunogenicity in humans. By characterising cross-
reactivity of engineered mAbs via an antibody screening process, antibodies 
with high specificity and affinity for their respective targets can be isolated for 
further development. An effective screen could reduce the length of time 
required for these therapeutic antibodies to reach the clinical trial stage. The 
majority of approved mAbs are based on the IgG1 isotype that interact with the 
FcγR [107], by screening a spectrum of mAbs for their Fc affinity towards this 
receptor then mAbs displaying a weak interaction can be disregarded.  
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The work presented herein concludes with a study related to a third application 
of antibody screening assay; vaccine development. Vaccines are undoubtedly 
one of the biggest scientific breakthroughs of the previous century. Antitoxins 
and vaccines against diphtheria, tetanus, anthrax, cholera, plague, typhoid, 
tuberculosis, and more were developed in the early 1900’s [108]. The mid 
1900’s saw rapid discoveries and innovations and as a result, vaccines could be 
produced in the laboratory, notably polio [109]. This vaccine against polio has 
since reduced the worldwide incidence of polio from an estimated 350,000 
cases in 1988 to just 223 cases in 2012 [110]. The future of vaccine 
development is promising with trial vaccines against AIDs and other new world 
diseases making good progress with some reaching phase III clinical trials 
[111]. 
An antibody screening array on the AR could be used to quantify the immune 
response by measuring IgG concentration in sera following vaccination and post 
exposure to the pathogen and by measuring the affinities of both the Fc and 
Fab antibody regions of pathogen specific antibodies. To understand how the 
AR could benefit the vaccines of the future, we first need to understand the 
principles of vaccine and the immune response following vaccination and 
subsequent expose to the vaccine-related pathogen.  
1.6.1 Vaccines and the Immunological Response 
Vaccines prime the immune system with the capacity to recognise, contain, and 
eradicate the pathogen before the bacterium has the opportunity to colonise. 
Pathogen colonisation is prevented by introducing a modified antigen to the 
naïve immune system in order to establish immune memory. The antigen can 
include the whole pathogen or components of the pathogen, such as virulence 
factors [89]. 
A simple form of vaccination is passive immunisation where specific IgG 
antibodies generated against an antigen are given direct to the host either as an 
antiserum or mAb. This therapy can offer good short term immunity as the 
protection is immediate. The vaccination is even more protective if the innate 
response is further triggered or the vaccines antigen is a virulence factor which 
may help neutralise the pathogen [112]. Once the antibodies have been 
destroyed the host no longer has immunity. 
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In contrast, active immunisation offers the host long-term protection by 
provoking a response similar to that of an invading pathogen. Innate immunity is 
initiated first which leads to the antigen presenting cells engulfing and 
processing the antigens resulting in an adaptive immune response. This 
process is how the long-term immunity is achieved by triggering both B and T 
cell responses. Additional steps can be taken to improve the efficacy of the 
vaccine such as a booster vaccine. The initial antigen exposure elicits a 
response that results in the rapid appearance of low IgG antibody titers. As B 
cells proliferate and differentiate into plasma cells, IgG antibody titers increase 
up to a peak value, usually reached 4 weeks after immunisation [113]. The short 
life-span of these plasma cells results in a rapid decline of antibody titers, which 
eventually return to baseline levels but memory cells remain. In secondary 
immune responses, booster exposure to antigen reactivates immune memory 
and results in a rapid (<7 days) increase of IgG antibody titer [114].  
The initial response is further enhanced by the used of an adjuvant, which is 
defined as an agent that can increase the stimulation of the immune system 
[89]; although the precise mechanism of action is not understood. The most 
common adjuvant agents are aluminium salts or emulsions. These can trap 
antigens at the injection site providing slow release into the immune system and 
therefore prolonged exposure and increased stimulation [115]. Other adjuvants 
are capable of directing antigen presentation or act by inducing the innate 
response [116]. There are many factors that can influence the efficacy of a 
vaccine which at present are tested in animal models. A technology that 
reduces the number of animal exposures and pre-screens vaccine candidates 
in the laboratory could significantly increase the rate of vaccine development. 
1.7 Aims and Objectives 
The preceding discussion points towards a need for a new technology capable 
of contributing to the field of biosensors and medical diagnostics by providing a 
platform that can be used for point-of-care clinical evaluation, real-time 
diagnosis of diseases and fast proteomic mapping for personalized care. The 
measurement of low concentrations of physiological molecules, such as 
antibodies, is critical for clinical research based analyses. The recent trend 
towards integrated and automated instruments based on bioassays has had an 
extraordinary impact on the speed and efficiency with which analytical and 
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diagnostic measurements can be made, subsequently reducing costs and 
improving patient healthcare. An example of this application is the point-of-care 
device Nanopoc, designed for the diagnosis of foot-and-mouth disease, 
brucellosis and Chagas disease [117]. Multiple analyte detection [118], 
microfluidics [119] and lab-on-a-chip [120, 121] concepts are clearly in the 
future of immunosensors, which will soon find wide application, with great 
impact in health care assessment, especially in developing countries.  
The aim of this thesis is: 
To evaluate the Array Reader as a possible point-of-care platform for real-time, 
label-free, high-throughput proteomic profiling with applications in the fields of 
personalised patient care, differential disease diagnosis and immune system 
response profiling. 
The thesis will focus on immunoassays that rely on antibody–antigen 
recognition of the target molecules (the analytes), this complex offers the high 
sensitivity and specificity required by a biomarker, relying on interactions that 
have already stood the test of time and can only aid the future of biosensing 
technology.  
The objectives of this thesis are: 
1. Determination of immuno-kinetic assay performance metrics; 
2. Optimisation of the immuno-kinetic assay design for complex fluid 
samples; 
3. Assessment of quantitative antibody screening arrays; 
4. Assessment of quantitative protein screening arrays; 
5. Application of antibody screening arrays to assess the efficacy of a new 
vaccine. 
To perform the evaluation, the thesis will concentrate on five objectives listed 
above, from optimising the platform and determining standard operating 
procedures (SOPs), to real-world applications. Firstly, the immuno-kinetic assay 
(IKA) performance metrics must be determined. Chapter 2 will address this 
objective by focussing on the principles behind the technology, steps involved in 
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extracting the appropriate information from the data and methods and analysis. 
Chapter 2 will report an investigation to optimise the immuno-kinetic assay 
design for label-free detection in complex fluid samples, leading to an SOP. The 
theme of screening in complex samples will continue into Chapter 3 which 
reports the development of an amplification technique to enhance the sensing 
capabilities of the AR platform. The amplification technique also led to a novel 
method to measure the plasmon field penetration depth directly for the gold 
nanoparticles at the heart of the sensor platform. The plasmon field penetration 
depth can be tailored to enhance the response of the assay over the 
background biological noise in human serum; it is a key advantage LSPR has 
over SPR and other label-free platforms. Optimisation of the AR will allow the 
platform to become a potential rival technology for other biosensors currently 
available commercially. 
The third objective is the assessment of quantitative antibody screening arrays. 
The first assay to be studied on the AR is the measurement of total IgG. Here 
the Fc-region specific interaction with recombinant protein A/G is used to 
characterise the Fc region binding affinity and trap the Fc region selectively for 
total IgG concentration determination. Specific assays using antigens can 
measure the Fab region affinity and determine specific concentrations. These 
assays can be used as a companion diagnosis present on a multiplex array to 
screen the efficacy of an immune response and or the concentration of 
antibodies to an autoimmune disease epitope or monitoring of vaccination. 
The fourth objective is the design and development of quantitative protein 
screening assays. For the AR to become successful as a multi-analyte 
biosensor for disease diagnosis, it is essential that protein levels can be 
screened from serum samples, complementary to the antibody screening. 
Screening changes in the human proteome or looking for foreign proteins is 
essential to understand and differentially diagnose disease states. Proteins 
present in serum, for example, can comprehensively sample the human 
phenotype, the state of the body at a particular point in time and their levels are 
highly dynamic. Global adoption of a sensor technology must have multiple 
applications and the ability to detect and measure protein concentrations at a 
level comparable to other available biosensors.  
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Reliable analytical tools are important for economical process development, 
production and batch release of vaccines. The fifth and final objective will 
expand on objective 3 by using the Fc and Fab antibody screening arrays to 
assess the efficacy of a new vaccine. Total IgG can be measured to assess the 
immune response of a test animal following vaccination, with the specific 
response measured to determine the concentration. The affinity of the 
antibody–antigen interaction is simultaneously measured adding additional 
value to the technique which can aid in evaluating the complex processes 
involved with understanding vaccination. This is a very promising application for 
the AR, making use of the key advantages this platform has over other 
commercial biosensors and the impact it could have on the field of vaccines.  
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2 Assessment of the Array Reader Particle 
Plasmon Biosensor Performance 
2.1 Introduction 
Currently the most trusted diagnostic tools for the detection and quantification of 
disease-related biomolecules include ELISA assays [122], Western blots [123], 
immuno-fluorescent microscopy [124, 125] and electrochemiluminescence 
[126]. All of the techniques suffer from one limitation, the need for a labelled 
marker, usually a tag that will induce a colour change which can be quantified. 
Even so, these techniques are still the benchmark assays performed in clinical 
chemistry laboratories globally. The success of these sensing technologies is 
mostly determined by the assays sensitivity, detection limit and specificity; 
defined in the following section. 
An example of one of the most commercially successful biosensors is a glucose 
electrochemical biosensor which shows high specificity. It is used to determine 
blood glucose levels electrochemically by encapsulating the enzyme glucose 
oxidase within polyethylene on a metal electrode and measuring the 
approximate amount of enzyme activity per unit volume of glucose [127]. Even 
with pressure increasing every year to develop new assays, few have reached 
the same recognition as that of the glucose sensor [128]. A big advance in 
glucose biosensors came in the last few years with the development of a 
labelled transcutaneous glucose microsensor which is minimally invasive and 
biodegradable, being resorbed by the surrounding tissue after more than 14 
days use. It weighs approximately 40 g and has dimensions of 16 × 65 × 145 
mm [129]. These sensors were shown to have an in vitro variation of 4.6% 
compared to 8.3% in vivo, giving them a high clinical confidence [130]. 
By contrast, label-free techniques require limited, if any, sample preparation and 
allow more quantitative data to be collected, such as reaction kinetics and 
thermodynamic properties. Label-free technologies, however, must compete for 
specificity and sensitivities of the labelled technologies for the clinical ranges of 
interest. Among the variety of label-free biosensors available, localised surface 
plasmon resonance (LSPR) is considered one of the most powerful and 
promising tools in the field [131-134], discussed in Chapter 1. Other label-free 
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techniques are available for clinical use, although the commercialisation of 
these biosensors has been slow; attributed to cost considerations and some key 
technical barriers [135]. For the obvious advantages of label-free sensors to be 
realised such low sample preparation times, multiple analyte screening and 
potentially biomarker discovery, the sensitivity, specificity, accuracy and limit of 
detection must be clinically useful and compete effectively with existing 
platforms.  
2.1.1 Assay Performance Metrics 
When designing an assay for a certain biomarker, criteria that will determine the 
usefulness of an assay and its limitations include sensitivity, specificity, 
accuracy and detection limit. Central to the understanding of assay 
development is the standard, or calibration, curve (Figure 2.1), allowing the 
definition of the assay performance parameters. 
 
Figure 2.1. Example standard curve with possible assay parameters that can be determined; x-axis 
= analyte concentration; y-axis = signal in arbitrary units (AU). Sensitivity = slope of the curve; LOD 
= the lowest possible analyte concentration that can be measured; Dynamic range = total range of 
the standard curve; Linear range = the linear portion of the standard curve. 
A standard curve can be defined as the variation of sensor signal with analyte 
concentration [136]. They are often plotted as the log of concentration (-axis) 
against signal (-axis) and the maximum slope of the curve is a measure of the 
assays sensitivity [137, 138]. Ideally the working of the assay should be linear 
but with the total dynamic range extending into the non-linear regions [136]. The 
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performance of an assay can be judged against a number of parameters which 
will now be considered in turn, including: limit of detection, sensitivity, specificity 
and reproducibility. 
2.1.1.1 Limit of Detection 
The limit of detection (LOD) is a measure of the lowest target analyte 
concentration which can be determined with a specified precision or 
reproducibility [139]. LOD is the closeness of agreement between independent 
results of measurements obtained under stipulated conditions; it is solely 
related to the signal-to-noise ratio (SNR) controlled by the random error in the 
measurements. 
Most frequently, the specified LOD is defined in terms of the concentration 
producing a signal equivalent to two or three times the standard deviation of the 
noise in a series of blank (baseline) measurements of a standard with a 
concentration close to the anticipated detection limit [140]. The use of 1.96 
standard deviations (σ) is the 95% confidence limit (assuming normal, random 
distribution of noise); anything above this limit is from the signal. The LOD is the 
most commonly used figure of merit adopted by researchers to discriminate 
between the analytical signal of the analyte and the instrumental noise [141]. As 
well as being related to the background noise it is also dependant on the 
calibration curve. Thus there are two options to optimise the LOD: reducing the 
instrument noise level, directly lowering the LOD, or increasing the sensitivity of 
the analysis method [137]. The LOD must also be below the lower limit of the 
clinical normal range of the target molecule. 
2.1.1.2 Sensitivity 
Sensitivity is a measure of signal magnitude change with concentration and is 
related to, but is not the same as, the detection limit. Two assays can be as 
equally sensitive giving rise to comparable signal changes but if one assay has 
better SNR it will have a better sensitivity. The sensitivity is defined directly from 
the slope (Figure 2.1) of the calibration curve [137], Equation 2-1. 
	
		
      
Equation 2-1 
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where,  is the change in signal (AU); and  is the change in analyte 
concentration.  
2.1.1.3 Specificity 
For an assay to be highly specific, the observed signal can only be attributed to 
the target molecule and includes the absence of any false signal. It is of no use 
to have an impressive LOD and be highly sensitive if it is impossible to 
distinguish between true signal and interference from other molecules present 
in the sample [142]; this is assay specificity. Specificity can also be thought of in 
terms of biomarker discovery where if the levels of a target analyte are not 
significantly different between healthy and diseased individuals, it is unlikely that 
the marker will ever succeed as a clinical biomarker. The number for specificity 
in this case, can be obtained by dividing the number of true negatives by the 
number of true negatives plus false positives. 
2.1.1.4 Reproducibility 
A further consideration in the design of the assay is its reproducibility. According 
to the IUPAC/Compendium of Chemical Terminology [143], repeatability and 
reproducibility refer to the closeness of the agreement between the results of 
successive measurements of the same target, performed in the same 
(repeatability) or different (reproducibility) conditions (such as the assay kit or 
operator). Reproducibility is expressed as a percentage, or coefficient of 
variation (CV), which is the ratio of the standard deviation, σ, to the mean, µ, of 
the signal [144]: 
   μ   100% 
Equation 2-2 
 Reproducibility can be measured in two ways: 
1. Intra-assay variation: the reproducibility of an assay tested independently 
but during the same experiment. 
2. Inter-assay variation: the reproducibility of an assay evaluated over 
several experiments by a number of operators. 
CV is typically < 5% for a clinically approved assay. 
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2.2 Aims and Objectives  
The aim of this chapter is to:  
Explain the principles behind the technologies and the optimisation of methods 
and SOPs to maximise the capabilities and sensing properties of the Array 
Reader platform. 
The objectives for this are to first explain the Array Reader platform and the 
physical principles behind localised surface plasmons. Array fabrication will be 
discussed, from the substrate the arrays are built on, to the functionalisation of 
the array spots with proteins; every step is key to gaining the maximum 
sensitivity and specificity possible. Following this is the assay SOP, including 
pre-assay steps such as washing and blocking, finishing on the standard SOP 
used for almost all assay presented in this thesis and how to interpret the 
response seen on screen. 
Post-assay analysis will complete this chapter with the focus on fitting binding 
interaction models to understand the kinetics behind the interaction. The model 
will be evaluated statistically to be sure of its correct use. The chapter will finish 
with an explanation of why the model may not capture the exact binding 
processes and what may be happening at the surface to affect this interaction.  
2.3 Materials 
The following were purchased from Sigma Aldrich: sodium borohydride 
(NaBH4), auric chloride (HAuCl4 · 3H2O, 99.9%), sodium citrate, glycerol, 
hexadecyltrimethyl ammonium bromide (CTAB), ascorbic acid, N-(3-
Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC), N-
hydroxysuccinimide (NHS), bovine serum albumin (BSA, 98%), and human 
fibrinogen (60% with 40% buffer salts; the protein content is >80% clottable 
fibrinogen), anhydrous N,N-Dimethylformamide (DMF), Lomant’s reagent 
(dithiobis[succinimidyl propionate] (DSP)), potassium thiocyanate (KSCN). 
Standard phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl and 10 
mM Na2HPO4, pH 7.4) purchased from Sigma-Aldrich in tablet form unless 
otherwise stated. For all binding studies, but not for surface preparation, 
5 × 10-5 Tween 20 (w/v) was added to the prepared PBS buffer. Recombinant 
protein A/G was supplied from Pierce. Sheep polyclonal antibodies to BSA 
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(aBSA) (23 mg/mL, IgG fraction) were supplied by AbD Serotec UK and goat 
polyclonal antibodies to CRP (aCRP) (10 mg/mL) were supplied by Abcam. 
Human Serum (male AB) was obtained from Biosera. The SAM components 
used were HS-(CH2)17-(OC2H4)3-OH (used as a ‘spacer’) and HS-(CH2)17-
(OC2H4)6-OCH2COOH (used as a ‘linker’), both were obtained from ProChimia 
Surfaces (Poland). 
2.4 In-House, Label-Free Localised Plasmon Sensing Array 
Technology  
Localised surface plasmons (LSPs), discussed in Chapter 1, are charge density 
oscillations confined to metallic nanoparticles which can be excited by radiation 
in visible or near infra-red range [145], the plasmon frequency (colour of the 
radiation) depends on the metal and nanoparticle size [66]. When the LSPs are 
excited by a light source at an appropriate wavelength, resonance can occur 
which results in strong light scattering and enhancement of the local 
electromagnetic field [146]. The intensity of this effect is determined by 
composition, size, and shape [147, 148], or used as an amplification technique. 
Oldenburg et al. [149], applied nanoparticles to biotinylated oligonucleotides in a 
microarray-based DNA hybridisation assay; the sensitivity was 60× greater than 
that of fluorescent labels alone. 
To exploit the properties of these LSPs confined to gold nanoparticles, we have 
developed a biophotonic array sensing technology, the AR [61, 77, 79, 80].  
2.4.1 Array Nanoparticle Synthesis  
Nanoparticles were first synthesised in a colloid by Michael Faraday in 1857 
[150]. Colloidal nanoparticles are typically in the size range 1 – 100 nm and 
their properties differ markedly from their bulk behaviour [150, 151].  
Gold seed nanoparticles are synthesised in solution, printed into the array 
configuration and then subsequently grown using our novel surface synthesis 
[61, 146] . The term ‘seed’ colloid refers to a colloid of small seed nanoparticles 
that will form a uniform size distribution before further chemistry and change of 
conditions allow these seeds to take many different sizes and shapes. The 
control of shape and size through synthetic means is the foundation of the array 
formation process in the AR. The method used for the gold synthesis has been 
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adapted from Murphy et al., [152] and has been discussed in detail in previous 
Array Reader publications [61, 77, 80] but will be described briefly below.  
2.4.1.1 Gold Seed Colloid Preparation 
The sodium borohydride (NaBH4) reduction of auric chloride was performed 
using 0.1 M NaBH4, 37.5 mg dissolved in 100 mL H2O purified water at room 
temperature (RT) then cooled to 0 °C for 20 mins. 200 µL of 50 mM auric 
chloride (HAuCl4 · 3H2O, 99.9%) is added to 40 mL of water and to this 100 µL 
of sodium citrate 0.1 M at RT. 2.4 mL of the cooled 0.1 M NaBH4 stock solution 
is added to the auric chloride solution very quickly whilst swirling to prevent 
aggregation (signs of aggregation include a film on the side of the bottle, or 
blue/pink solution colour). The citrate anion stabilises the forming nanoparticles 
acting as a charged ligand, binding to the surface and producing a negatively 
charged layer [153]. The solution is left for 10 minutes at RT and then heated 
for 10 minutes at 40 – 45 °C to destroy any remaining BH3. The ruby red colloid 
is then allowed to mature for 2-3 hrs at RT before printing.  
2.4.1.2 Gold Nanoparticle Surface Synthesis 
The seed nanoparticles are printed in 12 × 8 rectangular arrays using an inkjet 
printer (Arrayjet Aj100). 20% glycerol (w/w) is added to the colloid to ensure the 
correct 10 cP viscosity for printing, the glycerol also means that the spots once 
printed do not spread and hold therefore their shape. The Arrayjet printer allows 
control over the spot size by the printed volume, typically 200 pL, array 
dimensions and array spot pitch. The printed arrays are left for 3 hours before 
being washed with water to remove unbound gold and glycerol from the 
surface. 
The optical-scattering nanoparticles are synthesised on the surface in a 
surfactant mediated development process. 400 µL of HAuCl4 50 mM is added to 
40 mL of water. To this 40 mL of hexadecyltrimethyl ammonium bromide 
(CTAB) 0.2 M (dissolved at 30 °C) is added through a microfilter (0.2 µm) to the 
gold solution forming a yellow/brown coloured dispersion. 350 µL of 0.1 M 
ascorbic acid is finally added which, on addition, will turn the solution colourless. 
The solution is incubated at 28 °C for 30 minutes. The slides with printed seed 
particle arrays are then submerged in the developer solution at 28 °C for a 
further 30 minutes. At this stage the arrays, should be just visible by eye when 
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illuminated. The slides are then carefully but extensively rinsed with water, 
before being immersed in water overnight with stirring to remove excess CTAB. 
The finished arrays are then rinsed with IPA and dried in a stream of N2 and 
may be stored without degradation for up to a year. They are now ready for 
functionalisation. 
 
Figure 2.2. Image of an illuminated array after installation into the Array Reader. 
The image in Figure 2.2 is of a finished array after it has been installed into the 
AR; the spots appear uniform in size, shape and brightness. Each column is 
printed from an individual print-head nozzle; there are 8 in total forming what is 
known as a ‘spider’. However, the inconsistency of column 2 is present over all 
8 spots on the column since they were printed from the same nozzle. 
2.4.2 Array Spot Nanoparticle Characterisation 
Scanning electron microscopy (SEM) images were collected for the 
nanoparticle surface, Figure 2.3. The size and shape distributions of the 
nanoparticles was determined along with the surface density.  
 
Figure 2.3. SEM image of gold nanoparticles printed and grown on the glass substrate. 
The shapes visible in Figure 2.3 are predominantly spherical nanoparticles with 
a mean diameter of 90 ± 13 nm but also present are rods and flat ‘pancake-like’ 
Chapter 2 
32 
 
nanoparticles; this gives us a sensitivity that corresponds to typically 8×10-5 
refractive index units (RIU). The morphology and dimension of the Au 
nanoparticles depend on the concentrations of the seed particles and CTAB, in 
addition to the reactants [154]. Solution studies have shown that the presence 
of 5% Ag+ raises the yield of gold nanorods to nearly 100%, compared to 20-
40% in the absence of Ag+ [155]. Moreover, the slight changes in reaction 
conditions lead to other shapes of gold nanoparticles, such as blocks, cubes 
and tetrapods [154]. Despite several attempts to control the surface particle 
shape and size, the surface synthesis process always results in a distribution. 
Tailoring the optical properties of nanoparticles is important as the plasmon 
extinction (absorbance + scatter) is highly dependent on their shape, size and 
dielectric constant of the surrounding medium [156]. For example spherical 
particles have only a single plasmon extinction maximum, which shifts to longer 
wavelengths with increasing particle radius [157]. However, gold nanorods have 
two principal plasmon extinction maxima; one at shorter wavelength 
corresponding to a plasmon supported along the minor axis and a plasmon 
frequency at longer wavelength associated with the major axis [154].  
2.5 The Array Reader Instrument 
The design of the AR platform has been discussed in detail in a number of 
papers [61, 77, 80]; and will be described briefly here, concentrating on the 
modifications performed during the course of this thesis investigation. 
Near-field illumination of the array takes place using radiation from an LED light 
source (660 nm) collimated through a Dove prism. Light scattered by the 
nanoparticle localised plasmon is collected normal to the sensor surface by a 
video camera at ≈ 30 frames per second. The PC averages the images for 1 
second to improve the SNR. The change in scattered light intensity measured 
by the camera is associated with the change in the RI of the medium within the 
plasmon field and may be calibrated with a bulk solution change of known RI to 
give an instrument response in RIU. The array reader is shown schematically in 
Figure 2.4 together with the sample handling fluidics. 
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Figure 2.4. Schematic diagram of the Array Reader instrument. 
The injection loops are interchangeable in order to load different sample 
volumes which will become important with the length of measurements, 
discussed later. 
2.5.1 Sensitivity Analysis 
The nanoparticle arrays are washed with iso-propan-2-ol (IPA) and dried under 
N2 before being installed into the AR. The sensitivity of the array spots to both 
bulk and local RI changes are important parameters in the design of the array 
reader. The sensitivity to bulk RI is assessed by changing the composition of 
the buffer from the standard phosphate buffered saline (PBS) to another 
solution such as double concentrated PBS (2×PBS) or a solution of PBS 
containing a known quantity of sugar or alcohol, such as glycerol. Each solution 
has a RI value determined by a refractometer (Reichert AR200) to three 
decimal places. A change in the bulk RI from PBS to 2×PBS is shown in Figure 
2.5 with the data collected in brightness. 
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Figure 2.5. Typical data collected from the calibration process. Black dashed lines mark the 
injection of 2×PBS. The grey dashed lines represent the total change in brightness used for 
calibration; ∆RI – is 1.8 × 10-3 at 21 oC. 
The effect of the change in bulk RI on the light extinction scattering behaviour of 
the array can be used to describe the smallest detectable change of RI, or the 
absolute refractive index sensitivity (RIS); this may be written as: 
   √2    !   !  
Equation 2-3 
Where  is the mean scattered light intensity averaged over all 96 spots. 
Subscripts 1 and 2 would correspond to analytes with different bulk RI values, 
for example PBS has a RI value of 1.3345 with 2×PBS having a value of 1.3363 
corresponding to a change in RI of 1.8 × 10-3 at 21 °C. From Figure 2.5 the 
mean RIS over the array can be calculated as 1.28 × 10-5 RIU and is the overall 
detection limit of the gold nanoparticle array. 
The response may be normalised and expressed as percentage change and is 
used to compare spot-to-spot variations. RIS (nRIS) which is measured as the 
percentage change in signal per RIU, Equation 2-4.  
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     !   !     100% 
Equation 2-4 
The spot-to-spot sensitivity of the gold nanoparticles is presented in Figure 2.6 
as a surface plot, with the 12 × 8 array format each pixel in the map is a spot. 
The surface plot is useful as it helps identify any correlation between sensitivity 
irregularities and the printing protocol; for instance, if there is a particular 
column that may have a lower sensitivity compared to the rest, this could 
indicate an issue with the printer such as a blockage.  
 
Figure 2.6. 3D surface plot for the spot-to-spot sensitivity measured as nRIS (%RIU-1) presented in 
the same 96 spot format as the array. Each pixel represents a spot. 
The mean nRIS for this array is 550 ± 90 %RIU-1; arrays performing with an 
nRIS value of less than 300 %RIU-1 are routinely rejected. There are no obvious 
patterns present on the array that are column or row dependant, with only the 
bottom left section of the array having a lower average sensitivity. The same 
data can be presented in the form of a histogram seen in Figure 2.7.  
The histogram in Figure 2.7 shows the sensitivities of spots on the 96-spot array 
are normally distributed. Both Figure 2.6 and Figure 2.7 allow spots with low 
sensitivity to be identified and removed from the analysis of future experiments. 
The ideal array should have a large sensitivity and be normally distributed which 
depends on a number of factors in the surface synthesis process, principally the 
nature of the substrate.  
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Figure 2.7. Histogram for the sensitivity data presented in Figure 2.6 fitted with a Gaussian model; 
R2 = 0.946; χ2 = 7. 
Optimum surface coverage, surface growth, sample handling, reproducibility 
and minimisation of background signal can all be controlled by using the 
appropriate glass substrate. The surface chemistry can be varied to change a 
number of properties, principally surface charge, hydrophobicity and 
hydrophilicity. It is possible to change the fundamental charge of the substrate 
surface by controlling the pH of the sample. Many different chemically 
functionalised substrates are available including aminated, epoxy coated and 
aldehyde functionalised slides. The sensitivity of four substrate surfaces was 
assessed, Figure 2.8, silane (aminoalkylsilane) (Sigma-Aldrich); aldehyde 
(Corning Microarray Products), epoxide (Corning Microarray Products) and 
aminated, GAPS II (Corning Microarray Products) coated with γ-aminopropyl 
silane. The data are presented as the mean ± standard deviation for the 
sensitivity of three independent arrays, as used for array calibration.  
The array preparation on a GAPS II substrate showed enhanced stability over 
the other surface-functionalised slides (lowest value of σ) and sensitivity. GAPS 
II coated slides offer a clean uniform substrate with a high binding capacity for 
nanoparticles [158] and result in a reproducible print. After the gold 
nanoparticles have been printed and developed onto the selected GAPS II 
substrates and the array sensitivities used to reject low-sensitivity arrays, nRIS 
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(>300 %RIU-1), the remainder of the batch is then suitable for surface activation 
and bio-functionalisation. 
 
 
Figure 2.8. Sensitivity of the total gold nanoparticle surface ± 1σ. 
2.5.2 Nanoparticle Surface Activation and Bio-Functionalisation 
Before printing proteins onto the nanoparticle arrays the gold is activated by 
functionalising the surface with self-assembled monolayers (SAMs) which 
contain linker molecules suitable for covalent immobilisation of proteins. The 
use of a SAM is common in the design of SPR based experiments acting as a 
linker between the protein and the gold and can have very different 
characteristics. BIAcore offer a number of different functionalised chips that vary 
by linker length, binding site density and the required binding chemistry. The 
CM5 chip, for example, is BIAcore’s most widely used sensor surface and 
consists of a dextran layer that extends ≈ 100 nm from the Au surface forming a 
pseudo 3D matrix with increased surface binding ligand density [159]. The CM5 
chip can be functionalised with a wide range of ligands from small organic 
molecules to proteins, nucleic acids and carbohydrates [159]. This type of SAM 
would not be suitable for LSPR instruments due to the smaller sensing distance 
of the plasmon, so therefore a SAM is needed that has a much smaller linker 
length of only around 14 carbons atoms.  
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The SAM used in our experiments consists of two molecules known as ‘linkers’ 
and ‘spacers’ which are mixed at a specified ratio ranging from 1:1 to 1:10,000. 
Both molecules contain a thiol group on one end for thiol-coupling to the Au 
surface. At the other end, the ’linker’ contains a carboxyl group which can be 
activated for protein coupling and the ‘spacer’ contains an alcohol group (Figure 
2.9). The SAM components used were HS-(CH2)17-(OC2H4)3-OH (used as a 
‘spacer’) and HS-(CH2)17-(OC2H4)6-OCH2COOH (used as a ‘linker’), both were 
obtained from ProChimia Surfaces (Poland).  
 
Figure 2.9. Bio-functionalisation of sensor arrays by EDC/NHS coupling to carboxylic acid groups 
present in self-assembling monolayers (SAMs). 
The Au functionalised surface, Figure 2.9, is further activated at the carboxylic 
acid groups involving 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide (EDC) 
and N-hydroxysuccinimide (NHS) (EDC/NHS) chemistry, to produce 
succinimide esters reactive towards primary amino groups (such as lysine 
residues) and the formation of a stable peptide bond. The mixing ratio of linker 
and spacer SAM components used was 1:10 designed to reduce the bound 
protein density on the surface, reducing the surface capacity allowing more 
accurate determination of the binding affinity, discussed later in the chapter. 
The mechanism for amine coupling with EDC/NHS is presented in Figure 2.10. 
target binding 
site for proteins
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Figure 2.10. Schematic representation of the EDC/NHS amine coupling. 
The SAM is first activated for 1 hour with a 1:1 mixture EDC/NHS dissolved in 
anhydrous N,N-Dimethylformamide (DMF) to create reactive succinimide 
esters. The protein is then incubated on the surface for 2 hours to complete the 
peptide coupling.  
A single reagent combining the thiol and succinimide functionality is the 
Lomant’s reagent (dithiobis[succinimidyl propionate] (DSP)) to achieve the 
same peptide linking chemistry [160]. The EDC/NHS coupling has a short half-
life with response to hydrolysis and the slides are returned to the printer for 
protein functionalisation within 20 minutes [161]. 
For bio-functionalisation, target proteins are printed from an amine-free buffer to 
prevent competition with the surface succinimide ester functionalised sites and 
pH adjusted to below the isoelectric point (pI) of the protein. Under these 
conditions the amine group is protonated and is effectively pre-concentrated 
into the negatively charged SAM [134]. Unreacted esters are then hydrolysed to 
create an effectively unreactive surface between the coupled ligands. A solution 
of ethanolamine can alternatively be used to block unreacted ester in minutes 
rather than hours. Generally the arrays are incubated at RT for approximately 2 
hours, washed off with PBS and then they are ready to be installed in the array 
reader or stored dry at 4 °C for up to a month without loss of surface activity. 
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2.6 Immuno-Kinetic Assay Analysis 
There are five steps that form a Standard Operating Procedure (SOP) for the 
analysis of an analyte binding event. The length of the experiment is determined 
by the association and dissociation kinetics of the target assay. A general SOP 
sequence is presented in Figure 2.11 based on the following steps: 
1. Running buffer (PBS) is flowed through the flow cell to establish a stable 
baseline of more than 200 seconds. 
2. At t=0, a solution concentration of analyte in the running buffer is passed 
over the receptor monitoring the rise in RI in real time.  
3. At an appropriate time (discussed later) the analyte solution is replaced 
by buffer, and the antigen–analyte complex is allowed to dissociate. 
4. Many complexes in biology have a considerable half-life (≈ 1000 
minutes) so a regeneration solution is needed to disrupt binding and 
regenerate the free ligand. For example, an aqueous 100 mM solution 
phosphoric acid at pH 1.9, can be used for 4 minutes. 
5. Running buffer is re-introduced to the array bringing the signal back to it 
baseline position.  
6. Steps 2-5 can be repeated as required. 
 
Figure 2.11. An example of a standard binding experiment, as a function of time against response. 
Steps 1-5 in the SOP are discussed above. 
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The two most important steps in characterising the kinetics of the protein-
protein interaction are the association and dissociation phase. Although it is not 
necessary to reach equilibrium for the kinetics to be characterised, it is 
recommended that the association times used are sufficient for at least one 
analyte concentration to reach steady state but in general, the response should 
reach less than 50% coverage to minimise co-operative binding and allow the 
simple Langmuir model to be an appropriate description (section 2.7). The rate 
of sampling is also important to characterise each phase of the kinetics with 
confidence; the dissociation phase is a slower process and therefore will require 
more time. To determine the dissociation rate a measurable decrease in signal, 
at least 3σ above the background noise, should occur during the dissociation 
period. This is not always possible because of the very slow rate of dissociation 
for some antibody – antigen complexes. 
2.6.1 Langmuirian Analysis of the Immuno-Kinetic Assay 
Understanding all of the contributions to possible errors in the data is essential 
to derive the best possible kinetic parameters. Ligand print variation is caused 
by a number of factors such as whether the proteins were printed directly over 
the nanoparticle spots or become denatured. Further, the efficiency of the 
surface activation via EDC/NHS must be considered, which in the literature is 
quoted as a common cause for failed immobilisations [161]. The effects of this 
variation can be limited by averaging over a number of spots functionalised with 
the same ligand. Figure 2.12 contains two panels, (A) is the individual response 
from 16 assay spots (two printed columns of 8 spots each), the variation in 
response between spots is significant but by averaging the response from all 8 
spots (B) produces a low high-signal-noise ratio kinetic response. From (A) 
there is one assay spot that is significantly weaker in its response compared to 
the rest (marked with an asterisk); this spot is removed from the averaged 
signal seen in (B). Averaging spots will also reduce the SNR by √ If the 
variations are random. 
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Figure 2.12. aCRP (5 nM) binding to protein A/G: (A) is the response from 16 individual assay 
spots, the asterisks represents the assay spot removed before averaging; (B) is the averaged 
response from the remaining 15 individual assay spots. 
Comparisons of individual spot performance may be made by using an area 
under the curve (AUC) analysis and the standard deviation for each spot 
derived from the 10 minute association phase (more details in section 2.6.1) 
and this can be used to assess the averaging efficiency. AUC is a good total 
measure of the performance of any one experiment. The AUC was derived 
using a numerical integration based on the trapezium rule programmed in 
Matlab. Figure 2.13 compares the AUC for 16 spots against the mean 
percentage error of all possible combinations of 2-spots, 3-spots, 4-spots etc, 
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when n < 16. This experiment was repeated twice to calculate the intra-assay 
variability (reproducibility), Figure 2.13. 
 
Figure 2.13. Percentage error from two standard deviations calculated from the AUC of aCRP (0.31 
nM) binding to PAG. The red bar at 16 represents the inter-assay variability. 
The error associated with repeating the same experiment over two arrays (intra-
assay error) from the same print was calculated at 2.76 % (shown at n = 16, 
red) and the number of spots required to keep the σ below 10% was 12 assay 
spots. It may be concluded that > 12 assay spots are optimum for both assay 
and control spots on the array indicating a 96-spot array should contain 8 
channels. The inter-assay variation can also be measure to predict the 
reproducibility of the response (Figure 2.14). 
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Figure 2.14. 16-spot averaged signal of CRP binding to protein aCRP. A range of four 
concentrations was used with a duplicate at each concentration. (a) = 2 nM; (b) = 0.5 nM; (c) = 0.15 
nM; and (d) = 0.01 nM. 
The AUC was measured for the association phases (0 – 15 minutes) presented 
in Figure 2.14 to assess their reproducibility. The mean CV over the 
concentration range was 1.2 ± 0.7%. This is an excellent inter-assay variability 
given that a standard commercial ELISA has a CV up to 10%. 
2.7 Langmuir Adsorption Isotherm – Determination of the 
Kinetic Parameters 
The shape of the association and dissociation kinetics is fundamental to the 
immune-kinetic assay and a non-end-point assay process. The standard model 
for filling a biosensor surface is that of the Langmuirian adsorption isotherm 
[162], it allows a surface with a finite number of binding sites to be filled over 
time in a 1:1 ratio. There are three assumptions in the Isotherm: (1) the 
adsorption cannot exceed a monolayer, (2) the binding surface is uniform and 
all sites on it are equivalent, (3) the occupation of neighbouring sites does not 
affect a given molecule’s ability to adsorb to a particular site (non-interaction).  
The simple 1:1 binding interaction model has two parameters: the association 
rate constant, "#, and the dissociation rate constant, "$. The association phase 
("#) should follow a simple exponential curve as the surface is filled up; this is a 
measure of the number occupied sites per unit time (M-1s-1). The dissociation 
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phase ("$) also follows a simple exponential curve but, unlike the association, is 
independent of analyte bulk concentration and has units (s-1). Another 
parameter is %& which is the theoretical maximum surface coverage and is 
equal to 1. In an experimental setting '& is used which represents the response 
of the sensor at maximum surface coverage and is linked with the number of 
active binding site present on the surface and measured as the change in RI 
induced by the total protein mass on the surface.  
The model is described in terms of a simple first-order differential equation: 
(%(
   "#)*+1  %   "$% 
Equation 2-5 
where % is the surface coverage, a fraction of the occupied binding sites; )*+ is 
the concentration of protein (antibody) in solution; and "# and "$ are the 
adsorption and desorption rate constants, respectively. The positive term on the 
right hand side describes the filling up of the number of binding sites on the 
sensor surface. The rate depends on the concentration of P, a rate constant 
and the number of remaining available sites, 1  %. The second, negative, 
term is the dissociation of the protein from the surface binding site and is a 
simple first-order decay process. The integrated rate equation is given by [79]:  
%
  '
'&  "#
)*+"#)*+ , "$ 1  exp "#)*+ , "$
 
Equation 2-6 
where '
 refers to the experimental observable, namely the change in 
scattered brightness. In the case of very strong interactions when the 
dissociation is negligible, "$ 0 "1)*+, Equation 2-6 can be reduced to the 
following single exponential form: 
' 2 '& 1  exp "#)*+
 
Equation 2-7 
2.7.1 Fitting 1:1 Binding Interaction Model – the Global Fit 
The best method for determining all of the parameters is to use the Langmurian 
Isotherm to model the data not from just one binding event at one concentration 
but simultaneously multiple concentrations in a process called here, a global fit. 
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The objective of the modelling is to derive the parameters "# and "$ from which 
the affinity constant can be derived providing information about the fundamental 
interaction between the surface binding to the analyte at )*+. The strength of the 
antibody – antigen interaction is characterised by the equilibrium dissociation 
constant or affinity constant (34), the concentration required to maintain half of 
the population in bound state [163], Equation 2-8: 
34  "$"# 
Equation 2-8 
Whilst, 34 can be derived from a single concentration, there are some 
advantages in using the multi-concentration analysis, global fit. The variation of 
association rate with concentration provides information on the association rate 
constant. For example, a faster on-rate produces a better estimate of '&, 
whereas at lower concentrations the association will be less polluted by co-
operative binding and matrix effects (discussed in section 2.8). By combining a 
number of concentrations, the confidence in the parameters of the analysis is 
greatly improved and the effect of the concentration can be removed. Figure 
2.15 represents a typical data used for the global fit process. 
 
Figure 2.15. Example of the typical data used for the global fitting process of time vs. response at a 
range of user-defined concentrations. The association phase measurement is the period of which 
the analyte concentration can interact with the surface and runs from tstart to tfinish; the dissociation 
phase measurement runs from tfinish for a length of time dependent on the lifetime of the complex. ϑm is defined as when the maximum surface coverage of all available active sites is achieved. 
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The association phase measurement runs from tstart – tfinish before the 
dissociation phase measurement begins. The measured concentration range is 
labelled as '&1 for the upper concentration, followed by '&2, 3, 4, as the 
concentrations measured decrease. The quality of the global fit analysis 
provides the accuracy of the 1:1 model and the confidence estimates of the 
kinetic parameters. Addition binding contributions such as from co-operative 
effects are observed in a poor quality of global fit suggesting a further model 
such as 2:1 might be required. The propagation of noises within the global fit 
analysis is key to understanding the optimum measurement timescales for the 
SOP.  
2.7.2 Error Propagation in the Global Fit Process 
The accuracy in the determination of the kinetic constants using the global 
fitting process was tested using simulated data. Gaussian noise was added 
from a random number generator to produce experimental data for four 
concentrations of analyte over typical experiments timescale. All the data 
presented in this analysis were derived with the following kinetic parameters: '& 
= 100%, "# = 1 × 104 M-1s-1, "$ = 5 × 10-5 s-1 corresponding to a 34 of 5 nM. The 
association phase ranged from 0 – 10 minutes, with the dissociation phase time 
scale from 10 – 20 minutes (unless otherwise stated). These constraints 
allowed parameters such as length of dissociation measurement to be 
optimised. The data were simulated at a range of concentrations following a 2-
fold dilution from 32 nM; Gaussian noise was added as 1% to '&.  
The first optimisation method was to simulate the data that allowed '& to be an 
adjustable parameter, with a limit of 5% between the concentrations; all other 
parameters are fixed. The variation of '& in the experimental data is typically 
less than 5%.  
Figure 2.16 shows a comparison of the model data global fit for the variation in 
'& between panels (A – C) where the variation is increased from 0.5%, 3% and 
5%, respectively. The lower panel confirms the simple percentage propagation 
of the error in the determined value of '& derived from the global fit. 
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Figure 2.16. Global fit to simulated data with parameters set at ϑm = 100, ka = 1 × 10-4, kd = 5 × 10-5. 
Panels (A-C) data are fitted with the global model where ϑm is allowed to vary by: (A) = 0.5%, (B) = 
3%, (C) = 5%; x-axis = time (min); y-axis = response. The lower panel summarises (A-C); x-axis = ϑm 
due to relaxing the constraints on ϑm variation (y-axis) in the global fit. 
The confidence in the other kinetic parameter, "# and "$, depends on the time 
over which the association and dissociation phases are measured. The 
association phase measurement length of 10 minutes ensures confidence in "# 
but the measurement time of the dissociation phase is critical. Figure 2.17 
shows how the fitted error in '&(A), "#(B) and "$(C), varies with length of time 
over which the dissociation phase is measured. (A) shows that the error in '& is 
independent of the measurement time of the dissociation. (B) "# is also 
independent of the measurement time. (C) shows the critical dependence of the 
measurement time in the uncertainty in determining "$. (D) shows the global fit 
to all of the data.  
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Figure 2.17. Model data for comparison of the fitted parameters with dissociation time variation, 
Association phase (0 – 10 mins), Dissociation phase (10 – 30 mins); Panel (a) – variation in ϑm with 
respect to duration dissociation time; Panel (b) – variation in ka with respect to length of 
dissociation time; Panel (c) – variation in kd with respect to length of dissociation time; Panel (d) – 
model data used for defining change in parameter with respect to dissociation time.  
The dissociation phase measurement time can be estimated from the value of 
"$ expressed as a half-life. Equation 2-9 is the single exponential decay 
function used for the fitting process: 

  :  exp "$
 
Equation 2-9 
where, : is the amplitude. The equation can be evaluated at 
/! when, 

/:  0.5, to calculate the half-life of the dissociation phase, Equation 2-10: 

/!   1"=  ln 2 
Equation 2-10 
Values of "$ typically range within 1 × 10-4 – 1 × 10-6 s-1, the corresponding half-
lives for these values are 2 – 190 hours, respectively. The length of time for the 
signal to exceed a 3σ (99.7% confidence limit) is given by Equation 2-11: 
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  1"$  ln @
'&'&  3σB 
Equation 2-11 
Using the same range of "$ values, the measurement time for the dissociation 
phase is 5 – 500 minutes, respectively. A simple rearrangement of Equation 
2-11 in terms of "$ can benefit the user, since if the SNR is known then the 
value of "$ statistical relevant can be calculated for a given time range, 
Equation 2-12: 
"$   1
CD1EFGDCDHI  ln @
'&'&  3σB 
Equation 2-12 
The effect of the dissociation phase measurement time for "$=1 x 10-4 s-1 is 
shown in Figure 2.17D. The simulated noise level of 1% produced an error in 
the determined value of "$ of up to 30% in the first 5 minutes, falling to ~5% 
after 10 minutes.  
2.7.1 Evaluation of the Goodness-of-Fit for the Global Fit Model 
A number of statistical measures can be used to access the goodness-of-fit of 
the 1:1 model using the global fitting process detailed above. The validity of the 
model and hence the confidence in the parameters describing the underlying 
process, require the model to be an accurate description of the underlying 
kinetics. The choices and analysis of statistical measures is the only way of 
assessing the suitability of the 1:1 model. Some statistical measures are useful 
for optimisation of the fit while others are useful for the comparison of fits 
between assays. Firstly, the initial estimate of the parameters must be 
reasonably close to the fit minimum so the fitting routines do not explore the 
extremes of parameter space. The initial parameters are chosen to correspond 
to concentrations in the nM range at, "# = 2 × 105 M-1s-1, "$ = 5 × 10-5 s-1, tstart = 
0 secs, tfinish = 600 secs, with '& depending on the individual assay response 
but is generally around 1-3 mRIU (see Figure 2.15). The fit is optimised by 
minimising χ2. Three statistical measures of goodness-of-fit are considered: χ2, 
the residual (µ ± σ) and the correlation matrix. 
Statistical analysis with χ2 answers the question of how well the model 
describes the experimental data. The test is performed using one of the best 
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known methods, Pearson’s χ2 test, by grouping the residuals data into 25 bins, 
calculating the observed and expected counts for those bins, and computing the 
χ2 test statistic: 
χ!  J KL  ML!ML
H
LN
 
Equation 2-13 
where  is the number of bins; KL are the observed values; and ML are the 
expected values. The number of bins was set at  = 25, this compares the test 
statistic to a chi-square distribution with   3 degrees of freedom, to take into 
account the two estimated parameters. 
The inverse dependence of χ2 on the SNR in the data, changes the 
interpretation of the goodness-of-fit statistic. There are two components to the 
noise that can be present in our collected data; a high frequency (HF) 
component (typical Gaussian noise) and low frequency (LF) component or 
‘base line drift’, more commonly associated with experimental effects such as 
temperature fluctuations, flow rate and LED power fluctuations. Figure 2.18 
highlights the effect noise has on χ2 by comparing six sets of ten randomly 
simulated assays with varied constraints on '&, LF and HF. Each value along 
the -axis corresponds to the following: 
1. HF = 1%, LF is fixed at 0 and '& is allowed to vary by 2%. 
2. HF = 1%, LF is allowed to vary by 1 × 10-4 % s-1 and '& is fixed at 100%. 
3. HF = 1%, LF is allowed to vary by 1 × 10-4 % s-1 and '& is allowed to 
vary by 2%. 
4. HF = 0.5%, LF is fixed at 0 and '& is allowed to vary by 2%. 
5. HF = 0.5%, LF is allowed to vary by 1 × 10-4 % s-1 and '& is fixed at 
100%. 
6. HF = 0.5%, LF is allowed to vary by 1 × 10-4 % s-1 and '& is allowed to 
vary by 2%. 
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Figure 2.18. Comparison of χ2 values with varied parameters for the randomly simulated data. x-
axis: 1 – 3 HF is set at 1%, 4 – 6 is set at 0.5%. ϑm is varied by 2% in data sets 1+3; LF is varied by 1 
× 10-4 % s-1 in data sets 2+4; and both ϑm and LF is varied in data sets 3+6. 
It is clear that the value of χ2 increases when the SNR level is lower as in Figure 
2.18 parameters 4-6 with lower HF present all have increases values of χ2. If LF 
noise is added, this too increases the values of χ2, the same trend is true for '&. 
From Figure 2.18, varied parameter 2 most closely resemble typical 
experimental data, we propose a new rule of thumb that states that the χ2 value 
must be below 300; the mean value plus the standard deviation (χ2 = 130 ± 
170). It is also interesting to see the effect LF can have on a data set, typical LF 
noise doesn’t not contribute over the assay measurement time, however if it we 
to significantly then this would affect the value of χ2. 
The approximations in the χ2 analysis suggest a simpler measure such as the 
residual, the difference between the observed and simulated values, which can 
be characterised by: 
1. The mean value of the residual. This value will determine if the model is 
consistently deviating from the data in one direction. The model is either 
over estimating or under estimating the fit. For a perfect fit µ = 0. 
2. The standard deviation of the residual. This value gives a good indication 
of the goodness of fit as a larger standard deviation will suggest an 
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incorrect model. If needed this value could also be determined over 
either the association or dissociation phase which would help more 
accurately predict where the model may fall apart. For a perfect fit 
σ(residual)  σ(HF noise). 
Residual analysis of σ will get progressively worse with increased noise and is a 
simple, useful parameter for comparing different data sets.  
Finally, the confidence in the fitted parameters depends on their correlation 
which is a measure of their purity and how well they are determined by the data. 
Many kinetic processes may be present in a complex model but the data may 
not be sensitive to all of them and this will be reflected in the off-diagonal 
elements of the correlation matrix: highly correlated parameters have a 
correlation coefficient of 1 and are not well determined; ideally correlation 
coefficient for independent parameters would be 0. The input parameters 
include "#, "$ and '&; with '& allowed to vary for each assay concentrations. 
The global fit and correlation matrix is shown in Figure 2.19. The simulated data 
presented in Figure 2.19A had '& set at 100 RU (arbitrary response units), a 
value of "# at 1 × 105 M-1s-1, "$ set at 5 × 105 s-1 and the HF noise at 0.5 RU. 
The goodness-of-fit parameters for a typical global fit to a 1: 1 model are 
summarised in Figure 2.19, a visual inspection of (A) shows that the fit for the 
model is very good, as expected from simulated data. The residual mean for the 
global fit is 0 ± 0.49 RU (B) which means the model does not over, or under 
estimate the data signified by the mean value of 0 RU and the model does at no 
point deviate from the data, as the error (±2σ) of the residual is the same as that 
of the noise, set at 0.5 RU, the value of χ2 is below the bin count of n = 25, used 
for deriving χ2. 
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Figure 2.19. Output from the global model using simulated data over six concentrations following a 
2-fold serial dilution. (A) Simulated immuno-kinetic assay data fitted with the global model; (B) is 
the residual plot for all concentrations in the global fit which shows the deviation of the model from 
the data; and (C) is the correlation matrix from the global fit procedure. 
The correlation matrix for the global fit, Figure 2.19C shows some very highly 
correlated parameters notably between "# and '&. The matrix compares the 
rate constants and the six values calculated for '& ranging from the highest 
concentration ('&1 to the lowest concentration ('&6, a 32-fold dilution. All 
values of '& converge on the simulated value of '& set at 100 RU. The high 
correlation with "# at low concentrations is only resolved with all 6 
concentrations fitted simultaneously. 
From the preceding global fit sensitivity analysis, an optimised SOP can be 
devised to produce the highest confidence in the kinetic parameters from a 
correctly corrected data set. The data should be collected with an array 
sensitivity (>300 %RIU-1) and reproducibility (< 10% CV). At least 6 
concentrations over a significant concentration range and fitted globally. The LF 
noise of the instrument should be minimised either by instrument design or 
effective use of reference channel subtraction, typically (put in the figure here) 
ka kd θm1 θm2 θm3 θm4 θm5 θm6
ka 1.00 -0.47 -0.96 -0.97 -0.96 -0.92 -0.79 -0.57
kd -0.47 1.00 0.62 0.58 0.56 0.52 0.45 0.32
θm1 -0.96 0.62 1.00 0.96 0.95 0.90 0.78 0.56
θm2 -0.97 0.58 0.96 1.00 0.95 0.91 0.78 0.56
θm3 -0.96 0.56 0.95 0.95 1.00 0.89 0.77 0.56
θm4 -0.92 0.52 0.90 0.91 0.89 1.00 0.74 0.53
θm5 -0.79 0.45 0.78 0.78 0.77 0.74 1.00 0.46
θm6 -0.57 0.32 0.56 0.56 0.56 0.53 0.46 1.00
0 10 20 30
0
20
40
60
80
re
sp
on
se
 
(R
U)
time (min)
0 10 20 30
-2
-1
0
1
2
re
si
du
al
 
(R
U)
time (min)
A B
C
Residual (mean ± 2SD) = 0 ± 0.49 RU
Χ2 = 20
Chapter 2 
55 
 
The association phase should be measured for 10 minutes and the dissociation 
phase measurement length of at least 10 minutes but extended to 20 minutes if 
the initial estimates of "$ are < 10-5. The global fit measured with goodness-of-
fit analysis is important for both defining the extracted parameters and for χ2 < 
300 depending on the SNR for the assays. A simple comparison between fits is 
possible with a residuals analysis and the correlation matrix used to derive the 
correlation coefficients and errors and confidence limits for the parameters. A 
poor goodness-of-fit parameter may point to the 1:1 model being inadequate 
and new processes may need to be considered. 
2.8 Deviations from the 1:1 Binding Interaction Model 
The dominant confounding factors that are not well modelled by the 1:1 binding 
interaction model are non-specific binding [85], mass transport limitations [164], 
aggregation of analyte at the surface and multiple binding to the surface or 
surface avidity [83]. These factors begin to address the known concerns with 
interpreting assays in complex media such as matrix effects and dilution [165]. 
However, dilution is dependent on the target concentration and the appropriate 
level is not always possible. For point-of-care testing, limiting sample 
preparations steps is vital; some of these effects, such as non-specific binding, 
can be separated from the high affinity specific interactions easier than other 
pollution events.  
2.8.1 Reducing Non-Specific Binding 
Specific binding is characterised by having a strong affinity between analyte and 
ligand, typically these association rate constants are in the order of 105-106 M-
1s-1 [166]. Non-specific binding (NSB) may be defined as any kinetic interactions 
with an affinity of less than 10-7 M [167]. In an ideal experiment, analyte is 
flowed over the surface and the only response should come from the specific 
target with no binding of any background proteins; assay ‘specificity’. While 
discrete nonspecific protein-protein interactions (e.g., hydrophobic, electrostatic, 
van der Waals) are weak when compared to specific antibody-antigen binding, 
they still present a problem when analysing specific antibody-antigen 
interactions [167]. 
A good example of NSB is highlighted by the work of Leo Vroman [168] who 
studied how proteins in blood plasma adsorb to surfaces. He found that proteins 
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such as fibrinogen (Fbr) show no specific interaction with a surface like glass 
but adsorb to a microscope slide nevertheless. Firstly, Fbr is a large protein and 
has more points of contact with a surface [169]. Secondly, protein adsorption is 
also greatly influenced by the charge and distribution of charges on the surface 
of the protein molecule. Adsorption also depends on the stability of the protein 
structure; unfolding of a protein structure can lead to increased conformational 
freedom of the peptide chain and also make more sites available for protein-
surface contacts [170]. 
Methods used to reduce NSB in binding interactions studies include the use of a 
SAM layer, as this increases the coating of the reference protein meaning that 
there are no remaining spaces for the protein to bind. The –OH groups present 
on the SAM linker molecules also create a hydrophilic coating over the 
remaining surface for which proteins tend to adsorb less readily with [171]. The 
addition of a blocking agent [172] filling all the un-functionalised sites on the 
sensor surface can help. Bovine serum albumin (BSA) is commonly found in 
commercial buffers as a blocking agent but as BSA is often present as a control 
channel in our assays then human serum albumin (HSA) can be used as an 
alternative. Surfactants can be added to the running buffer which can aid in the 
reduction NSB. The non-ionic polyoxyethylene surfactant polysorbate 20 
(Tween 20) is widely employed in immunoassays, AFM, and SPR to reduce 
nonspecific adsorption of proteins due to hydrophobic interactions [167, 173]. 
Tween 20 is added to all our binding interaction studies at 5 x10-5% (w/v). 
Another method for eliminating the effect of NSB is the subtraction of a 
reference channel from a sample channel. There is however an assumption that 
the NSB effects in the reference channel are the same as in the sample 
channels. The reference channel also allows for the effects of change in bulk 
RI, temperature dependence and electronic instrumental instabilities to be 
removed. Nevertheless, it remains a significant challenge to remove all of the 
effects from complex fluids such as serum by subtraction. We have discovered 
that a high-surface concentration of Fbr (2 mg/mL) cover the reference spots 
fully and provide a very resilient control channel with low NSB. The subtraction 
method is shown in Figure 2.20 showing both data before and after subtraction 
of the Fbr reference. 
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Figure 2.20. Effectiveness of the Fbr reference subtraction. (A) raw data of the assay (red) and 
control (black) response; with the control subtracted from the assay channel in (B). Baseline 
collected: -4 – 0 mins; association phase: 0 – 10 mins; dissociation phase: 10+ mins. 
NSB issues with serum samples are still a problem but are helped by the fact 
that the solutions are diluted in the range of 25 – 150,000-fold depending on the 
assay design. If complex samples are not suitably diluted it can lead to matrix 
effects at the assay surface.  
We performed some studies using the chaotrope, potassium thiocyanate 
(KSCN) to reduce NBS in complex samples and have published this study 
(Appendix C) [174]. In brief, the study addressed the problem of clinical 
variation of HSA in patient serum samples; and the effect on the specificity and 
sensitivity of the immuno-kinetic assay. The use of a chaotropic agent present 
in the buffer solution of complex media could alter bulk protein-protein 
interactions by surrounding the proteins with a highly charged layer [175]; this is 
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turn could aid the interaction of the target analyte with the surface antigen. The 
study concluded that the addition of the KSCN chaotrope somewhat improves 
the integrity and accuracy of the assay although there is a slight reduction in 
LOD. A surface event that cannot be removed and is a fundamental interaction 
for many antibodies is avidity.  
2.8.2 Surface Avidity 
An assumption of the 1:1 complex formation model is the presence of one 
binding site on the surface. The antibody is however bi-dentate with two Fab 
regions which may, in principle, bind to the surface either sequentially or 
simultaneously. Affinity is the interaction between one Fab region and the 
binding site; avidity allows for more than one specific interaction and can be 
thought of as a 1:2 interaction. 
The binding of a bivalent analyte to the ligand initially follows the standard 
pseudo-first-order model but it is possible for the second Fab arm to bind to an 
epitope if it is in the correct proximity [176]. Figure 2.21 compares the binding of 
an antibody to an antigen with multiple epitopes; (A) is an example of a 1:1 
binding interaction model of a polyclonal analyte as there are more than one 
form of epitope present on the antigen, however no avidity occurs; (B) could be 
either polyclonal or monoclonal due to the repeated epitope on the surface and 
shows the presence of avidity.  
 
Figure 2.21. Comparison of antibodies binding to a multivalent antigen. (A) has a variety of unique 
epitopes resulting in no avidity; whereas (B) has repeating epitopes that avidity is possible. 
multivalent antigen 
with different epitopes
multivalent antigen 
with a repeated epitope
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Avidity is evident in the dissociation phase as these multi-bound molecules will 
have drastically different dissociation kinetics. The half-life can become 
essentially infinite and for the molecule to dissociate both binding site must 
detach at the same moment [177]. Avidity is, therefore, derived as the product 
of the two affinity constants or the sum of the two interaction energies and not a 
simple sum of their affinities, Equation 2-14: 
2)AbR#S+ , )Ag+   34,    34,! 
Equation 2-14 
The formation of the secondary binding will depend on the flexibility of the 
analyte and ligand; and also the availability of free ligand [178]. We routinely 
used antibody screening methods so avidity could take place, however as our 
data fit the 1:1 binding interaction model well the affect avidity may have on the 
analysis is small. A final surface event is the mass transport effect, which is a 
fluidics based problem affecting the initial surface analyte concentration. 
2.8.3 Mass Transport Effects 
Binding of analyte to ligand at the sensor surface is a two step process. Firstly, 
the analyte is transferred out of the bulk solution towards the sensor surface. 
Secondly, the binding event takes place. The first step is called mass 
transport/transfer and is controlled by both convection and diffusion and also 
electrostatic acceleration [179, 180]. Mass transport depends on the flow cell 
dimensions, the diffusion coefficient of the analyte and the flow rate of the bulk 
solution [180]. If mass transport is not addressed by optimising the flow rate, the 
diffusion from the bulk solution to the surface interface is slower than the rate of 
binding of the analyte to the ligand, reducing the effective surface concentration; 
the opposite will be true for the dissociation phase. Therefore, calculated kinetic 
constants with partial mass transport reflect the rate of mass transport rather 
than the true binding kinetics. A way of minimising mass transport effects is to 
increase the rate of flow to at least 50 µL min-1 [173]. A paper previously 
published by Shaw’s lab [77] found that mass transport was predominately 
eliminated at a flow rate of >20 µL min-1, however to be confident, especially 
when using complex samples the flow rate was kept above 100 µL min-1 at all 
times. 
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2.9 Performance of the Array Reader Technology – Conclusions 
Throughout this chapter I have discussed problems and potential solutions for 
analysis of purified and complex protein samples on SPR platforms. SOPs have 
been developed and optimise to produce reliable data from the Langmuir model 
and remove events that may pollute the 1:1 binding interaction model. 
From the SOPs devised in this chapter, the AR platform is comparable to ELISA 
assay in terms of reproducibility and accuracy. The AR, is however, capable of 
multiplex detections with up to 8 assays of 12-spots possible on a 96-spot array 
allowing for 2 reference channels of 12-spots each. The effects of HF have 
been investigated and generally will average away, or can be normalised for. LF 
noise is a bigger issue as if the rate is comparable to the measured kinetics 
then they cannot be determined but the subtraction process is a very useful 
method to remove this effect.  
Complex samples will always provide a source of pollution for the model, 
sample dilution was suggested as a method to remove undesirable event at the 
sensor surface. However, this is not always possible due to low target analyte 
concentration. An approach to this problem can be by using amplification 
methods to enhance a small signal, improving the LOD. Chapter 3 presents a 
novel method of signal amplification by using two mutually specific antibodies to 
form a polymerising bio-stack on top of the primary signal to act as an 
amplification technique. The bio-stack method is also used to measure the 
penetration depth of the AR; a characteristic that is known to be smaller in 
LSPR compared to SPR. The smaller penetration depth can offer other 
advantages when analysing serum as the smaller plasmon field means the 
sensor is less susceptible to “bio-noise” from background proteins flowing just 
above the surface, improving our noise and therefore also our detection limit. 
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3 Assay Enhancement and Amplification Based 
on an Antibody Bio-Stack Technique 
3.1 Introduction 
The previous chapter discussed the optimisation of the Array Reader platform 
both in experimental design and data analysis procedures, by determining the 
immuno-kinetic assay performance metrics in buffered and complex solutions. A 
further method devised to improve the sensitivity and reduce NSB by the 
addition of a chaotropic agent, potassium thiocyanate, was explored but offered 
mixed results and did not improve assay performance significantly. However, 
two new strategies will be considered here to maximise our detection limit and 
optimise the analysis of complex fluids: characterising the intrinsic properties of 
the nanoparticles plasmon field and an antibody bio-stack amplification 
technique. 
Methods of signal amplification in SPR have been explored to reduce the low-
mass limit of the technique and to make small molecule detection viable, such 
as metabolites for label-free analysis [181]. Ideally, the targeted analyte must be 
detectable in complex media such as serum and even whole blood [182] where 
large concentrations of background/non-specific proteins are present, such 
albumen, which accounts for ≈ 50% of serum protein content [183]. The 
concentration of different components in the blood proteome ranges over 10 
orders of magnitude from the low-concentration, low-mass cytokines to high-
mass, high concentrations proteins such as antibodies, Complement and serum 
albumin [184, 185]. SPR assays can detect antibodies or high-mass biomarkers 
(macromolecules) in the nanomolar to picomolar range but at lower 
concentrations NSB becomes a significant challenge [182]. 
3.1.1 Limits of Detection for SPR Instruments 
In Chapter 2, the LOD was defined in terms of the concentration needed to 
produce a signal equivalent to two or three times the standard deviation of a 
series of blank (baseline) measurements. In this context, the sensing 
capabilities of the AR are assay dependant but are usually around 0.1 – 1 nM 
for antibody-antigen interactions. There are however, other ways to think about 
the detection limit, it’s mass and rate dependence. 
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SPR is by definition a mass sensing technique and therefore relies on the mass 
of the analyte binding to the surface to produce the change in the local RI and 
hence, signal. For a target analyte that has a low mass, the binding event may 
be undetectable. Antibody screening assays are based on an analyte with a 
typically mass of 150 kDa, if the analyte had a mass of only 15 kDa then the 
concentration would need to be 10× that to produce a similar response.Given 
the available surface binding sites, it is unlikely that 10× the number of 
molecules would be able to bind to the sensor surface [85, 186]. For this reason 
SPR biosensors are generally focussed on monitoring macromolecule 
interactions. The low-mass limit of SPR platforms is now improving as result of 
the optimisation of the signal-to-noise ratio (SNR) and the sample delivery. In 
2002 BIAcore released the BIAcore S51, this platform was designed with the 
focus on small molecule detection and resulted in a platform capable of 
detecting an analyte with a mass of less than 90 Da [51]. 
The final definition of LOD, is linked to the kinetic interactions and is the ability 
to detect very fast or very slow binding events, or very low- or high- affinity 
interactions. Typically SPR platforms can measure interactions in the range of 
102 – 108 M-1s-1 for association rate constants, and 1 – 10-6 s-1 for dissociation 
constants [164]. For example a slow dissociation rate constant in the order of 
10-6 s-1 will require a long period of time, days in fact, to determine the kinetics 
and this length of time is far greater than the instrument stability, with low 
frequency noise (baseline drift) dominating the response over this time scale. 
3.1.2 Continuous vs. Particle: Instrument Contrast 
As the predecessor to LSPR, SPR sensors currently dominate commercial 
instrumentation, LSPR offers many of the same advantages for biosensing with 
some limitations and key advantages for complex media [67, 187], summarised 
in Table 3-1.  
A physical difference between the two sensors is the size of the sensing area, 
generally SPR based sensors are at least 10 × 10 µm in area. LSPR sensors 
are capable of being a single nanoparticle in size (the smallest being 20 nm) 
[188]. The use of a smaller sized footprint and the flexibility in the layout and 
design of LSPR sensors make multiplex experiments far easier on this platform 
compared to SPR where a continuous surface is required.  
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Table 3-1. Comparison of SPR and LSPR sensors. Adapted from Haes 2004 [189]. 
Feature / Characteristic SPR LSPR 
Label-free detection Yes Yes 
Distance dependence (ld) ≈ 1,000 nm ≈ 30 nm 
Refractive index sensitivity 2 × 106 nm RIU-1 2 × 102 nm RIU-1 
Modes of detection 
Angle shift, wavelength 
shift, imagine 
imaging 
Temperature control Yes No 
Field portability No Yes 
Commercially available Yes No 
Cost US $150,000 – 300,000 
US $5,000 (multiple 
particles), US $50,000 
(single nanoparticle) 
Spatial resolution ≈ 10 × 10 µm 1 nanoparticle 
Non-specific binding Minimal Minimal 
Real-time detection 
Time scale = 10-1 – 103 
secs, planar diffusion 
Time scale = 10-1 – 103 
secs, radial diffusion 
Multiplexed capabilities 400 channels 
5000 channels tested so 
far 
Low-mass limit 
(concentration dependant) 90 Da ≈ 1 kDa 
Microfluidics compatibility Yes Yes 
 
There is also a comparative difference in RI sensitivities and the characteristic 
electromagnetic field decay lengths. SPR sensors exhibit large RI sensitivities 
(2 × 106 nm RIU-1) [68], the LSPR sensor on the other hand has a modest RI 
sensitivity of (2 × 102 nm RIU-1) [190]. However, even with four orders of 
magnitude apparent difference in sensitivity, it is not always the case and the 
two sensors are more comparable in their sensitivities due to the short (and 
tuneable) characteristic electromagnetic field decay length, penetration depth 
(ld), which provides the LSPR sensor with its enhanced sensitivity [191, 192]. 
3.1.3 Continuous Surface vs Particle: Assay Contrast 
A biosensing event measures a change in the plasmon field [146, 193]. The 
interaction of the plasmon field, through the polarisability of the adsorbing 
species, correlates directly with the mass and composition by penetrating into 
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the medium above a gold surface. The plasmon field decays exponentially into 
the medium with a characteristic penetration depth falling by 1/e of its initial 
surface value, U= (Figure 3.1).  
 
Figure 3.1. The fundamentals of SPR vs LSPR. The decay of the plasmon field is greater on the 
LSPR (Array Reader) platform leading to a faster decrease in the observed sensor response [69]. 
The radiation intensity is the square of the electric field strength and therefore it 
decays with distance normal to the surface, V given by, exp  2V U$⁄ . The 
average probed refractive index < W> can be calculated with the depth integral 
as:  
XWY  2 U$⁄ Z WV exp 2V U$⁄  dV\]  
Equation 3-1 
where WV is the RI at height V normal to the surface [68]. The integration of 
Equation 3-1, assuming WV  W#^#_`ab within a layer of analyte and WV 
WSc_d above it, gives the plasmonic sensor response [68], R: 
  e∆W1  g  2(/U$ 
Equation 3-2 
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where e is sensor sensitivity ∆/∆h to changes in the bulk refractive index, 
∆W is the difference of bulk and analyte refractive indexes and ( is the thickness 
of the adsorbed layer. When the analyte layer is composed of a number of 
individual sub-layers (    (L, where n is the number of adsorbed sub-layers 
of characteristic thickness (L. 
From Equation 3-2 it follows that bio-assays in complex media on continuous 
surfaces, where U$>>(, are vulnerable to bio-noise, within the plasmon field 
above the 10 nm associated with the surface-bound assay. By contrast, gold 
nanoparticles have a smaller U$, comparable with (, so the sensing volume 
overlaps the bio-assay more precisely. Consequently, LSPR methods have a 
significant advantage in the analysis of complex fluids such as whole blood and 
serum [70]. The sensing of bio-noise due to the platform penetration depth is 
the main disadvantage that SRP systems have compared to LSPR systems. 
3.1.4 Bio-Noise Amplification  
Any bio-noise contribution to the plasmon field will have a direct effect on the 
sensitivity and specificity of the sensor, reducing the SNR and limit of detection. 
Yonzon et al. demonstrated the impact of these sensing volume differences in a 
study describing the binding of Concanavalin A to saccharide monolayers [187, 
194]. SPR and LSPR sensors functionalised with either mannose or galactose 
were exposed to micromolar concentrations of the lectin-binding protein 
Concanavalin A. During the dissociation phase, the SPR signal decreased by 
60%, while the LSPR signal decreased by only 14%. The larger signal decrease 
for the SPR sensor can be explained by the fact that a larger fraction of the 
SPR response arises from bulk media changes due to its relatively long EM 
field decay length, or penetration depth (Figure 3.2). 
 
Figure 3.2. Response of the same analyte injection on both an SPR and LSPR platform as a 
comparison of the difference in signal decrease from the dissociation phase attributed to the bulk 
effect contribution. 
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By controlling the U$, and therefore the effect the complex fluid will have on the 
assay sensitivity, the LOD can remain unpolluted from the higher RI of the 
sample above. The U$ parameter is dependent on the nanoparticle composition, 
shape and size [194]. The fundamental importance of U$ for LSPR studies has 
prompted many attempts to measure it experimentally by depositing various 
material layers of known thickness (aluminium oxide, alkanethiols, 
polyelectrolytes) onto the nanoparticles while monitoring the sensor response 
[195-197]. There are many uncertainties in these methods including the effect of 
the choice of coating material perturbing and independent measures of the layer 
thickness. The penetration depth also depends on the polarisabilty of the 
material in the plasmon field and the measurement clearly perturbs the value 
obtained. It suggests U$ should be measured with a biomaterial similar to the 
composition of the assay.  
Once the intrinsic sensitivity of the particles and the plasmon field sampling 
volume have been optimised for LSPR, it has a higher LOD and cannot match 
the sensitivity of the fluorescence-based labelled techniques suggesting the 
need for some signal amplification methods. The benchmark technique for 
laboratory measurement of biomarkers are ELISA assays, which are 
reproducible, reliable and are subject to considerable quality control procedures 
but are not suitable for multiplex detection of many targets within an individual 
sample [198, 199]. This concern becomes especially acute when there is only a 
limited quantity of biological sample. Difficulties are also faced when comparing 
levels measured by two different ELISA assays, each under somewhat different 
conditions. Further, a major limitation of ELISA-based assays is the dynamic 
range in which the target molecule concentration must fall within, requiring 
careful dilution for each sample preparation [200]. 
3.1.5 Amplification Techniques in LSPR 
The sensitivity of SPR techniques depends principally on the detection of the 
smallest possible change in the optical properties of the plasmon associated 
with the change in the local RI. Different techniques have been used based on 
intensity measures [193], angle changes [201], interferometry [202] and phase 
changes, with a minimum detectable change in the RI typically of 10-5-10-6 with 
Chapter 3 
67 
 
some differential phase techniques able to detect 10-7 routinely [203, 204]. 
There have been a number of modifications to increase the sensitivity by the 
construction of tailored Au surfaces such as nanohole arrays [205] and 
additional amplification steps. The unusual optical transmission characteristics 
of nanoholes arrays can be used to achieve a sensitivity ten times that of prism-
based SPR, proven by Ji et al [206]. Haes and Van Duyne [207] used biotin 
functionalised gold nanoparticles exposed to 100 nM streptavidin, this caused a 
LSPR λmax shift of 83 nm, compared to a 27 nm shift for streptavidin alone; an 
enhancement of 300%. Whilst in many cases the novel surfaces offer extreme 
enhancements in the electric field, the quantification of assays depends critically 
on the reproducibility of the surface fabrication and the uniformity of the 
enhancement structures. 
One amplification technique is to label a secondary antibody with gold 
nanoparticles, resulting in a high molecular weight adsorbing species, giving 
larger changes in refractive index, and hence a bigger signal [208]. The first 
reported use of gold nanoparticle-labelled secondary antibodies for SPR 
response enhancement was described by Buckle et al., in 1993 [209]. Human 
serum albumin (HSA) proteins were electrostatically conjugated to gold colloids, 
and then exposed to an SPR surface functionalised with aHSA antibodies. The 
detection limit for this assay was improved 1,000-fold lower compared to the 
nanoparticle-free assay, presumably linked with the increased analyte mass. 
Hall et al. [210] also demonstrated increased observed response from LSPR 
sensors and improved limits of detection of analytes using gold nanoparticle-
labelled antibodies. Their work suggests that using nanoparticle-labelled 
antibodies can increase the LSPR sensitivity by up to 400%, compared with the 
antibody alone. This corresponds to an antibiotin antibody detection limit of 6 
pM. The overall increase in the change in the RI is due to the increased mass of 
the gold nanoparticle and additionally, plasmonic coupling between the gold 
nanoparticle label and the nanoprism substrate [210]. 
The future of biomarker analysis requires the use of multiplex formats, where 
many biomarkers may be measured simultaneously. Array formats for 
fluorescence based techniques for gene expression analysis and protein 
microarrays are now commonplace but subject to the same semi-quantitative 
analysis problems. Given the large overhead in the preparation of materials for 
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the array, a qualitative measurement seems an unacceptable waste of 
materials. To continue to exploit the data rich immuno-kinetic assay arrays, 
methods of improving the limit of detection are required.  
Here, we present a method of signal amplification which can be used 
simultaneously to determine the penetration depth of the plasmon field directly 
from a biological immuno-assay and improve the LOD. Two mutually specific 
antibodies are involved in a stepwise polymerization process to produce a 
multilayer surface with controlled, repeating step sizes and known layer 
thickness. A sequence of goat-anti-rabbit-IgG and rabbit-anti-goat-IgG allows 
alternating layers of the antibodies to form a bio-stack on top of a PAG 
functionalised surface. The increase in the locally deposited mass directly 
improves the assay sensitivity. The useful number of amplification steps, n, is 
limited by the amplification of noise, signal and specific and non-specific affinity. 
3.2 Aims and Objectives 
The potential of the array reader technology to be applied to a larger proportion 
of the proteins in the blood proteome requires the detection limit to be improved 
from the nM for antibodies to pM and/or reducing the mass limit. To this end, a 
series of amplification studies has been performed resulting in a new 
amplification technique and a method for the determination of the plasmon field 
penetration depth of the nanoparticles. The aim of this chapter is to: 
Improve the limit of detection of the array platform assays and reduce the low-
mass limit of SPR techniques using an antibody oligomerisation, bio-stacking 
event. 
The objectives are to construct an antibody screening array using the Fc-
specific binding protein, protein A/G (PAG), to produce an oriented antibody 
array. PAG is at the heart of many studies presented in this thesis and can bind 
up to six antibodies via the Fc region in solution [211]; this is discussed in great 
detail in Chapter 4. From the PAG surface, two anti-IgG from different animals, 
goat-anti-sheep and sheep-anti-goat, that stack mutually specifically on one 
another, are used to form a bio-stack. 
The amplification is achieved by using the bio-stack technique to increase the 
specific binding mass, comparing the results between the AR LSPR platform 
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and continuous surface SensiQ platform. Differences between the signals 
derived from the two platforms can then be used to assess the role of the 
penetration depth from the two configurations in determining the limits of the 
bio-stack amplification process. 
The performance of the bio-stack amplification technique is assessed in a 
clinical application, for the identification and amplification of specific binding 
proteins in patients with known peanut allergy. The effect on the LOD can then 
be discussed and compared to the buffered study. 
3.3 Materials  
All materials were obtained from Sigma Aldrich and used without further 
purification unless otherwise stated: N-(3-Dimethylaminopropyl)-N'-
ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), bovine 
serum albumin (BSA, 98%), and human fibrinogen (60% with 40% buffer salts; 
the protein content is >80% clottable fibrinogen). Recombinant protein A/G was 
supplied from Pierce. Rabbit polyclonal antibody to goat IgG-H&L-HRP (rabbit-
anti-goat-IgG), and goat polyclonal antibody to rabbit IgG-H&L-HRP (goat-anti-
rabbit-IgG) were supplied by Abcam and used without modification.  
Raw allergens proteins: defatted ground peanut, cat dander, dog dander, and 
sifted mite samples were obtained from Allergon AB. The serum sample was 
obtained from a patient who had tested positive for peanut allergy by specific 
IgE using the Phadia ImmunoCap system in the laboratory at Derriford Hospital, 
Plymouth. The sample was classed as RAST grade 5. 
3.4 Experimental Methods 
The experiments on the amplification techniques were performed on two 
platforms: the continuous gold surface platform made by SensiQ (discussed in 
section 3.4.2 below) and the in-house Array Reader platform. The sets of 
experiments on the continuous and nanoparticle based platforms followed a 
standard procedure and injection sequence similar to that defined in Chapter 2. 
Here PBS buffer is passed over the sensor surface until a stable baseline is 
obtained. The first injected antibody is captured by protein A/G resulting in the 
primary response. Subsequent n analyte injections alternating between rabbit-
anti-goat-IgG and goat-anti-rabbit-IgG result in the growth of a [IgG]n polymer 
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chain stacking away from the surface (n=9 for the AR and n=25 for the SensiQ). 
The analytes were injected over the sensor surfaces for either 10 minutes, at a 
flow rate of 25 µL min-1 and a concentration of 100 nM (SensiQ), or for 20 
minutes at 100 µL min-1 with a concentration of 50 nM (AR). The intermittent 
PBS wash steps allowed only specific, high-affinity binding of the antibodies to 
their respective epitopes maintaining the 3D-integrity of the bio-stack. After the 
binding experiment was complete the surface was regenerated with a 4 minute 
long injection of 10 mM hydrochloric acid (HCl).  
3.4.1 Array Reader Particle Plasmon Surface 
The array preparation is as detailed in Chapter 2 however the shape and size of 
the nanoparticles is critical to this study and further optical characterisation was 
performed. SEM images of the sensor surface were used, from which the 
nanoparticle mean size and standard deviation were derived (mean ± σ); two 
example SEM images can be seen in Figure 3.3. The spherical particles 
diameter distribution had a mean and standard deviation of 90 ± 13 nm, with the 
disc particles having a diameter of 147 ± 17 nm. The rod-shaped particles are 
characterised by the length × width of 250 ± 60 nm × 65 ± 15 nm. The 
nanoparticle density was calculated at 1 nanoparticle per 220 ± 60 nm2. The 
proportion of the three distinct shapes was: spherical nanoparticles (85%), rod 
shaped nanoparticles (10%) and flatter disc shaped nanoparticles (5%). 
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Figure 3.3. SEM images of the gold nanoparticle surface. A total of five images were used to derive 
the nanoparticle mean size and standard deviation. 
The standard arrays were functionalised using Lomant’s activation, discussed in 
Chapter 2, and were functionalised according to the array keys presented in 
Figure 3.4. 
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Figure 3.4. Array functionalisation key for; (A) the purified antibody study; (B) the serum study. 
Antigen proteins were printed along with Fibrinogen and BSA control spots 
surfaces, with the rest as specific assay spots.  
3.4.2 SensiQ Propagating Plasmon Surface 
The continuous gold surface platform produced by SensiQ Technologies 
(Oklahoma City, USA) is called the SensiQ Discovery (Model – 200). This SPR 
platform uses a continuous Au surface interrogated at fixed wavelength (860 
nm) with a detector array that monitors a range of reflection angles (62 – 74 
degrees) to determine the minimum in reflected light intensity. The change in 
angle is given by Equation 3-3: 
i%j   k1i , c2i( 
Equation 3-3 
the constants c1 and c2 relate the SPR angle at a given wavelength λ to the 
change in refractive index, n, at the surface and the change in thickness, d, of 
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the surface layer [212]. The change in RI within the plasmon field alters the 
SPR angle, which is detected and generates the signal. Like many other SPR 
devices the SensiQ contains two channels providing an assay surface to detect 
the target analyte and a control surface to act as a reference channel. 
The proteins (PAG and Fbr) were immobilised on the sample and reference 
channels of the SensiQ chip by conventional peptide coupling. The SensiQ 
chips used were carboxylated COOH1 biosensors supplied by Labtech. Once 
installed, the sensor surfaces were first cleaned with 10 mM HCl solution for 10 
minutes at 10 µL min-1. The carboxyl groups were activated with 5/25 mM 
NHS/EDC aqueous solution, injected for 4 minutes at a rate of 50 µL min-1, 
forming amine-reactive succinimide ester groups. Immediately after the 
activation step, 2 mg mL-1 solutions of recombinant PAG and fibrinogen in 10 
mM sodium acetate buffer (pH 4.9) were injected at a flow rate of 5 µL min-1 for 
50 minutes. Following the protein immobilisation step, both surfaces were 
capped with 1 M ethanolamine, and after a 10 mM HCl wash, the running buffer 
was changed to PBS.  
3.5 Results 
Two mutually specific antibodies were used to form a polymerised bio-stack for 
a sequence of amplification steps for both purified buffered samples and 
clinically relevant samples for the identification of peanut allergy. The buffered 
sample experiments were performed on the nanoparticle based LSPR Array 
Reader and the continuous surface SPR SensiQ platform for comparison. 
3.5.1 Antibody Amplification Bio-Stacking 
A series of experiments was performed to study the effect of the antibody chain 
amplification on the two detection platforms to assess the degree of specific and 
non-specific amplification using the bio-stack process. Analyte solutions of 50 
nM IgG (AR) and 100 nM IgG (SensiQ) were prepared in PBS and injected over 
the respective sensing surfaces. A 20 minute association phase, followed by a 
10 minute dissociation phase was performed on the AR. On the SensiQ, where 
the concentration was doubled, the injection time was halved to allow the larger 
number of injections (10 minute association phase, 5 minute dissociation 
phase). The reason to half the injection was to reduce the effect of LF noise by 
minimising the assay time necessary. 
Chapter 3 
74 
 
To begin with, the bio-stack sequence was alternated to compare the relative 
affinities of both rabbit-anti-goat-IgG (rabbit-stack) and goat-anti-rabbit-IgG 
(goat-stack) antibodies to the initial PAG surface. The primary response would 
allow us to distinguish between the binding in the first amplification step (second 
antibody injection) to either the immobilised protein or the IgG molecules non-
specifically bound to the surface after the primary injection; therefore, to show 
that the stack is not dependent on the starting antibody injection.  
 
Figure 3.5. Dependence of specific and non-specific binding during the primary and the first 
amplification steps on the choice of the primary analyte antibody observed in AR experiments: 
panel (A), goat-anti-rabbit-IgG. Panel (B), rabbit-anti-goat-IgG. Both experiments ware started with a 
fresh clean surface. The sensor channels are: (a) PAG, specific; (b) fibrinogen, non-specific and (c) 
BSA, non-specific.  
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The association and dissociation kinetics for each of the two antibodies to the 
PAG Fc binding surface is shown in Figure 3.5: goat-stack has better specificity 
for the PAG surface compared to rabbit-stack, which shows NSB to the 
reference fibrinogen and BSA proteins resulting in the deposition of antibodies 
on both channels in the first amplification step. The smaller NSB in the primary 
step of the goat-stack will delay the coating of these reference surfaces with 
specific IgG, hence leading to a better overall amplification performance over a 
larger n range before the amplification returns diminish. The binding of rabbit-
anti-goat-IgG to BSA and to a small extent Fbr, is surprising as these proteins 
are regularly used as a blocking agent for Western blots and 
immunohistochemistry. However, it has been suggested that BSA can contain 
trace amounts of bovine IgG [213] and many secondary antibodies, including 
anti-goat-IgG, can interact with bovine IgG due to sequence homology [214] – 
this could explain why a response was seen. 
The overall specific signal is ≈ 30% smaller for the goat-IgG compared to the 
rabbit-IgG, a reason for this may be linked with the properties of the PAG 
(discussed in detail in Chapter 4). PAG is a fusion protein of proteins A and G, 
comprising of four IgG binding sites from protein A and two from protein G 
[215]. Both goat and rabbit antibodies have a strong affinity (34) with PAG, and 
protein G, however, goat-IgG does not bind to protein A [216] and therefore has 
a reduced number of binding sites on the PAG surface resulting in a lower 
surface coverage.  
The goat-stack sequence was: goat-anti-rabbit-IgG, rabbit-anti-goat-IgG, goat-
anti-rabbit-IgG and so on. The alternate sequence starting with rabbit-anti-goat-
IgG was also used to build the bio-stack up to a total of n=9 steps on the AR,  
Figure 3.6, and, n=25, on the SensiQ, Figure 3.7. In each case, the PAG 
surface was regenerated with a 4 minute injection of 10 mM HCl. 
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Figure 3.6. Response of the AR platform to the goat-stack. Panel (A), AR platform raw response: 
specific (a) PAG channel, non-specific (b) BSA channel and the non-specific (c) Fbr channel; (PR) 
primary recognition step, goat-anti-rabbit-IgG; (1) amplification step, rabbit-anti-goat-IgG; (2) 
amplification step, goat-anti-rabbit-IgG. Panel (B), AR platform with Fbr subtraction: (a) PAG 
specific response, (b) BSA non-specific response. Wash-off step is indicated by *. 
The change in the scattered light intensity from the array spots in  
Figure 3.6A shows three goat-stacks to the assay spots. There is an initial early 
response in the PAG channel at the start of the goat-stack to PAG via its six Fc-
region specific binding sites [211]. The first amplification step with the rabbit-
anti-goat-IgG, acting as a classical secondary antibody, shows a larger 
response to the target goat-anti-rabbit-IgG-PAG channel compared to the 
reference surfaces. The same can be seen for the SensiQ platform in Figure 
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3.7A. In each case in panel B, the Fbr NSB binding step is subtracted to 
compare the difference in the formation of the bio-stack from each specific 
(PAG) or non-specific (BSA) base.  
 
 
Figure 3.7. Response of the SensiQ to the formation of a goat-stack on the specific (a) PAG and (b) 
non-specific Fbr channel Panel (B) shows the difference between the PAG and Fbr channels. 
Wash-off step is indicated by *. 
The change in ∆RI on the SensiQ for the primary binding step (goat-anti-rabbit-
IgG – PAG) is ≈ 2.5 mRIU compared to ≈ 0.7 mRIU on the AR, indicating a 
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difference in performance between the sensors linked with both the PAG 
density and RI sensitivity. 
The mean ∆RI over ten amplification steps on the AR is 1.1 ± 0.4 mRIU 
compared with 2.5 ± 0.6 mRIU on the SensiQ. After the initial amplification 
steps, subsequent steps are similar in ∆RI terms for the continuous gold and 
particle surfaces although after 11 steps the amplification layer becomes larger 
on the fibrinogen channel than the PAG channel. The surface regeneration step 
removes the entire antibody population to recover the initial fibrinogen and PAG 
layers. There is clearly a significant gain in the sensitivity from the amplification 
process, demonstrated by the NSB base to the goat-stacks and this can be 
applied to low IgG binding to specific proteins. This has been demonstrated for 
the clinically relevant screening of the serum from peanut allergy sufferers to 
profile the concentrations of antibodies for each allergen protein.  
3.5.2 Peanut-Specific Antibody Screening in Peanut Allergy Patient Serum 
Understanding even low concentrations of specific binding to peanut allergy 
proteins may be important in the classification and diagnosis of the risk posed to 
peanut allergy sufferers. The bio-stack amplification process can be used to 
enhance the LOD in this clinical setting. Serum samples from 10 patients were 
screened against a four-allergen screening array: cat dander, dog dander, dust 
mite and the peanut allergen protein Ara h1. The work was performed in a 
parallel study in the laboratory and has been published [78]. 
In this experiment, serum from a patient with peanut allergy was flowed over the 
allergen screening array resulting in the primary response (PR), followed by two 
identification steps: goat-anti-human-IgG for IgG detection and goat-anti-
human-IgE for IgE detection. The bio-stack amplification was used after the first 
step to lower the LOD and screen for lower concentrations of IgG or IgE. Figure 
3.8A is the raw response, Figure 3.8B is this signal with the Fbr control channel 
subtracted. 
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Figure 3.8. Response of the AR platform to the allergy sufferers serum followed by secondary 
recognition and bio-stack amplification. Panel (A), AR platform raw response. Panel (B), AR 
platform with Fbr reference subtractions. Specific assay: peanut – green. Non-specific assays: 
BSA – red, dust mite – blue, cat dander – cyan, dog dander – pink. Wash-off step is indicated by *. 
For the data to be comparable against the PBS buffered goat-stack (Figure 3.6), 
the subtracted response presented in Figure 3.8B can be zeroed from the start 
of the goat-stack after the anti-human-IgG recognition steps, Figure 3.9. 
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Figure 3.9. Zeroed response at the start of the goat-stack sequence with Fbr subtraction. Specific 
assay: peanut – green. Non-specific assays: BSA – red, dust mite – blue, cat dander – cyan, dog 
dander – pink. Grey panels represent the association phase. 
The response of the multiplex allergy array with the goat-stack is clearly more 
complex than the PBS-buffered goat-stack data set. There are clearly signs of 
amplification on the non-specific assay channels with varying degrees. Dust 
mite shows the largest non-specific amplification and dog dander shows the 
least signal amplification. 
3.6 Discussion 
Specific and non-specific binding to surfaces is a persistent problem for any 
labelled or label-free detection technologies where the specificity is provided by 
the antibody-antigen interaction. The binding affinity of antibodies measured by 
the affinity constant, 34, is typically 10 nM which may be compared with the 
biotin-streptavadin interaction of 10 pM. Weaker binding affinities correspond to 
the protein-protein interactions which are not stable with respect to a thermal 
collision, 34 = 3.6 mM at 25 °C. The binding free-energies equivalencies for the 34 values are: 10 pM ≡ 62.7 kJmol-1 and 3.6 mM ≡ 2.47 kJmol-1 which appears 
to define the spectrum of all protein-protein interactions. Binding the Fc region 
of IgG to PAG is a specific interaction with a binding affinity, 34, typically in the 
picomolar range [217], a stronger affinity than the typical antibody-antigen 
interaction in the low nanomolar range. There is also some variability in the 
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interaction of the Fc - regions with PAG for different species discussed in the 
results section and in detail in Chapter 4. 
Each of the steps in the bio-stack amplification is specific, indicating that the 
epitope on the deposited antibody is stable on the surface and accessible. 
Hence the layers build up with epitope-stable, intact antibodies maintaining their 
3D structure and consequently a well-defined step size corresponding to the 
distance between the Fc and Fab midpoint, about 12 nm [218]. The antibodies 
in the [IgG]n chain are not monoclonal and so have access to more than one 
competing epitope resulting in a highly branched and cross-linked polymer 
structure. 
Despite the relative constant step size in the bio-stack, the data show that at 
each stage the step size, '&, is decreasing with increasing number of steps, n. 
This was especially pronounced in the SensiQ data (Figure 3.7), which had 3× 
the number of steps, compared to the AR experiments. It is proposed that this 
observation is a direct consequence of the exponential decay of plasmon field 
with increasing distance from the surface. The bio-stack amplification process 
could therefore be considered as a novel way to measure the penetration depth. 
3.6.1 Penetration Depth 
The best penetration depth measurement, U$, is obtained from the PAG channel 
where the first and all subsequent steps in the bio-stack are well-defined. The 
initial binding rate may be characterised by the combined parameter '&"#, (as 
derived in Chapter 2) and is calculated for each of the n steps in the bio-stack, 
Figure 3.10. 
Chapter 3 
82 
 
 
Figure 3.10. Calculated values of ϑmka plotted against stack step number for the PAG surface. 
Panel (A), AR platform, averaged over 48 spots; Panel (B), SensiQ platform. 
The alternating intensity in each step is consistent with the differences between 
the '& of the rabbit and goat polyclonal antibodies. The length of the antibody in 
the stack and the number of epitopes available on each antibody determines 
the thickness of each of the stacking steps and includes the antibody orientation 
and water content. The goat-anti-rabbit-IgG consistently displays a bigger value 
for '&"# (Figure 3.10). A contributing factor for this could be a greater spectrum 
of polyclonal IgG present in the goat-anti-rabbit IgG. There may also be some 
variation in antibody size between the rabbit and goat species due to different 
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glycosylation patterns [219], mechanical flexibility of the antibody structure, or 
slight differences in molecular weight [218], although this effect is considered to 
be small. 
Common to the observations on both the nanoparticle and continuous gold 
surface, is the exponential decay in the sensor response for each successive 
bio-stack step, Figure 3.11.  
 
Figure 3.11. Exponential variation of ϑmka with bio-stack step number for the PAG – goat-stack. The 
exponential fit was obtained for both the: Dashed-lines = species specific rabbit or goat IgG. Solid 
lines are the averaged exponential decay. (a) AR, goat-anti-rabbit-IgG R2 = 0.98, rabbit-anti-goat-IgG 
R2 = 0.99; (b) SensiQ, goat-anti-rabbit-IgG R2 = 0.97, rabbit-anti-goat-IgG R2 = 0.98. 
Fitting the exponential decay of the parameter '&"#, observed for both the 
continuous gold surface (SensiQ data) and the nanoparticles based surface 
array data gives a characteristic decay length of 13.6 ± 0.6 steps for continuous 
and 5.3 ± 0.3 steps for the nanoparticle surfaces. These characteristic decay 
lengths are attributable to the decay in the plasmon field and hence a measure 
of the penetration depth in each configuration.  
The propagating plasmon field penetration depth may be written:  
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where j] is the wavelength of the excitation radiation, p& is the real part of the 
relative permittivity of the metal film and η is the RI of the medium [220]. The RI 
for IgG has been estimated at 1.41 [221]. The penetration depth, U=, for a 
continuous gold surface for the protein layer is calculated from Equation 3-4 (j] 
= 860 nm (SensiQ specifications), pC = 10.0, [222] η = 1.41 [221]), to be 238 nm 
indicating a step length of 17.5 ± 0.8 nm. From this stacking step calibration, the 
plasmon field penetration of the nanoparticle surface is 93 ± 10 nm which is 
comparable to the particle diameter measured by electron microscopy. The 
derived step length of 17.5 nm is consistent with IgG protein dimensions derived 
from neutron scattering data in the solution phase [223]. The long-axis 
dimension of IgG was determined to be in the range 16-18 nm in solution, 
depending on the species in which it was raised. The step length determined 
here points to the integrity of the IgG molecule on the sensor surface. 
The derived U= for the nanoparticles of 93 ± 10 nm is the same as the measured 
diameter of the spherical nanoparticles of 90 ± 13 nm which make up the 
majority of the gold nanoparticles present, ≈ 85 % (Figure 3.3). The penetration 
depth of the plasmon field for the spherical nanoparticle, therefore, is the same 
as the diameter. The penetration depth measurement may be compared with 
the sensing depth reported for other LSPR-based sensors. There is no 
consistency in the literature values, with 12 nm diameter spherical particles 
reported as having a sensing depth of 24 nm, 15 nm diameter particles have a 
reported sensing depth of 20-25 nm and 39 nm particles have a reported 
sensing depth of 40 nm [224-226]; all sensing depth determinations appear to 
be within 1-2 particle diameters. A further measure of the plasmon field 
penetration depth is the plasmon interaction range which has been estimated to 
be the order of the particle diameter for 10, 20, 150 nm diameter particles [195]. 
The effect of shape is also not clear: flat nanoprisms with a side width of ≈ 100 
nm and a height of 50 nm display saturation of the LSPR response when coated 
with multi-layer alkanethiols of 30-50 nm thick [197, 207]. In some plasmonic 
systems an extreme long-range sensing is reported, 70 nm discs and 
nanoholes arrays exhibit plasmon sensing at > 300nm [227]. The field extension 
range can also be indirectly inferred from a study of interacting nanoparticle 
pairs, for 50 nm diameter discs the interaction is insignificant at a distance of 60 
nm or 1.2 particle diameters [228]. The interaction range may be compared with 
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our particle surface density of 1 nanoparticle per 220 ± 60 nm2, indicating the 
penetration depth measurement results predominantly from non-interacting 
particles [229].  
Future optimisation of an LSPR sensor may include tuning of the particle 
plasmon field penetration depth in order to maximize the contribution from the 
surface adsorbed analyte to the instrument response. The bio-stacking 
measurement of U= using IgG, a potential bio-assay species, provides a 
convenient method of measuring U=, indicating an exponential decay in the 
plasmon field, and confirms the antibody integrity at the gold surface, both 
important parameters in the sensor optimisation process. Conversely, once the 
penetration depth has been calibrated, it can be used as a ruler to measure the 
solution dimensions of protein bio-layers: a significantly simpler measurement 
than neutron scattering. 
The continuous SPR surface has an U= of 238 nm in the current configuration 
could also be optimised when studying samples with higher levels of bio-noise. 
The antibodies binding to the surface will only occupy an area of < 20 nm 
meaning there is > 200 nm sensing distance above the bound target analyte 
that can only contribute negative effects to the assay. The measured range of 
the reflected incident angles is currently 62-74 degrees but by changing the 
incidence angle that the propagating light-beam follows, then the sensing 
volume can be tuned. The angle of incidence of light coupled into a prism can 
be easily varied over a wide range, allowing straightforward control of the 
evanescent field U= from the critical angle to grating incidence [230]. 
Measuring the penetration depth was not the primary aim of the study but has 
provided some useful insight into why nanoparticle sensors are more immune to 
bio-noise than continuous gold surfaces. This would improve our SNR, 
subsequently improving our LOD. However given the mass dependant sensing 
capabilities of LSPR an assay amplification technique would provide a valuable 
tool for identifying low concentration analytes that may be below the current 
LOD. 
3.6.2 Amplification via Antibody Oligomerisation Bio-Stacking 
Returning to the primary objective of designing a bio-stacking amplification 
technique, the current detection limit of the AR is in the order of 10-9 – 10-10 M 
Chapter 3 
86 
 
for antibodies from pure buffered solution. Improving the detection limit by an 
order of magnitude would bring the performance of the AR assays closer to the 
routine ELISA assays used in the clinical chemistry laboratory. The optimum 
number of steps in the bio-stacking amplification must be determined by 
considering the increase in the SNR. 
 
Figure 3.12. Schematic representation of the amplification process on the sensor surfaces: (A) - 
specific sensor surface functionalised with PAG; (B) - reference surface, supporting only non-
specific binding at the beginning of the experiment.  
The amplification process is shown schematically in Figure 3.12 and the 
amplification for each step may be discussed in terms of the surface coverage, 
'&, which is dependent on the mass of antibody present on the surface at each 
step. 
There is a significant amplification in the first three binding steps (Figure 3.13) 
dominated by the specific primary binding of the goat-anti-rabbit-IgG to PAG. 
However, the amplification of the NSB of the BSA accidental binding, possibly 
via the bovine IgG contamination, populates the BSA surface with a significant 
antibody surface density which is subsequently amplified. The BSA channel can 
effectively be thought of as a representation of low concentration specific 
binding, which is a step behind the PAG amplification. Non-specific binding on 
a
b
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fibrinogen channel requires more steps before any significant amplification; 
behaving as a better reference channel. However, Fbr does dominate the 
response nearer the end of the experiment at injection seven, producing the 
negative delta signal.  
 
Figure 3.13. AR values of ϑm for both PAG and BSA subtracted with ϑm from the control Fbr spots, 
plotted against injection sequence. PR = primary response; rb-a-gt = rabbit-anti-goat-IgG; gt-a-rb = 
goat-anti-rabbit-IgG. 
It is interesting to see the delayed amplification of the reference channel; this 
demonstrates the usefulness of Fbr as a control assay but also highlights the 
fact that all spots, however useful as a control, become less advantageous after 
a limited number of injections. To highlight this late enhancement process 
Figure 3.13 can be presented in terms of amount of amplification, by dividing 
each step by the initial PR (Figure 3.14). 
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Figure 3.14. AR amplification derived by dividing all values of ϑm by the PR, for both Fbr subtracted 
PAG and BSA vs injection sequence: (A) = amplification for PAG and BSA; (B) = amplification for 
PAG; PR = primary response (= 1); rb-a-gt = rabbit-anti-goat-IgG; gt-a-rb = goat-anti-rabbit-IgG. 
The amplification gain against the injection sequence is presented in Figure 
3.14, with the PR having an amplification of 1 from being divided by its self. 
Figure 3.14A contains the specific amplification from both the expected PAG 
response and the unexpected BSA response. The amplification factor varies 
significantly between these assays due to the much larger '& from the PR of 
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the PAG assay. Figure 3.14B is solely the PAG amplification which reaches a 
maximum enhancement of ×2.5 after three stacking steps. The secondary 
control spots functionalised with BSA can be considered a specific interaction 
due to the stability of the resulting antibody bio-stack. Therefore, there is 
potential for a much larger rate of amplification; in this case ×60 for low 
concentration target analytes. The high amplification factor could be especially 
useful for complex samples, such as serum, when the analyte concentration 
may be unknown. The LOD for the IgG-PAG is typically 0.2 ± 0.1 nM, if the 
response was near or below this LOD then it may be possible to detect IgG 
concentrations as low as 3 ± 2 pM (450 ± 300 pg/mL). An average human IgG 
ELISA kit will have an LOD of ≈ 200 pg/mL, the AR could have a similar 
detection level, with the assay still requiring less than half the time of a standard 
ELISA sandwich assay SOP. The bio-stack amplification process does not 
however benefit assays that show a detectable signal in the PAG channel. To 
test the bio-stack amplification on clinically relevant samples the experiment 
was performed on a prefabricated allergen array from a patient sample with a 
RAST 5 peanut allergy. 
Analysis of the allergen screening array with the bio-stack amplification is an 
immediate clinical application. The peanut-specific antibody detection and 
subsequent amplification provided extra challenges in whole serum with 
significantly increased NSB to contribute to noise amplification. The serum was 
diluted 20-fold to reduce the NSB and secondary identification detections steps 
were used to identify the antibody classes present on each of the allergen 
assays, anti-human-IgE showed no response (Figure 3.8A, ≈ 40 minutes) but 
there was a large response with anti-human-IgG for the peanut and BSA 
assays, with a decreasing signal from dust mite, cat dander and dog dander 
assays respectively, allowing the amplification process to be performed. 
The responses shown in Figure 3.8 were converted to '& values and presented 
in Figure 3.15. Also present is a significant response from the dust mite assay, 
which steadily increases in signal over the first three amplification steps, 
suggesting that maybe this patient is also allergic to dust mite but not to the 
same extent as peanut.  
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Figure 3.15. AR values of ϑm with serum PR for all assay spots subtracted with ϑm from the control 
Fbr spots, plotted against injection sequence. Red – BSA assay, green – peanut assay, blue – dust 
mite assay, cyan – cat dander assay, pink – dog dander assay; PR = primary response; gt-a-h = 
goat-anti-human-IgG; rb-a-gt = rabbit-anti-goat-IgG; gt-a-rb = goat-anti-rabbit-IgG. 
A similar trend is followed in Figure 3.15 as when using the buffered primary 
analyte. The initial signal seen is as expected in the specific assay, followed by 
a response on the other assay spots which in this case act as further controls 
unless the patient has an allergy against a secondary allergen. From the PR it is 
clear that the patient is allergic to peanut, with negligible signal seen from other 
assays. Again, there is late signal seen from BSA after the goat-anti-human-IgG 
but this is not amplified by the rabbit-anti-goat-IgG, as seen previously and in 
fact the following goat-anti-rabbit injection produces the second largest value for 
'& over the whole time course. The nature of this response suggests that the 
stacking process is responsible for the signal rather than an amplification 
process from the primary response. The cat and dog dander assays both show 
a small response that steadily rise for three and two steps respectively. 
Figure 3.16 shows the amplification factors from the serum experiment. Again, 
like in the PBS buffered experiment, the BSA signal has the greatest signal 
enhancement, this time reaching a level of ×30. The specific signal has an 
amplification factor of ×1.5 reached after three injections, or two amplification 
steps after the PR. The amplification is clearly smaller for the complex serum, 
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given the background protein levels, this is not surprising, as Fbr is likely to 
show more NSB than previously. 
 
Figure 3.16. AR serum amplification derived by dividing all values of ϑm from all assay spots 
subtracted with ϑm from the control Fbr spots with the value of ϑm from the PR; plotted against 
injection sequence. Panel (A) = all antigen assay amplifications; Panel (B) = PAG assay 
amplification; red – BSA assay, green – peanut assay, blue – dust mite assay, cyan – ca dander 
assay, pink – dog dander assay PR = primary response (= 1); gt-a-h = goat-anti-human-IgG rb-a-gt = 
rabbit-anti-goat-IgG; gt-a-rb = goat-anti-rabbit-IgG. 
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The enhancement observed for each of the parameters on each of the 
amplification steps could be optimised with a careful choice of a specific animal 
antibody pair, in particular selecting for fast association and lower affinity 
constant, 34. This would be a simple screening process in an assay 
development programme. The 1.5× amplification from serum is an improvement 
on the primary response and given the background proteins adding bio-noise to 
the primary response reducing the SNR then this amplification could be useful 
at a clinical setting for confirming the primary response rather than amplifying a 
signal below the detection limit. It could be argued however that given the 
amplification factor of the control spots of 30× then if the surface is better 
blocked to reduce the effects of non-specific amplification then a specific 
amplification factor closer to 30× would be clinically significant. Reducing a 
detection limit of 200 pM to as little 6 pM (900 ± 600 pg/mL), almost two orders 
of magnitude. 
3.7 Conclusion 
We have demonstrated the effects of antibody oligomerisation as a bio-stack 
amplification process on both the AR particle surface, and the SensiQ 
continuous gold surface and developed a simple method of measuring the 
overall U$ of an LSPR plasmon field. The bio-stack method provides a simple 
method that allows surface regeneration for further studies owed to the 
biological nature of the stacking technique. The particles were predominantly 
spherical and suggestive of a positive correlation with nanoparticle size and U$. 
For instance, by growing smaller particles of around ≈ 50 nm then the sensing 
range of the plasmon field may be similar to that of the assay complex (≈ 40 
nm). However, with more complex nanoparticles structures the effect on the U= 
will be more apparent and the relationship may not be linear. Nanotriangle 
particles fabricated by nanosphere lithography offer some of the best sensing 
capabilities [67] but the effect size and density has on the U= of these structures 
is unknown. Much work on the fabrication of other nanoparticle sizes and 
structures would be needed to characterise the optimum U= using the bio-stack 
method. 
The performance of the bio-stack as an amplification process is clear; three bio-
stacking steps in buffered samples offer the optimum amplification before a 
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small amount of initial non-specific binding, present on the reference channel is 
amplified. The number of steps able to selectively amplify the specific signal is 
initially linked to how well the surface is blocked but even low quantities of non-
specific binding trigger a large amplification cascade, limiting the number of 
useful amplification steps. If this technique is applied to complex assay 
samples, then an unknown amount of non-specific binding will always be an 
issue, controlling the useful range of bio-stacking steps. However, it may be 
useful in amplifying the signal of low molecule weight and/or low concentration 
targets by forming a bio-stack based on antibodies with a MW of 150 kDa, 
subsequently improving the sensing capabilities. The amplification factor for the 
small amount of specific signal on the BSA channel was amplified 60- and 30-
fold, for the buffered and serum sample, respectively, this can significantly 
increase the LOD of the AR platform, to as little as pg/mL for IgG detection. 
The AR instrument has now been sufficiently optimised for use with immuno-
kinetic assays; the previous chapter focused on the interpretation of the binding 
interactions and gaining the most out of the collected analyte response, while 
this chapter looked at methods to improve our primary signal via amplification 
and tailoring the penetration depth. The next chapter builds on what has been 
learnt and is focused on antibody screening assays and takes advantage of the 
special binding properties of PAG, only hinted in this chapter, to aid in the 
characterisation of antibody-antigen interaction and move the technology one 
step closer to being a platform with real clinical significance. 
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4 Total IgG Concentration Assay 
4.1 Introduction  
Determining immunoglobulin (Ig) levels in blood is important clinically as they 
provide information on the humoral immune response status [231]. Higher than 
normal Ig levels are observed when infection is present and may occur in 
chronic inflammatory diseases [232]. Whereas, lower than normal levels are 
indicative of some humoral immuno-deficiencies [233]. Immunoglobulin levels 
can be useful if determined over a time course for a patient with liver disease 
[234, 235]. As discussed in the introduction, antibodies are divided into five 
classes, or isotypes: IgG, IgA, IgM, IgD and IgE, which have different 
properties. These were summarised in Chapter 1, yet one difference that was 
not discussed was structure, as shown in Figure 4.1.  
 
Figure 4.1. A schematic illustration of the five antibody isotypes depicting differences in their 
monomeric structure. In green is the variable antigen binding site, blue is the constant region. The 
red hexagons represent sites of protein glycosylation. 
There are significant differences in the constant region between the subclass 
structures. These include the length (number of amino acid residues), the 
sequence and properties of the “hinge” region, the number of disulfide bonds 
between adjacent chains, the location and extent to which the sequence is 
glycosylated and the overall function. Also, the final quaternary structure of the 
antibody isotypes is not always monomeric, with IgA forming a dimer and IgM 
forming a pentamer [87]. The main differences have been discussed in Chapter 
IgG IgM IgD
IgEIgA
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1. The variety of possible monomer combinations has resulted in a number of 
different methods used to isolate immunoglobulin from samples for both 
purification and quantification [236-238].  
The isotypes are found in varying concentrations in different bodily fluids. The 
serum concentrations vary significantly, with IgG being the dominant class 
accounting for ≈ 80% of antibody content, with an average concentration of ≈ 
12.5 mg/mL. Table 4-1 is a section of that table that summarises the antibody 
properties relevant in this chapter. 
Table 4-1. Properties and biological activities of classes and subclasses of human serum 
immunoglobulins. Adapted from [89]. 
 
IgG1 IgG2 IgG3 IgG4 IgA1 IgA2 IgM IgE IgD 
Molecular weight 
(kDa) 150 150 150 150 
150-
600 
150-
600 
900 190 150 
Possible monomer 
units per Ig 
1 1 1 1 1-4 1-4 5 1 1 
Heavy chain 
component 
γ1 γ2 γ3 γ4 α1 α2 µ ε δ 
Average serum level 
(mg/mL) 9 3 1 0.5 3.0 0.5 1.5 3×10
-3
 0.03 
Percentage of total 
immmunoglobulin 
≈ 80% 13% 8% 
< 
0.01% 
< 1% 
 
As well as differences between isotype serum concentration, there is also 
variability from patient-to-patient, with the normal range of IgG typically 5 – 16 
mg/mL for adults [239]. There can be significant differences in IgG among 
patient subgroups defined by age, sex and common toxicant exposures such as 
smoking and alcohol consumption [231, 240, 241]. For example, a study by 
Gonzalez-Quintela et al. [231], found serum IgA concentration to be positively 
associated with age, the male sex, heavy drinking and obesity, whereas serum 
IgG concentration was associated positively with age but negatively with 
smoking and moderate drinking. IgG levels can vary between healthy and 
immuno-deficient individuals [242]. For example, individuals with certain lung 
diseases such as bronchitis [243] may display IgG levels increased by 2 – 3-fold 
compared to the mean value for healthy subjects. IgG levels can also decrease, 
during septic shock [244] where levels initially drop before rising a few days 
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later. Patients with low IgG levels are predisposed to post-operative infections 
after colorectal cancer [245], solid organ transplantation [246] and cardiac 
surgery [247]. If the levels are monitored over time then polyclonal intravenous 
immunoglobulins (IVIG) can be administered; which is the current treatment for 
low IgG levels. IVIG is also used for patients suffering from neurologic, 
hematologic and rheumatologic diseases [248] and the monitoring of which 
could be a useful point-of-care diagnostic. 
4.1.1 Current Assays for Measuring Total IgG 
Measuring the level of serum IgG is a standard clinical test performed daily in 
most hospital settings. Total IgG can be determined as a concentration, or 
alternatively as a ‘titer’, and it is important for these to be defined as they are 
not directly comparable. Concentration is well defined with correct SI units of 
the total mass of IgG per unit sample solution volume, mg/mL, or as molar 
concentration, in units of moles per litre, M [249]. Titer, is the functional 
concentration, or dilution-factor, of a stock solution of antibody for a given 
immunoassay and is quoted as the largest dilution required for the assay to still 
show a positive response. 
A simple, low-tech method to determine the concentration of an antibody in 
solution is to measure the absorbance at 280 nm. Yet this technique requires a 
high degree of purification and is not always appropriate. In a mixed sample the 
antibody concentration can be measured using photo-, fluoro-, or luminometric 
detection as well as turbidimetry. The assays most often used in quantitative 
clinical immunochemistry are ELISA and immunoturbidimetric assays [250].  
ELISA assays are among the most sensitive immunoassays available [251], 
even though ELISA-based assays can be more time consuming and labour-
intensive than other techniques owing to the multiple incubation periods. The 
general protocol for ELISA assays [252] for total Human IgG employs an 
antibody specific for Human IgG coated onto the surface of each of the wells in 
a 96-well microtitre plate. Concentration standards and samples are pipetted 
into wells that have been functionalised with an antibody specific to the IgG 
present in a sample, this is then captured. The wells are washed and 
biotinylated anti-Human IgG antibody is added. After washing away unbound 
biotinylated antibody, horseradish peroxidise (HRP)-conjugated streptavidin is 
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introduced linking to the biotin specifically and with high affinity. The wells are 
again washed then a colour-less substrate such as tetramethylbenzidine (TMB) 
before HRP is added to each well. The enzymatic oxidation results in a coloured 
product whose concentration is proportional to the amount of IgG bound. The 
enzyme is incubated with TMB for a fixed length of time, after which a Stop 
Solution (often sulfuric acid) stops the reaction and changes the product colour 
from blue to yellow. The intensity of the colour is measured as optical 
absorbance at 450 nm [253]; this type of ELISA is an example of a sandwich 
assay discussed in Chapter 1. 
The dynamic range, sensitivity and accuracy of ELISA differ greatly compared 
to, for example, immunoturbidimetric assays. In general the dynamic range of 
an ELISA, specifically for IgG, is pg/mL – ng/mL. The dynamic range will vary 
from different suppliers but will generally cover two orders of magnitude and 
have a CV < 10% [251]. 
Immunoturbidimetric assays are used for the quantitative in vitro determination 
of IgG from human serum, plasma and cerebrospinal fluid (CFS) [250], based 
on the principle of immunological agglutination. aIgG antibodies react with 
antigen in the sample to form an antigen/antibody complex which then 
agglutinates so changing the turbidity (the loss of transparency due to the 
presence of suspended particles) of the solution. Following agglutination, the 
turbidity is measured by the loss of light intensity. Some assays also involve the 
addition of PEG and/or Tween 20 which allows the reaction to progress rapidly 
to the end point, this increases sensitivity and reduces the risk of samples 
containing excess antigen producing false-negative results [254], improving 
assay specificity.  
Sensitivity and specificity of immunoturbidimetric assays varies from supplier to 
supplier. The Royal Devon and Exeter Hospital use a Tina-quant IgG Gen.2 
assay on a Roche automated clinical chemistry analyzer for quantifying IgG, 
with a dynamic range of 3 – 35 mg/mL (one order of magnitude) and detection 
limit of 0.30 mg/mL. As the assay was designed to measure IgG in the normal 
range of 6-16 mg/mL, the LOD is suitable. However, the precision of the assay 
is good with a CV, 0.9 %. Both immuno-assay techniques are the standard 
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clinical assays currently used against which the performance of any new assay 
should be judged. 
4.1.1.1 Antibody Purification 
Ig purification is often performed with complex samples before continuing with 
the assay. A successful purification step in the assay can remove the majority of 
interference effects from the other proteins, potentially of high concentration, in 
the sample. These interference effects change the reproducibility, sensitivity, 
specificity and accuracy of the assay but require the intervention of a skilled 
technician or an automated process in the preparation of the sample. In 
addition, there may be large sample volume requirements. The purification 
techniques may be broadly classified into three groups: 
• Physicochemical fractionation – this includes size exclusion 
chromatography [255] and ammonium sulphate precipitation [238, 256]. 
• Antigen-specific affinity – this separates antibodies via their specific 
antigen-binding domain without regard to antibody class or isotype [238]. 
• Class specific affinity – this group can separate antibodies of a target 
class without regard to antigen specificity via biological ligands such as 
proteins and lectins [238, 257] and includes Protein A, G and A/G 
discussed in the following sections. 
Purification via antibody class is one of the most common techniques currently 
used. In this method ligands are covalently immobilised onto porous substrates 
such as agarose or magnetic beads [256]. The proteins, A and G, discussed in 
detail in section 4.1.3, can each bind a number of antibodies via the Fc region. 
The Fc-specific binding allows functionalised beads to also act as a secondary 
antigen purification technique as the antigen region remains free, an example of 
which is immunoprecipitation [258]. Other advantages of forming complexes via 
the Fc region are described in the following section. 
4.1.2 Antibody Fc Region  
The opsonisation of an antigen by Igs proteins is one of the important 
processes underlying the removal of an antigen from circulation in the body and 
is part of the innate immune response. The opsonisation process is started from 
cells expressing specific Fc-receptors (FcRs) on their surface, recognising the 
Fc region of antibodies after the Fab region has bound to the outer surface of 
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an invading pathogen [259]. The Fc receptor recognition process provides a link 
between antibody–antigen complexes and cellular effector machinery which 
initiates phagocytosis of the foreign antigens recognised by antibodies [93]. 
Besides phagocytosis of antibody-opsonised particles, or endocytosis of 
antibody-antigen immune complexes, other mechanisms are activated, e.g. 
plasma cell antibody production, antibody dependent cell-mediated cytotoxicity 
(ADCC) and secretion of pro-inflammatory cytokines that in turn activate other 
components of the immune system [260, 261]. There are different FcRs for 
each immunoglobulin class (Table 4-1) and it depends on the respective cell 
type, the IgG subclass and the type of FcR as to which effector function is finally 
elicited. Therefore, it is the position of FcRs that mean they can act as a 
gateway to both cellular and humoral aspects of the immune cascade: this 
makes them an attractive target for immunotherapies [262]. 
The FcRs for the main serum immunoglobulin IgG can be subdivided into three 
groups, each with a different affinity for the Fc region. FcRI (CD64) has the 
highest affinity at 10 nM, attributed to an extra (third) binding domain and is 
expressed on monocytes, macrophages and cytokine-activated neutrophils 
[262]. The slightly lower affinity FcR is called FcRII (CD32), has an affinity of 
500 nM and is the most widely distributed FcR found on both immune and non-
immune cells such as B cells, eosinophils, granulocytes and macrophages. 
Finally there is FcRIII (CD16) with the lowest affinity of 2 µM, the main Fc 
receptor on neutrophils [263, 264]. The differences in affinity are an important 
aspect in the biological response of these receptors. IgG isoforms exert different 
levels of effector functions increasing in the order of IgG4< IgG2 < IgG1 < IgG3. 
Human IgG1 displays high ADCC and is the most suitable for therapeutic use 
against pathogens and cancer cells [265]. Natural killer cell–mediated ADCC is 
a critical mechanism of action for many approved humanised mAbs for 
therapeutic use [266]. 
Humanised antibodies are therapeutic antibodies which are produced in a 
different species, usually a mouse, that have had their protein sequence altered 
so they have a higher degree of homology with human IgG (typically 95%). The 
homology allows an effective Fc-mediated immune response [267] and means 
that they will be less likely to be identified as foreign by the immune system and 
are more valuable therapeutically. The Fc domain is engineered to increase the 
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affinity for Fcγ receptors expressed on various effector cells, and associated 
cytotoxicity [268]. The stronger Fc-receptor interaction, is directly linked with the 
clinical outcome from patients receiving chimeric therapeutic monoclonal 
antibodies (mAbs) such as rituximab [269], trastuzumab [270], or cetuximab 
[271]: patients that show a higher affinity in this interaction achieve much better 
response rates [268]. High-affinity antibody complexes surrounding a target 
antigen with optimised Fc region affinity are the ideal solution for an effective 
natural immune response to pathogens, immunotherapy for cancer and the 
protection derived from vaccines. We will return to vaccine efficacy in Chapter 
6.  
Characterisation of Fc region of the antibody is difficult but there are a number 
of methods, some of which rely on bacterial immunoglobulin binding proteins 
(IBPs). IBPs have evolved in bacteria to bind the Fc region of antibodies 
specifically as a method of evading the immune response. They are located on 
the surface of bacterial cells and help protect against the action of Complement 
and decrease the rate of phagocytosis [272]. IBPs are not specific for human 
immunoglobulin and IBPs from different bacteria can form complexes with 
antibodies from a variety of species with varying degrees of affinity. These IBPs 
could be a good candidate for the basis of an assay to quantify total IgG and 
simultaneously measure the affinity of the interaction. 
4.1.3 Bacterial Immunoglobulin Binding Proteins 
Staphylococcus protein A (SPA) and Streptococcus protein G (SPG) are 
examples of surface proteins with immunoglobulin-binding properties. It is 
thought that these play a role in pathogenicity by sequestering a layer of host 
antibodies on the bacterial surface so partially concealing the infecting 
organisms from the host immune response; known as immune system evasion 
[272, 273]. Both of these proteins contain antibody binding sites that vary in 
number and in the way they interact with their ligand. However, they have in 
common an ability to bind via the C-terminal fragment of the IgG heavy chain. 
This unique binding property makes these proteins of significant value for both 
detecting and isolating IgG [274]. However differences in their binding 
characteristics between the proteins are apparent.  
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SPA, Figure 4.2, includes a signalling sequence called the S-region [216] which 
has five homologous IgG-binding domains (E, D, A, B, and C) each consisting 
of 58-62 amino-acid residues [275] and a C-terminal sequence which secures 
SPA in the cell wall and contains 150 amino-acid residues (X and M in Figure 
4.2) [276, 277]. Sjodahl [277] discovered only four IgG binding sites present on 
SPA by analysing tryptic fragments of the protein retaining the Fc-binding 
activity: the apparent lack of a fifth binding site is common between native SPA 
proteins and helps explain the heterogeneity in molecular weight [216]. 
 
Figure 4.2. Structure of SPA. (A) Scheme of SPA structure. S is signalling sequence; D, E, A, B, and 
C are IgG-binding domains; XM is the region fastening the SPA molecule in the cell wall. (B) Spatial 
structure of the Ig-binding E-domain of SpA (PDB-code 2JWD) (Redrawn from [216]). 
In SPG, Figure 4.3, the IgG-binding domains are located nearer the C-terminus 
with a peptide fragment separating them from the albumin-binding region 
located in the N-terminal region [216]. Again, like in SPA, the number of 
domains can vary from strain-to-strain, with the albumin-binding domains 
regularly removed from recombinant forms of the protein [278]. The albumin 
binding domain must play a similar role to the IgG domains for immune system 
evasion. The IgG-binding SPG domains consist of approximately 55 amino acid 
residues packed as a β-sheet, which is built of two anti-parallel and two parallel 
β-strands with the α-helix situated along its diagonal (Figure 4.3b) [279-281]. 
S D E A B C X M
Immunoglobulin-
binding region
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N
C
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Figure 4.3. Structure of SPG (A) Scheme of the SPG molecule. Ss, signalling peptide; A1-A3 and 
C1-C3, albumin- and IgG-binding domains, respectively; (B1, B2) and (D1, D2) are regions of the 
polypeptide chain separating, respectively, albumin- and IgG-binding domains; S, region of the 
polypeptide chain separating functionally different regions; W, fragment fastening the protein in 
the cell wall. (B) The spatial structure of the IgG-binding domain of SPG (PDB-code 2NMQ) 
(Redrawn from [216]). 
SPG and SPA share no sequence or structural homology even though they 
compete for a similar binding site with IgG [282]. SPG in general binds all IgG 
subclasses with a higher affinity, whereas SPA does not bind IgG3 [236, 283]. It 
is also worth noting that SPG also interacts weakly with Fab regions, however 
its binding affinity for Fab is only about 10% of its affinity for the Fc regions 
[283]. Therefore IgGFab:SPG has a 3r value at ≈ 109 M-1, compared with ≈ 1010 
M-1 for the IgGFc:SPG complex (Table 4-2). 3r is the association equilibrium 
constant and is calculated as 1/34: typical values of 34 for antibody – antigen 
interactions are ≈ 109 M [83]. 
Interaction with Fab is more common in SPG compared to SPA, however, SPG 
cannot bind IgM, IgA and IgD. Binding of the Fc region in both IgM and IgA is 
controlled by the Fc receptor FcµR present on cell surfaces. The FcµR, when 
compared to other FcR groups present on cells lacks some conserved residues 
and contains a different number of charged groups that interact: unlike other 
FcRs, the major cell types expressing FcµR are adaptive immune cells, 
including B and T lymphocytes [284]. SPA can interact with IgA and IgM as well 
as IgG, so therefore there must be sequence homology to that of FcµR lacking 
on SPG [272, 285]. SPG can also pose a problem when purifying IgG from 
A
Immunoglobulin-
binding region
63 kDa
N
C
β1
α β4
β3
β2
Ss E A1 A2B1 B2 A3 C1S D1 C2 C3D2 W
Albumin-
binding region
B
Chapter 4 
103 
 
complex samples as it contains an albumin binding site seen in Figure 4.3A 
[272, 286]. 
Compared with SPA, SPG also contains an albumin-binding domain and differs 
in the number of immunoglobulin binding domains. Akerstom and Bjorck [273] 
determined the number of IgG binding sites on SPG to be at least two per 
molecule. While Sjodahl [277] discovered four IgG binding sites present on SPA 
by analysing tryptic fragments of the protein retaining the Fc-binding activity. 
These four sites were shown to have high sequence homology, each consisting 
of 60 similar amino acid residues. The binding interactions and forces also 
varied between the two proteins with each developing different methods of 
attachment. The SPG:Fc complex involves mainly charged and polar contacts, 
whereas the SPA:Fc complex is held together predominantly through non-
specific hydrophobic interactions [282]. 
Table 4-2. SPA and SPG antibody-binding affinities derived as KD for the antibody complex; n/b, no 
binding. Adapted from [216]. 
IBP kDa 
st (pM) No. of Ig 
binding 
domains 
Human 
mouse rat goat rabbit 
ΣIgG IgG1 IgG2 IgG3 IgG4 
SPA 
41-57 
[287] 
23 
[273] 769 476 n/b 294 38 56·10
3
  n/b 19 
4-5  
[275, 288] 
SPG 
63 
[289] 
15 
[273] 500 323 164 213 24 714 71 14 
2-3  
[290] 
 
There is a significant pH-dependent interaction for antibody binding to both SPA 
and SPG. SPG binding the IgG was found to be strongest at pH 4 and 5 and 
weakened with increasing pH [273]. Whereas with SPA the opposite is 
observed with binding being lowest at low pH and highest at pH 8, due to the 
charges present on the proteins [273].  
The difference in pH-dependent interactions between SPA and SPG does mean 
that for many applications one is more suited than the other. Due to these 
differences Eliasson et al. [215], prepared a chimeric molecule combining the 
binding characteristics of both protein A and G. This provided a better all round 
protein for immunoglobulin isolation called recombinant protein A/G (PAG).  
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4.1.4 Chimeric Fusion Protein A/G 
PAG is a recombinant fusion protein derived from Staphylococcus protein A 
(SPA) and Streptococcus protein G (SPG) [282], first produced by Eliasson in 
1988: since then it has become a powerful tool in immunological studies [215, 
291, 292]. It contains six antibody binding sites (2 + 4) from SPG and SPA 
respectively, with less dependence on pH, binding well in the range of pH 5 – 8 
easily covering the physiological pH at which antigen-antibody binding is best 
suited. For these reasons PAG is an ideal candidate for an immunoglobulin 
assay in LSPR: this is especially true when combined with other assays on the 
same array because the optimum binding for all antigens will be at a 
physiological pH and therefore optimised for both antibody(Fab):antigen and 
antibody(Fc):PAG interactions [293]. Sikkema [294] summarised the different 
binding characteristics of the two proteins and also found that this chimeric 
protein excluded the albumin binding site associated with SPG. These findings 
are presented in Table 4-3. 
Table 4-3. Relative binding affinities of Protein A, Protein G and recombinant Protein A/G with IgG 
from different species. Adapted from [294]. 
Species IgG SPA SPG PAG 
Human + + + 
Mouse + Weak + 
Rat - - - 
Chicken - - - 
Monkey + + + 
Rabbit + + + 
Guinea pig + + + 
Pig + + + 
Cow - + + 
Dog + - + 
Cat + - + 
Horse - + + 
Goat - + + 
Sheep - + + 
 
Given the affinity both SPA and SPG have for IgG, the chimeric PAG has good 
potential for IgG based assays on our Array Reader platform. For instance, in 
this chapter we are interested in the binding affinities of human IgG – PAG but 
in Chapter 5 we will attach goat derived antibodies to the PAG surface to test 
our protein screening capabilities. Chapter 6 will use IgGs derived from mouse 
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and monkey which are involved in developing methods for vaccine testing. 
Given the comparatively high concentration of immunoglobulin in serum (> 10 
µM), along with the high affinity and the detection limit of the LSPR platform of 
typically ≈ 1 nM, considerable dilution of a sample perhaps over 1000-fold 
indicates a good LOD and significant reduction in matrix effects from the other 
blood proteins. Consequently, sample preparation can be simplified and 
automated on a chip with the potential for a point-of-care bedside assay. Such 
an assay would be useful for patients receiving intravenous immunoglobulins 
(IVIG) to act as a diagnostic test to monitor the dosing regimen [248]. 
4.2 Aims and Objectives 
The aim of this chapter is: 
the development of a method and protocol for quantifying total IgG from crude 
serum samples by applying an antibody purification protein (PAG) to the Array 
Reader LSPR platform 
The design of an array assay will be presented using protein A/G functionalised 
array elements, from which the IgG binding affinities will be derived. Purified 
protein will be used initially to characterise the binding of known antibodies to 
PAG, deriving the binding properties from a multi-concentration global fit to the 
kinetic data. Then finally, the total IgG concentration determinations will be 
made for whole human serum in a blind study, comparing the results with the 
laboratory standard calibration. 
4.3 Materials 
Self-assembling monolayer (SAM) components: HS-(CH2)17-(OC2H4)3-OH (used 
as a ‘spacer’) and HS-(CH2)17-(OC2H4)6-OCH2COOH (used as a ‘linker’), were 
obtained from ProChimia Surfaces (Poland). N-(3-Dimethylaminopropyl)-N'-
ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), bovine 
serum albumin (BSA) (98%), human fibrinogen (Fbr) (60%, with 40% buffer 
salts; the protein content is >80% clottable Fbr), C-reactive protein (CRP) (1 
mg/mL) and human serum albumin (HSA) (>96%) were obtained from Sigma-
Aldrich. Recombinant Protein A/G (PAG) (5 mg) was purchased from Pierce. 
Sheep polyclonal antibodies to BSA (aBSA) (23 mg/mL, IgG fraction) were 
supplied by AbD Serotec UK and goat polyclonal antibodies to CRP (aCRP) (10 
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mg/mL) were supplied by abcam. Human Serum (male AB) was obtained from 
Biosera. For the secondary antibodies, all were polyclonal and produced in 
Goat with aIgG (H+L), aIgG (Fc), aIgA, aIgD and aIgE all purchased from Bethyl 
labs at a concentration of 1 mg/mL, while aIgM was also produced in Goat but 
purchased from R&D Systems in the form of recombinant lyophilised protein 
(0.1 mg). All materials were used as shipped without further purification.  
All solutions were prepared in 18 MΩ·cm3 deionised water and unless otherwise 
stated protein solutions were prepared in standard phosphate buffered saline 
(PBS, 137 mM NaCl, 2.7 mM KCl and 10 mM Na2HPO4, pH 7.4) purchased 
from Sigma-Aldrich in tablet form. For all binding studies, but not for surface 
preparation, 5 × 10-5 Tween 20 (w/v) was added to the prepared PBS buffer. A 
flow rate of 100 µL min-1 was used to ensure concentration limited kinetics [77]. 
4.4 Experimental Methods 
All experiments were performed using the Array Reader platform as described 
in detail in Chapter 2 and elsewhere [61, 77, 80]. All data shown in the 
subsequent figures are calibrated as discussed in Chapter 2 and presented as 
the change in RI, ∆RI with respect to control spots functionalised with 
fibrinogen.  
4.4.1 Assay Surface Functionalisation 
Gold nanoparticle arrays were prepared as before and first cleaned with water 
and iso-1-propanol (IPA). They were then functionalised with 1:10 
(linker:spacer) mixture of the SAM components before being activated with 
EDC/NHS for 1 hour. The activated arrays were then functionalised with 
proteins by printing 1 mg/mL BSA, CRP, fibrinogen and 2 mg/mL PAG solutions 
in PBS directly onto the array elements according to the protein key in Figure 
4.4.  
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Figure 4.4. Protein functionalisation array key. 
The PAG was used as the primary assay, with BSA and CRP used as specific 
assay channels for the purified antibody experiments. For the human serum 
study, aBSA and aCRP can act as secondary negative controls. 
4.5 Results 
The sensitivity and detection limits of the PAG assay were first determined for 
both aBSA (derived from sheep) and aCRP (derived from goat) and followed by 
an experiment with a mixed solution (1:1) of the two. The binding kinetics where 
analysed using the global fit procedure and the kinetic parameters derived. 
Similar analysis was then performed with human serum to derive an SOP for 
the determination of total IgG.  
4.5.1 Purified Antibody Binding Characteristics 
4.5.1.1 IgG – PAG 
The immuno-kinetic assay was performed for two purified antibodies with typical 
traces shown in Figure 4.5. Each signal is corrected for spot RI sensitivity and 
referenced against the fibrinogen control spots for temperature and LED 
intensity drift. The antibody concentration ranges from 0.16 to 10 nM and the 
samples were injected in a random order. Each assay was 30 minutes in 
duration: a 5 minute baseline stabilisation, a 10 minute association phase 
measurement time followed by a 5 minutes dissociation, before the array was 
regenerated for 4 minutes and the baseline left to stabilise before repeating with 
the next concentration. 
Fibrinogen
PAG
BSA
CRP
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Figure 4.5. Immuno-kinetic assays for purified antibody binding to PAG studies. Association 
phase, 0 – 10 mins; dissociation phase, 10 – 15 mins, followed by a 4 minute regeneration (not 
shown). Samples of known 10 nM (based on purification and dry weight of the antibody supplied) 
followed by successive 2-fold dilutions: (A) aBSA (sheep) – PAG; (B) aCRP (goat) – PAG; and (C) 
mixed aBSA + aCRP (1:1) – PAG. The black line is the signal from the AR and the red line is a 
global fit to all concentrations. 
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The global fit to the kinetic response using the Langmuir isotherm (Chapter 2) is 
in excellent agreement with the data: with χ2 values of 307, 996 and 162 in 
panels (A), (B) and (C) of Figure 4.5 respectively. The variation in χ2 is caused 
by different noise levels in each experiment: two standard deviations (± 2σ) 
variation measured from the baseline as 19.2 RIU for (A), 16.8 RIU for (B) and 
19.9 RIU for (C). The fit is still significant for (B) if the mean ± σ of the residual 
plot for these data are compared; by subtracting  the experimental data from the 
fitted model. In this case the σ from the residual of panels (A-C) are, 8.5 ± 37.9 
(A), 0.3 ± 23.3 (B), and 4.9 ± 30.0 (C): meaning that the model favours (B) by 
this measure. The statistical analysis is summarised in Table 4-4. 
Table 4-4. Statistical analysis of the purified antibodies binding with PAG. 
Analyte R2 χ2 Residual (µ ± σ) (µRIU) 
aBSA 0.999 307 8.5 ± 37.9 
aCRP 0.999 .</ 0.3 ± 23.3 
aBSA + aCRP 0.999 162 4.9 ± 30.0 
 
The correlation matrices of parameters derived from the fits with each 
concentration having its own value of '& can also be used to interrogate the 
model (See Appendix A) and perform as expected. 
4.5.1.2 IgG – Antigen 
The purified antibodies also interacted with the specific antigens printed on the 
array, Figure 4.6A shows the aBSA – BSA complex formation and Figure 4.6B 
shows the aCRP – CRP. Compared with Figure 4.5 the shape of these curves 
has greater variation. Figure 4.6A shows a linear fit suggesting that '& will 
reach a higher maximum than Figure 4.6B. Both these fits also reach a smaller 
value of '& compared with when PAG is the ligand. The global model does not 
fit Figure 4.6B as accurately as the other data sets suggesting that this process 
may be more complex; although for a direct comparison the single exponential 
model is still used. 
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Figure 4.6. Immuno-kinetic assays for purified antibody binding to their specific antigens studies. 
Association phase, 0 – 10 mins, dissociation phase 10-15 mins, followed by a 4 minute 
regeneration (not shown). Samples of known 10 nM (based on purification and dry weight of the 
antibody supplied) followed by successive 2-fold dilutions: (A) is aBSA – BSA; and (B) is aCRP – 
CRP. The black line is the signal from the AR and the red line is a global fit to all concentrations. 
Statistical analysis of the data in Figure 4.6 data found the noise (± 2×σ) of 
these assays to be similar to that of the PAG assays with the BSA assay having 
a noise value of 16.0 RIU and CRP 13.8 RIU: therefore the sensitivity of the 
antigen spots are similar to that of the PAG assay spots. The statistical analysis 
from global fit procedure is shown in Table 4-5. 
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Table 4-5. Statistical analysis of the model fits of the purified antibodies binding their respective 
antigen kinetic data. 
Assay R2 χ2 
Residual 
(µ ± σ) (µRIU) 
aBSA-BSA 0.999 44 0.3 ± 13.0 
aCRP-CRP 0.999 197 1.3 ± 20.1 
 
Considering that the fit in Figure 4.6B does not look as accurate as (A) the 
value of χ2 is small. The aBSA – BSA fit has a χ2 value of 44, aCRP – CRP has 
a value of 197 which on visual inspection appears to be low given the deviation 
from the data throughout the global fit process. The mean and standard 
deviation for the models were 0.3 ± 13.0 µRIU for BSA and 1.3 ± 20.1 µRIU for 
CRP, both having a small deviations from zero in the residual plot. The 
correlation matrices (Appendix A) show reasonable correlation and suggest that 
this model is suitable for this data set.  
4.5.2 Human Serum Total IgG 
The same protocol was followed for human serum total IgG assay but with a 
much larger dilution ranging from 10-fold down to a 165,000-fold to locate the 
samples correctly on the linear response part of the calibration curve and cover 
the full assay dynamic range. Figure 4.7 presents the collected immuno-kinetic 
assay data for the PAG-IgG
 
human serum assay. 
 
Figure 4.7. Immuno-kinetic assay for IgG from human serum binding to PAG. From top to bottom: 
the initial concentration is a 10-fold dilution of human serum (black), followed by a 1:40 (red) then a 
1:3 dilution from there; the final injection is a blank with no human serum present (navy blue). 
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From Figure 4.7 it can be seen that the responses from the dilutions follow the 
expected trend. It is interesting to note that the noise levels do not increase 
when the complex sample is introduced, which would not be a problem if the 
camera captured the change in brightness from below, therefore the bulk 
solution would not interfere with the resulting signal. However, the response is 
captured through the bulk solution meaning that it is possible for the bulk 
solution to have an impact on the signal noise level. The noise present before 
the serum injection was 15.8 RIU, for the low concentration (165,000-fold) the 
noise was 17.2 RIU and for the highest concentration (10-fold) the noise was 
22.3 RIU. The increased noise does follow a positive trend with increased bulk 
concentration of ≈ 50% from no serum present to a 10-fold human serum 
dilution. Over this period however the HF noise is practically unchanged.  
4.5.3 Immunoglobulin Isotype Specificity  
As discussed in the introduction, the PAG has high affinity for all 
immunoglobulin isotypes including IgG, IgA, IgM and IgE [236, 272, 273] the 
relative concentrations of which can be determined via secondary binding 
recognition events. Secondary studies on a PAG surface can be difficult as the 
secondary antibody will bind to available sites on PAG as well as the captured 
primary analyte so the PAG surface must be first completely saturated before 
the secondary analysis. 
The data presented in Figure 4.8 panels (A) and (B) underwent the saturation 
method of flowing human serum over the surface at a dilution of 1:2,500 until 
the same response was observed in successive injections indicating saturation 
of the PAG surface with primary analyte. Residual changes visible before the 
vertical dashed line are attributed to non-specific binding and are removed 
consistently each time during the wash step. No further change in '& was 
observed following, typically, 7 repetitions of the serum binding steps. In panel 
(A) the secondary detection antibodies were injected in the order of typical 
immunoglobulin isotype concentration in human serum (IgG > IgA > IgM > IgD > 
IgE), with this order reversed in panel (B). Also injected were secondary 
antibodies against the Fc portion of IgG (aIgGFc) and the heavy and light chains 
of IgG (aIgGH+L). 
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Figure 4.8. Secondary analysis of isotype class binding to the primary serum analyte. (A) the 
secondary detection antibodies were injected in the order of typical Ig from high to low; Panel (B) 
the secondary detection antibodies were injected in the order of typical Ig from low to high; (1) = 
aIgGH+L; (2) = aIgGFc; (3) = aIgA; (4) = aIgM; (5) = aIgD; and (6) = aIgE. Gray dashed lined represents 
the point at which the PAG surface is saturation. Regeneration is indicated by the asterisk. 
As expected the majority of the secondary signal is from the aIgGs consistent 
with the largest IgG serum concentration, a small signal is present from aIgA 
and aIgM but aIgD and aIgE showed only a response equal to or less than that 
of the small reproducible signal from the saturation process attributed to NSB. 
0 60 120 180 240 300 360 420
0
3
6
9
12
15
∆R
I (m
R
IU
)
time (min)
*A
0 60 120 180 240 300 360
0
3
6
9
12
15
∆R
I (m
R
IU
)
time (min)
*B
1
2
3 4 5 6
6 5 4
3
2
1
Chapter 4 
114 
 
4.6 Discussion 
The aim of the work presented in this chapter was to develop a method and 
protocol for quantifying total IgG from crude serum samples by using an 
antibody purification protein (PAG) in an assay on the AR platform. By doing so 
the total IgG assay could be added to any other specific protein assays as a 
secondary diagnostic to aid in the diagnosis or monitoring of patients. It could 
also be used as a primary diagnostic for conditions such as sepsis which is 
consistent with an initial drop in antibody levels or in the treatment of patients 
with IVIG. 
Initial experiments to assess the PAG – IgG assay involved purified polyclonal 
antibody solutions in PBS derived from two different species. To these data the 
global fit model, discussed in Chapter 2, was used and the binding kinetics 
derived. The choice of the polyclonal purified antibodies allowed two species to 
be compared: goat and sheep. Also the polyclonal antibodies are a better 
representation of the nature of antibodies present in serum. In fact, as the PAG-
IgG complex forms via the Fc region, whether the analyte is polyclonal or 
monoclonal should not make any difference due to the Fc regions being 
conserved between different IgG antibodies from the same species. These 
initial experiments help to characterise the assay and assess its sensitivity, 
specificity and reproducibility. 
4.6.1 Purified Polyclonal Antibody Binding Kinetics 
4.6.1.1 Inter-PAG Assay Comparison 
The data were fitted to the global model allowing the parameter '& to vary 
independently. The goodness-of-fit was discussed in the results section with 
values of χ2 quoted and the correlation matrices interrogated. Statistical 
analysis of the residual plot showed the deviation of the model from the data to 
be minimal (< 40 RIU). The sensitivity was similar over all assays and the same 
was also true for the LOD, which could be calculated as three standard 
deviations which correspond to a concentration of ≈ 0.16 nM for the PAG assay 
and ≈ 1 nM for the specific antigen assays. Table 4-6 is a summary of the 
constants derived from the data presented in the results section.  
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Table 4-6. Derived rate constants from the global fit analysis of the immuno-kinetic assays. 
Ligand Analyte 
"# 
( × 105 M-1s-1) 
"$ 
( × 10-5 s-1) 
34 
(nM) 
'& 
(mRIU) 
PAG 
aBSA 6.94 ± 0.10 18.8 ± 0.1 0.27 ± 0.01 4.02 ± 0.12 
aCRP 5.96 ± 0.02 6.83 ± 0.04 0.12 ± 0.01 3.99 ± 0.10 
Mixture 4.96 ± 0.11 7.20 ± 0.35 0.15 ± 0.02 5.05 ± 0.16 
BSA aBSA 0.53 ± 0.01 2.84 ± 0.41 0.53 ± 0.04 5.92 ± 0.24 
CRP aCRP 2.58 ± 0.01 26.0 ± 0.90 1.01 ± 0.04 1.54 ± 0.05 
 
The limiting surface coverage, '&, derived from the model shows the 
occupancy of the surface and is a fraction of the occupied binding sites due to 
their close proximity hindering total coverage '&. The pure polyclonal antibodies 
for BSA and CRP surface coverage’s have a '& value of 4.02 ± 0.12 mRIU and 
3.99 ± 0.10 mRIU respectively. These values reach the same value of '& 
indicating the same occupancy of the binding site on the PAG surface. The two-
component mixture however shows a '& value 25% greater than that of the 
individual samples of 5.05 ± 0.16 mRIU. The reason for the increase in '& for 
the mixed sample must be linked with antibody packing on the surface. Species 
variation in the tertiary structure for sheep (aBSA) and goat (aCRP) antibodies 
may result in the epitope position varying on the Fc region allowing tighter 
packing of IgG from two species. 
The aBSA and aCRP dissociation constants, "$, were (18.8 ± 0.1) × 10-5 s-1 and 
(6.83 ± 0.04) × 10-5 s-1 respectively, therefore the aBSA – PAG complex 
dissociates ≈ 3× faster than aCRP-PAG; owing to structure variation in the Fc 
region of the antibodies [295]. Table 4-2 highlights the different affinities the IgG 
subclasses have for SPA and SPG with 34 values varying by up to 3× on each 
protein. The IgG subclass binding spectrum could lead to the polyclonal 
antibodies having a similar range in their derived kinetic constant values. The 
mixed sample has a "$ value of (7.20 ± 0.35) × 10-5 s-1 which is in between the 
individual values but allowing for the error is also the same as the "$ value for 
aCRP. There may also be slight species- variation although from Table 4-3 it 
can be seen that both goat and sheep antibodies have a high affinity for PAG 
but the extent of which is unknown.  
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There is less variation between the association values for all three samples 
(Table 4-6) with only 15% variation between the individual aBSA, "# = 6.94 ± 
0.10) × 105 M-1s-1, and aCRP, "# = (5.96 ± 0.02) × 105 M-1s-1, samples. The 
trend however is the opposite of the "$ values seen, with aBSA having a faster 
association and dissociation rate. The "# value of the mixture was (4.96 ± 0.11) 
× 105 M-1s-1 which is lower than the individual values by 20 – 30%, or put 
another way, reaches the surface 20 – 30% slower than the individual 
antibodies. One possible explanation for this is that the antibodies may interact 
with each other to a small extent or the aBSA, with a faster association and 
dissociation reaches the surface before aCRP but then leaves again before 
aCRP has chance to bind. However, over the whole 10 minute association 
period the aCRP can slowly replace the aBSA, allowing the dissociation rate to 
better represent that of aCRP and not the aBSA which dissociates faster. 
The equilibrium dissociation constants, 34, show that the goat IgG interacts 
stronger with PAG resulting in a higher affinity (0.12 ± 0.01 nM) over the sheep 
IgG–PAG interaction (0.27 ± 0.01 nM). Elliasson et al. [215], compared IgG 
from different species against the relative quantity of polyclonal 
immunoglobulins required to give 50% inhibition of rabbit polyclonal IgG binding 
toward PAG and found that value for sheep was 11 whist the value for goat was 
2.9, a ratio of 1:3.8. This ratio agrees with the affinity values presented here: 
goat IgG has a higher affinity for PAG than sheep IgG; 0.12 nM and 0.27 nM, 
respectively. This ratio however, is different with the goat, aCRP-PAG, affinity 
being 2.25-fold larger than the sheep, aBSA-PAG. The mixture has a 34 value 
of 0.15 ± 0.02 nM, which lies between the individual values calculated. It follows 
the expected trend given the 1:1 mixture of the samples but considering the 
variation in "# and "$ is surprising and is an indication that purely the 
association or dissociation rate on their own does not represent the true nature 
of the interaction. 
4.6.1.2 Antibody-Antigen Complex Comparison 
Global fit analysis of the kinetic parameters for the aBSA-BSA binding shows a 
value of '& of 5.92 ± 0.24 mRIU and for aCRP – CRP 1.54 ± 0.05 mRIU, 
indicating a lower surface occupancy. The value of '& varies significantly for the 
antigen-antibody complexes binding at the Fab region whereas the Fc region 
binding to PAG is significantly more consistent. The larger variation in '& may 
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be explained by different binding site densities on the sensor surface. In the 
case of BSA and CRP the number of binding sites is controlled by the epitope 
presentation and for PAG the number of Fc-region binding sites available at the 
surface. The efficiency of the EDC/NHS immobilisation chemistry, which may 
vary slightly from protein to protein, and the orientation of the ligand on the 
surface, is also important, as some binding sites may be inaccessible. 
The polyclonal nature of the antibody allows binding to multiple epitopes on the 
protein surface increasing the total binding site density and hence the total 
protein load. The difference in '& suggests that there could be a greater variety 
of epitopes present, or antibody diversity, in the pAb aBSA sample compared 
with the pAb aCRP. In the PAG assay '& is more controlled owing to the shared 
number of binding sites for the pAb and the homologous nature of the Fc region 
and means that apart from species-to-species variation a polyclonal sample can 
effectively be classed as a monoclonal sample binding to the same surface 
binding sites. 
The same reasoning for the variation in '&  can be used when comparing the 
derived rate constants. The equilibrium dissociation constants (34), 
interestingly, are both larger for the antibodies binding to their native protein. 
The smaller value of 34 for the IgG-PAG complex means that it is more strongly 
bound than IgG-antigen: this is further evidence that PAG is a very efficient tool 
to quantifying IgG especially when other background proteins are present in 
complex samples. Specificity was also very high with no observable binding 
present in any control assay spots. 
The correlation matrices for the model (Appendix A) show that values of '& are 
highly correlated with "#, higher concentrations in some cases, such as aBSA – 
BSA (Table 4-7), having a correlation value of -1 due to parameter pollution. 
This number generally reduces with concentration, with the lowest 
concentration at 0.31 nM having a value of -0.09. The same is true for "$ but to 
a much lesser extent due to the dissociation constants being ≈ ten orders of 
magnitude smaller than "# and more importantly because both "# and '& are 
determined together during the association. "$ is also determined in the 
association phase but the dissociation phase predominately controls the value 
of "$. 
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Table 4-7. Correlation matrix for the global fit of aBSA – BSA. 
 
uv uw xy 
Global Global 10 nM 5 nM 2.5 nM 1.25 nM 0.63 nM 0.31 nM 
uv Global 1.00 -0.70 -1.00 -1.00 -0.99 -0.98 -0.76 -0.09 
uw Global -0.70 1.00 0.73 0.73 0.72 0.71 0.55 0.06 
xy 
10 nM 
-1.00 0.73 1.00 1.00 1.00 0.98 0.76 0.09 
5 nM 
-1.00 0.73 1.00 1.00 0.99 0.98 0.76 0.09 
2.5 nM 
-0.99 0.72 1.00 0.99 1.00 0.98 0.76 0.09 
1.25 nM 
-0.98 0.71 0.98 0.98 0.98 1.00 0.74 0.08 
0.63 nM 
-0.76 0.55 0.76 0.76 0.76 0.74 1.00 0.07 
0.31 nM 
-0.09 0.06 0.09 0.09 0.09 0.08 0.07 1.00 
 
Calibration of the immuno-kinetic assay is essential to produce a quantitative 
result, for example, ELISA assays regularly use a 4-parameter curve fitted as 
log(analyte concentration) against response [296]. Two calibration procedures 
were tested using different parameters determined from the data to create a 
standard curve that best represents the assay: '& and the combined parameter 
'&"#, (chosen as the correlation coefficients are small), before area under the 
curve (AUC) was finally selected. 
AUC was selected as it is easy to determine, the area changes rapidly for low 
concentrations, slower for higher concentrations and is less susceptible to 
noise, therefore determined more accurately. It also allowed the greatest 
dynamic range due to the poor fit for the model at higher concentrations, while 
AUC is not reliant on the shape of the curve. Both single and double 
exponentials were fitted to the data but both were limited in their dynamic range 
and accuracy. Secondary problems may also arise from using two exponentials. 
For example, the time constants must be significantly different, typically two 
orders of magnitude and the parameters can also be highly correlated and 
therefore are not stable. The AUC does not however require any functional form 
and is entirely empirical and with a SNR dependent only on instrumental 
factors. 
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Table 4-8. Comparison of calibration procedures using the single and double exponential fits to the 
AUC. Values were calculated by allowing each dilution to become an unknown and back 
calculating the concentration from the remaining points.  
Dilution 
Double exponential 
(9 standards) 
(Accuracy % ± 2 σ) 
Double exponential 
(7 standards) 
(Accuracy % ± 2 σ) 
Single exponential 
(4 standards) 
(Accuracy % ± 2 σ) 
1:5 - - - 
1:10 - - - 
1:40 250 ± 120 - - 
1:160 203 ± 135 192 ± 70 - 
1:640 46 ± 126 56 ± 61 - 
1:2,560 182 ± 30 165 ± 7 - 
1:10,240 98 ± 48 62 ± 71 97 ± 4 
1:40,960 97 ± 56 85 ± 288 102 ± 8 
1:163,840 - - - 
 
From the single and double exponential analyses there is some significant 
variation in the accuracy and dynamic range of the standard curves. Clearly 
when all concentrations are considered even the double exponential fit is not 
accurate. The reasons for this are that at higher concentrations monolayer 
equivalent '& is reached before the end of the association phase therefore any 
increase in signal after this point is owed to the formation of a more weakly 
bound secondary layer on top of the mono-layer. To avoid effects such as mass 
transport, steric hindrance, crowding and aggregation the loading of the sensor 
surface should be kept closer to ≈ 50% coverage. The effect is reduced when 7 
standard points (dilutions) are used but as the double exponential is still used to 
fit the data then the surface is still not following a 1:1 binding model. The 
standard curve gives the optimum performance with a dilution of 640-fold (≈ 50 
nM) or greater as the 1:1 binding model then better defines the data. 
The accuracy level is 10% when constructing the calibration curve from the 
single exponential fit of the Langmuir equation but the dynamic range is limited 
to two orders of magnitude. A calibration curve relating AUC to analyte 
concentration is shown in Figure 4.9, fitting the data to a five-parameter logistic 
curve (5-PL) conventionally used in ELISA assay calibration curves, according 
to the equation below [297]: 
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AUC  ( ,    (1 , @)#^#_`ab+| B}~ 
 Equation 4-1 
where, , is the value for AUC at the minimum asymptote, , is the hill slope, k, 
is the concentration at the point of inflection, (, is the AUC value for the 
maximum asymptote, , is the asymmetry factor and )analyte+ is the bulk 
analyte concentration. 
 
Figure 4.9. Calibration curve of AUC against human serum IgG concentration (µg/mL). Black line 
represents the 5 parameter fit; red line represents the 95% confidence limits; R2 = 0.999. 
The choice of fitting the data with the 5PL standard curve in Figure 4.9 has 
reduced the assay error and increased the dynamic range to include all data 
from the dilutions studied. The data are also now plotted as concentration rather 
than dilution. An external QA-controlled laboratory (Clinical Chemistry 
Laboratory, Royal Devon and Exeter Hospital Trust) was used to determine the 
IgG concentration in the human serum sample which was then used as a 
secondary standard in our experiments. The IgG concentration of human serum 
was determined by an immunoturbidimetric assay and found to be 5.7 ± 0.1 
mg/mL. From this the detection limit from the raw data of our PAG assay was 
determined to be 0.16 ± 0.10 nM (24 ± 15 ng/mL) from ±3σ of the noise from 
the largest dilution data, Figure 4.7. 
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The total dynamic range for the assay in Figure 4.9 is from 34 ng/mL to 567 
µg/mL (0.2 nM – 3.7 µM) with a linear range of 140 ng/mL to 35 µg/mL (1 – 233 
nM); three orders of magnitude; an increase of 1-order of magnitude over the 
single exponential used in Figure 4.7. The detection limit of the PAG assay is 
much lower than an IgG immuno-turbidometric test at ≈ 0.3 mg/mL but is not as 
low as a standard IgG ELISA kit at ≈ 150 pg/mL. As the normal range of 
concentrations of IgG in serum is 5 – 16 mg/mL the IgGtotal assay is accurate 
and sensitive for the clinically useful concentrations.  
An advantage of our assay over both the ELISA and immuno-turbidometric 
assay is an increase in the dynamic range. Our assay has a dynamic range of 
three orders of magnitude, compared with 2.5 for an ELISA assay and only 1 for 
a turbidometric assay, with also a larger linear range: the accuracy is also 
comparable to the two other assays. With these advantages in mind, a standard 
operating procedure (SOP) may be derived for the array reader platform 
allowing this assay to be incorporated readily into a clinical biomarker array 
design if required.  
4.6.2 Total IgG Assay Standard Operating Procedure  
To determine total IgG from a serum sample the follow SOP can be used: 
1. Install an array functionalised with PAG and two negative controls (e.g. 
fibrinogen and BSA). 
2. Clean the array with 2 × 4 minute regeneration steps of 100 mM 
phosphoric acid. 
3. Block the array by injecting a 2 µM HSA solution for 10 minutes followed 
by a 4 minute regeneration step. 
4. Calibrate the array with 2×PBS calibration switch. 
5. Perform both the calibration and unknown sample assays in a 
randomised order: 
a. Calibrate the array with human serum at three dilutions (1:2,500, 
1:5,000, and 1:10,000). 
i. Two repeats at each dilution in a randomised order. 
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ii. After a baseline of 4 minutes, inject sample for 10 minutes 
followed by a 4 minute regeneration step. 
b. Perform injections of the unknown serum sample at the same 
three dilutions (1:2,500, 1:5,000, and 1:10,000). 
i. Two repeats at each dilution in a randomised order. 
ii. After a baseline of 4 minutes, inject sample for 10 minutes 
followed by a 4 minute regeneration step.  
6. Collect a blank response with PBS over the same time course as step 5. 
7. Calculated area under the curve (AUC) for all injections over 10 minutes 
and plot a standard curve with the calibration points using the 5PL fit on 
a semi-logistic plot (Figure 4.10).  
The SOP was validated using two unknown dilutions of human serum. The 
standard curve produced is shown in Figure 4.10 (R2 = 0.999) indicating a 
detection limit of 24 ng/mL. 
 
Figure 4.10. Standard curve for the SOP validation study. R2 = 0.999. With two replicates at each 
point. 
The results are summarised in Table 4-9 with the two unknown samples 
labelled S1 and S2. The concentration of the two unknown samples was 
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determined with 5% of the expected values although there is an apparent 
systematic error causing the concentration to be under estimated. 
Randomisation of the order of the samples improves the determination probably 
due to the degradation of the surface following the regeneration steps. 
Table 4-9. Unknown samples with calculated AUC and derived concentration from the standard 
curve. 
Unknown 
Sample 
AUC / 
(1 × 106) Derived Concentration (µg/mL) 
Known Conc. 
(µg/mL) 
Error 
(%) 
S1 0.881 0.904 0.907 0.4 
S1 0.874 0.890 0.907 1.9 
S2 0.579 0.430 0.453 5.1 
S2 0.586 0.435 0.453 4 
 
Comparison between the determined sample concentration and those 
determined from the clinical chemistry laboratory using the 
immunoturbidometric IgG assay is shown in Figure 4.11. The data fall on a line 
with slope 0.98 ± 0.02 with intercept 0.031 ± 0.011. As the gradient is less than 
1, it suggests that the assay will underestimate at higher concentrations. 
 
Figure 4.11. IgG determination of S1 and S2 with replicates following the AR SOP plotted against 
the known IgG concentration calculated externally via an immuno-turbidometric IgG assay. The 
linear fit has an equation of y = 0.03 + 0.98x with R2 = 0.999. 
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To check the reproducibility of this experiment five repeats at one dilution were 
collected and their AUC compared. Figure 4.12 contains the response of five 
different dilutions with five repeats collected at the middle dilution. These were 
collected in a randomised order with a variation in AUC calculated for the five 
repeats of 0.68%. The assay therefore had an inter-assay variability (CV) of 
1.4%, which is comparable to the immuno-turbidometric assay and much lower 
than the inter-assay ELISA variability of 10%. 
 
 
Figure 4.12. IKA of IgG in human serum at five different dilutions. Present in the centre bind are five 
repeats of 10,000-fold dilution marked with an asterisk. 
Table 4-10 summarises the findings of the AR IgG assay and compares them 
against the standard clinical methods of IgG determination. The AR platform 
has both a larger dynamic and linear range than the other assays, although it 
has a larger detection limit than the ELISA assay. For IgG determination a 
detection limit of 24 ng/mL is far lower than necessary but can help reduce the 
sample volume required as higher dilutions are possible with a reduced chance 
of the sample falling outside the assay range. 
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Table 4-10. Comparison of ELISA, Tubidometric and Immun-kinetic assay for total IgG assay 
performance.  
Property 
ELISA IgG 
assay 
Turbidometric 
IgG assay 
Array Reader 
IgG assay 
Dynamic range (orders of 
magnitude) 2.5 1 3 
Linear range (orders of 
magnitude) 1 1 1.5 
Detection limit 150 pg/mL 0.3 mg/mL 24 ng/mL 
Accuracy (CV) < 10% < 1% < 5% 
Assay time scale 6 hrs 2 hrs 2 hrs 
Cost of assay £200 £20 £10 
 
Table 4-10 also highlights the higher cost involved in an ELISA assay, both in 
time and money, which is an important factor in a clinical laboratory as quick 
results mean that patients can be treated more efficiently, potentially freeing up 
beds for the next patient. The 2 hour time scale also allows for the calibration 
process. If it were possible to perform the calibration at an earlier time 
independently, for example at the start and end of the day, then the actual 
assay time could be reduced to as little as 20 minutes making this potentially a 
point-of-care procedure that could be performed at the patient bedside.  
4.6.3 Immunoglobulin Isotype Specificity Analysis 
The performance of the immuno-kinetic assay for the detection of IgG has been 
demonstrated to be superior to the conventional assay platforms and has the 
potential to be extended to a quantitative assay for the other antibody isotypes. 
The data presented in Figure 4.8 were analysed by fitting the Langmuir 
equation to each binding step to determine '&. Due to the high dilution of the 
serum the single exponential fitted the response without showing signs of a 
more complex interaction. '& values for the seventh serum injection (at the 
point of surface saturation) was ≈ 0.42 mRIU and subtracted from all 
subsequent secondary '& values. Figure 4.13 shows the '& values derived 
from the exponential fit for the primary response (the first injection of serum) 
and the secondary responses minus the final '& value from the primary 
saturation: this removed the NSB and the remaining signal could therefore be 
classed as a specific interaction.  
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Figure 4.13. ϑm values for primary and secondary analytes flowed over the PAG surface. Dark grey, 
immunoglobulin low-high serum abundance; Light grey, immunoglobulin high-low serum 
abundance. 
The theory behind this second step identification was that the extent of Ig 
isotypes interacting with PAG was unknown and could reduce the assay 
specificity if a portion of the signal was not derived from IgG. It is interesting to 
see that if the aIgG is injected first it inhibits other secondary aIgs binding to the 
PAG apart from IgM. The blocking of other secondary aIgs is partially due to 
steric effects when the surface has been essentially saturated with aIgG. When 
the sequence is reversed IgM is again identified but so is a small portion of IgA.  
The binding of IgM and IgA may be explained by the properties of SPA. SPA 
contains regions similar to the Fc receptor FcµR capable of binding both IgM 
and IgA which could be conserved in the chimeric protein: this could explain the 
signal present of both these isotypes. The second option is that it binds via the 
Fab region. Jansson et al. [298], suggested that SPA binding domains possess 
Fab binding as well as Fc binding and Bjork et al. [283], found that Fab can bind 
to SPG but with only 10% the affinity than that of the Fc region. Therefore there 
is a possibility that both IgM and IgA may bind via the Fab region. Along with 
the larger molecular weight of the pentameric IgM and dimeric IgA, this could 
account for the signal of both isotypes: for example one dimeric IgA molecule 
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binding to the surface would result in twice the signal seen for IgG. The smaller 
value seen than what is present in serum could be due to the fact that both IgM 
and IgA if interacting with PAG via the Fc region would need to form a complex 
that lies flat to the surface which could be sterically unfavourable as these sites 
are more masked than in the other isotypes. 
Binding via the Fab region was tested in the isotype experiment by flowing aIgG 
over the saturated surface specific for the heavy and light chains (H+L) and an 
aIgG specific for the Fc region. Signal from the aIgGFc would indicate Fab 
binding as the Fc region should have already formed a complex with the PAG 
surface and therefore be unavailable. In fact aIgGFc bound to ≈ 30% to that of 
the aIgGH+L signal seen. This produced a ratio of 3:10 that highlights the fact 
that binding via the Fab region is possible on the PAG surface but to a lesser 
extent due to the lower binding affinity. 
This secondary analysis study has shown that a small proportion of the mass on 
the sensor surface is due to other isotypes and not only IgG. The percentage of 
each is summarised in Table 4-11.  
Table 4-11. Summary table for the percent of each isotype compared to the total immunoglobulin 
primary response from Figure 4.13. Low – high represents the relative serum abundance. 
Isotype Low – High (%) High – Low (%) 
IgG 89 99 
IgA 6 0 
IgM 5 1 
IgD 0 0 
IgE 0 0 
 
The signal is predominately IgG with a small proportion due to IgA and IgM, 
which are the second and third most common Igs present in serum. In an 
average adult the serum immunoglobulin levels are: IgG, 80%, IgA, 12 – 15%, 
and IgM ≈ 8% [239], which is still a larger percentage than observed in Table 
4-11 which leads to the conclusion that while PAG can bind both IgA and IgM 
these antibodies bind with lower affinity than IgG. 
It is also worth considering a phenomenon known as the Vroman Effect [170, 
299, 300], which is generally more applicable for non-specific interactions: when 
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proteins have similar nonspecific association rates the lighter proteins are 
displaced by the heavier ones [174, 301-303]. Over a longer time scale this 
process could also occur for specific interactions where the complex formed 
with the heavier analyte is more likely to occur. Over the course of the standard 
association phase (10 minutes) this process may be unlikely but over what is 
effectively a 70 minute association phase this effect could be possible. 
From the isotype specificity study it can be concluded that a portion of the signal 
is attributed to IgM and IgA. The small proportion of IgM and IgA could increase 
the assay error by up to 10%, making this assay more comparable to ELISA in 
terms of accuracy. However, this error could also be considered as removed by 
the calibration procedure which also used serum containing all Ig isotypes. An 
experiment that could confirm if the interaction is via the FcµR like mechanism 
would be to also print recombinant versions SPA and SPG with the albumin 
binding region removed from SPG. The mechanisms of interaction could then 
be determined more precisely by comparison of the individual responses: with 
SPG potentially exhibiting no binding of IgM. Antibody fragments could also be 
purchased to interrogate either the Fab or Fc region for example. Fragments 
could even be produced in the laboratory by proteolytic cleavage of the disulfide 
bond in the antibody hinge region with either pepsin or papain [304]: pepsin 
could cleave the Fc and Fab regions forming two complexes [305], whereas 
papain could be used to separate the Fc region but also the two Fab regions 
forming three complexes for kinetic comparison [306]. Although these smaller 
complexes may not reflect the true affinities of whole antibody regions with 
PAG, owed to the reduction in mass and also size which may be sterically more 
favourable. 
In the purified antibody experiments the IgG-PAG binding constants of 
polyclonal sheep IgG (aBSA) were compared with polyclonal goat IgG (aCRP): 
a difference in affinity was found with goat IgG having a stronger affinity than 
sheep IgG. The stronger affinity of goat is consistent with the literature values 
for the binding affinity of different IgG species with SPG: this ability to measure 
the affinity of the Fc region could have applications in the production of 
therapeutic antibodies. Another application could be to measure the affinity of 
antibodies produced after vaccination, as the Fc region of these antibodies is 
critical for the body to respond to the invading pathogens. Therefore, an 
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antibody with a higher affinity for the Fc receptors will be better suited at 
responding when the immune system is compromised.  
The large numbers of binding sites present on each PAG (2 + 4, from SPG and 
SPA, respectively) increases the binding capacity and therefore the dynamic 
range. The six binding sites also assure that all immobilised PAG molecules will 
have at least 2 or 3 active binding sites due to orientation, providing both a 
more uniform and more sensitive assay surface. Initial experiments showed the 
accuracy of the assay to be very high with an inter-assay variability of just 1.3%. 
The specificity of the assay was calculated at > 90% although with more work 
performed on the binding characteristics of PAG with human serum this number 
could be improved. Even so, when all sources of error are combined, the value 
of ≈ 10% is still comparable to that of the IgG ELISA assay. 
4.7 Conclusion 
Several studies indicate that IgG deficiencies may be associated with immuno-
deficiency disorders [242] and a number of respiratory tract infections such as 
bronchiectasis [307] and bronchitis [243]: immuno-deficiency may also be 
present at the onset of sepsis [308]. In other cases IgG levels may increase 
such as in patients with pneumonia [309] and many autoimmune diseases 
[310]. In the majority of these cases immune system monitoring is required over 
time so if this test could be simplified or measured outside of a clinical 
laboratory then monitoring IgG in patients as a point-of-care device would be 
most beneficial.  
A protocol for quantifying total IgG has been developed and combines common 
antibody purification techniques with an SPR platform for label-free 
quantification in real time using a small sample volume. The ease of this assay 
allows it to be combined with many other serum biomarkers on the same array 
for use as a multi-assay detection array. In contrast, detection of multiple 
ligands using both ELISA and turbidometric techniques, must be performed 
independently. Multiplex arrays for autoimmune disorders would be a good 
candidate as total IgG will supplement the specific IgG levels derived.  
There are both advantages and disadvantages when comparing the AR PAG 
assay to ELISA and turbidometric assays. ELISA is a more sensitive assay with 
a much lower detection limit but it is more time consuming and costly. 
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Considering the average concentration of IgG in serum, the superior sensitivity 
and LOD are not necessarily required in this assay: although they help to 
reduce the matrix effects and NSB attributed to the bulk serum solution. 
Turbidometric assays are the method of choice for determining total IgG in 
hospital setting as this is a fast and reliable technique and is not as expensive 
to perform as ELISA. The issue with this IgG assay is its detection limit at only 3 
mg/mL, just below the normal range of IgG. The high LOD means that repeats 
must be performed at similar dilutions to each other and at high concentrations. 
Therefore, a larger serum sample is required and it is less diluted leaving high 
background protein concentrations that could interfere with the assay. Working 
with higher concentrations also reduces the possibility of working with whole 
blood, especially for optical based biosensors such as immuno-turbidometric 
assays. 
There is an issue with immunoglobulin isotype specificity for the IgG-PAG 
assay: although secondary detection confirms the effect is minimal. Protein G is 
an alternative which could solve this problem, but this protein has far fewer 
binding sites and its optimal binding does not occur at physiological pH meaning 
that the chance to apply other assays to the same array could be limited. 
Without first altering the pH the binding of IgG to protein G would not be as 
efficient or reliable as to PAG. The use of PAG is also more beneficial when 
studying other species due to its better affinity for a broader range of 
immunoglobulins. For these reasons the PAG assay is a reliable method for 
quantifying IgG from human serum with a need for a small sample quantity due 
to the dilutions required and a larger assay dynamic range than current 
techniques in clinical use.  
The use of this assay combined with other biomarker assays as a multiplexed 
device is where this assay would stand out. As mentioned, autoimmune 
disorders would be a good starting point. However, it could also be present on 
protein screening arrays which have far more flexibility in disease diagnosis with 
many protein biomarkers well documented for disease. Chapter 5 addresses 
protein screening arrays as this is an important step for the clinical application 
of the AR, especially as point-of-care device. Protein screening is achieved by 
using the properties of PAG to specifically attach capture antibodies raised 
against the target proteins. 
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Another interesting application of importance later in this thesis is the use of this 
assay for vaccine development. If added to an appropriate assay chip, 
quantification of both total IgG and specific IgG could help determine the best 
vaccine for a given disease by measuring the total IgG concentration, the 
specific IgG concentration, and the affinity values for the antibodies produced in 
the serum after vaccination. Chapter 6 applies this idea to help determine the 
best vaccine for the plague bacterium Yersinia pestis, by firstly, measuring the 
affinity of the antibodies raised in mice against two virulence factors in plague, 
F1 and LcrV, followed by secondly, measuring the systemic response of IgG 
production after macaques are immunised with these vaccines produced 
against the virulence factors. 
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5 Optimisation of Protein Screening Assays and 
their Application in Clinical Settings 
5.1 Introduction 
Immunoassay and the associated protein-protein interactions are the theme 
throughout this thesis, with the emphasis thus far on screening for antibodies. 
However, this chapter addresses protein screening arrays and the clinical 
significance of measuring protein analytes from serum. The blood proteome is a 
highly attractive target for LSPR label-free protein screening arrays, due to the 
fact that proteins will constantly perfuse from tissue into the blood stream. The 
human proteome is therefore, a highly dynamic system, containing millions of 
proteins [311] that can vary in concentration by up to 1010 in the blood proteome 
alone [30], offering a significant degree of protein differentiation that is unique to 
each patient.  
It is well recognised that the complexity of the human proteome far exceeds that 
of the genome. Proteins are responsible for performing most catalytic, signalling 
and structural functions in living organisms. The measured change in level of 
these proteins can be used in clinical research applications such as patient 
stratification, disease diagnosis and therapeutic monitoring as proteins 
characterise molecular malfunctions that may be related to disease [312]. New 
identified biomarkers have the potential to be from novel pathways and to be 
complementary to previously identified biomarkers. However, few biomarkers 
have successfully transitioned from proteomic discovery to routine clinical use. 
Immunoglobulins (Ig) are one of the most abundant proteins in the serum 
proteome. Antibodies, particularly IgG, are an ideal target due to their 
availability and large size. In contrast, proteins are present in varying 
concentrations, with a mass ranging from 9 kDa up to as large as 340 kDa for 
Fibrinogen. IgG has a molecular weight of 150 kDa, which is a high mass 
analyte that will produce a significant change in the local RI and hence signal 
but there is a low-mass limit for SPR, which has an effect on the LOD. The AR 
has an LOD for IgG of ≈ 0.1 nM, but the LOD scales with the mass of the 
analyte (to first approximation) and the LOD will increase proportionately. 
Detecting low molecular weight serum proteins can therefore prove 
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troublesome, especially given the important role they have in pathological 
conditions such as cancer [313], diabetes [314], and cardiovascular and 
infectious diseases [315]. Only 1% of the entire serum proteome is made up of 
proteins considered to be in low abundance but of high clinical value for disease 
diagnostics [183]. In contrast, a single protein, HSA, comprises ~ 50% of the 
serum proteome and indeed only 10 proteins constitute ~90% of the proteome.  
The demands on constructing an antibody capture surface are also high for the 
surface to function correctly and to have the best possible chance of detecting 
proteins the antibody orientation is vital. The random nature of the attachment 
can cause some of the immobilised antibodies to lose binding activity due to 
steric hindrance, either by the surface itself, or by adjacently immobilised 
antibodies [316]. Therefore, a requirement for antibodies to retain their activity is 
to tether them to the surface via the Fc region, allowing the antigen binding sites 
to remain available for the target proteins. Protein A/G, or similar proteins, can 
provide this role and is commonly used to do so [317, 318]. However, this type 
of immobilisation requires multiple steps and can therefore suffer from lower 
surface density [319]. Although, there will be a higher fraction of active 
antibodies compared with standard coupling methods, such as EDC/NHS. 
Anderson [312] analysed the US Food and Drug Administration (FDA) approved 
protein assays in 2008 and found 205 assays available for different proteins, 
this provided quantitative measurements for only ≈ 1% of the human protein 
gene products with the introduction of new biomarkers averaging only 1.5 per 
year over the last 15 years. However, there is a growing surge in the 
identification of new biomarkers with improving technologies, suggesting this 
number will likely rise, mostly through the use of multiplexed biosensors 
increasing throughput. The most commonly approved protein-based assay is for 
C-Reactive Protein (CRP) with 378 individual assays on the market [312]. CRP 
is an ideal target for initial binding studies, due to its large size, its serum 
abundance and the fact that it has clinical relevance; its properties, functions 
and use as a biomarker are discussed below. 
5.1.1 C-Reactive Protein 
CRP is part of the non-specific acute-phase response to most forms of 
inflammation, infection and tissue damage and is synthesised by the liver [320, 
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321]. Other acute-phase proteins [322] such as proteinase inhibitors do not 
display nearly the same sensitivity, response speed and dynamic range 
compared to CRP: the nearest rival is serum amyloid A protein (SAA) [322]. 
CRP is however, of limited diagnostic value but it is measured routinely in 
hospitals along with red and white blood cell counts as a marker of systemic 
infection [323].  
In apparently healthy people, the serum concentration of CRP is below 5 µg/mL 
indicating little or no acute phase response but upon an acute inflammatory 
event, CRP levels rise as high as 20 – 500 µg/mL [324]. In the general 
population the median concentration of CRP is 0.8 µg/mL, therefore, after an 
inflammatory event the levels can increase more than 500-fold [323]. It has 
even been known for CRP levels following acute-phase stimulus to increase 
from less than 50 ng/mL to 500 µg/mL, an increase of 10,000-fold [325]. Given 
these levels, a three tiered system was proposed to classify CRP blood levels: 
low risk (<1 µg/mL); average risk (1-3 µg/mL); and high risk (>3 µg/mL) [326, 
327]. 
The human CRP molecule has a molecular weight of 115-118 kDa and is 
composed of five identical non-glycosylated polypeptide subunits each ≈ 23 kDa 
in weight [328]. These subunits are non-covalently associated around a central 
pore, with each having a size of 3×3×3 nm, with the whole CRP molecule 
occupying a space of 10×10×3 nm (Figure 5.1). CRP in the presence of 
physiological conditions of calcium, pH and ionic strength is remarkably stable, 
with a serum half-life of 19 hours under all conditions [323]. Even so, CRP can 
occur as two different conformations, the highly stable pentameric structure, 
which is found in circulation and a monomeric structure, mCRP [329]. mCRP 
can be produced in the laboratory with denaturing conditions, however, the 
importance of mCRP is currently not well understood in vivo. One theory is that 
the dissociation mechanism of CRP to mCRP is mediated by activated platelets 
[330]; this change can significantly alter the inflammatory profile and is related 
to cardiovascular risk [331]. Functionally, CRP is constituted by a recognition 
face and an effector face [328, 332]. The recognition face is the ligand-binding 
site, while the effector face, at the opposite side of the CRP pentamer, 
recognizes the Complement pathway component (C1q) and cell surface Fcγ 
receptors (FcγRs) [333]. 
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Figure 5.1. Crystal structure of CRP viewed from above (front/back face) and the side edge (PDB-
code 1GNH). 
Currently, three main types of CRP assay are used clinically: the conventional 
or routine CRP (CRP), high sensitivity CRP (hs-CRP) and cardiac CRP (c-CRP) 
assays [334]. Conventional CRP assays can be qualitative, semi-quantitative 
and quantitative and used for evaluating infection, tissue injury and 
inflammatory disorders and typically have a cut-off of ≈ 5 µg/mL. High sensitivity 
CRP assays, as the name suggests, have a detection range that extends below 
that of conventional CRP assays to ≤ 1 µg/mL. hs-CRP assays are used in 
cases where patients show no signs of inflammation but have condition thought 
to be associated with these processes. Cardiac CRP assays have a similar cut-
off of ≤ 1 µg/mL and are used alongside other techniques, or as an independent 
marker, to monitor individuals at risk of future cardiovascular disease.  
One of the earliest assay methods for sensing CRP is latex agglutination [335] 
which is still used today but since the development of antibodies and better 
purification strategies many other methods are now available, such as enzyme 
immunoassays, immunoturbidimetry and nephelometry [336]. The majority of 
commercially available CRP assays are based on ELISA-tests and are 
therefore well established [337-339]. These tests usually rely on serum samples 
and as often with photometric assays, the response is influenced by the colour 
of the medium and its composition [340]. A number of other samples types are 
becoming of interest, for example, inflammatory bowel disease (IBD) [341] and 
colon cancer [342] are linked with CRP content in faeces and would require 
significant sample preparation for conventional ELISA assays. 
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Other common methods for determining low concentrations of biomarkers found 
more often in clinical laboratories, are based on particle enhanced method, 
such as immunonephelometry or immunoturbidimetry, which have a detection 
limit near 2 µg/mL and a dynamic range up to 200 µg/mL [339, 343]. These 
detection limits, with modification can be lowered to less than 0.2 µg/mL, this 
alters the assay from a CRP assay to that of a hs-CRP assay [344]. Many 
nanoparticle based detection systems are now becoming available [345], for 
example nanoparticles can be used to enhance immunoturbidimetry assays 
[346]. An interesting use of nanoparticles to provide a rapid detection system 
has been proposed by Kris et al. [347], who charged super-paramagnetic 
nanoparticles with monoclonal aCRP, as a labelling agent, along with polyclonal 
aCRP conjugated silica micro-particles, generating a magnetic permeability 
detection assay. This assay has an LOD of 0.2 µg/mL and can be performed in 
as little as 11.5 minutes. A simpler system was also proposed based on 
magnetic nanoparticles of iron oxides conjugated with aCRP, this method has a 
assay time of 10 minutes under magnetic fields. The LOD was 0.12 µg/mL but 
only had a dynamic range of 1.2 – 3.1 µg/mL [348]. 
SPR based CRP-assays are becoming available as the field grows. Hu et al. 
[349], use an immobilised layer of protein G to create a well-ordered and 
orientated layer of aCRP to use as a detection system. They determined their 
LOD as 1 µg/mL, which is capable of detecting CRP as a normal marker of 
inflammation but is not suitable for the detection of hs-CRP. A similar method 
will be proposed in this chapter to optimise protein screening arrays. The Fc 
region specific binding of PAG (as discussed in Chapter 4) ensure the 
presentation of antibody Fab regions and high surface density, derived from the 
multiple binding Fc binding sites. Furthermore, PAG separates the antibody 
from the gold surface – a potential concern for Fab-region denaturing that has 
been speculated. The assay surface stability can be further enhanced for re-use 
after regeneration, by cross-linking the Fc regions of the antibody to the PAG 
with gluteraldehyde.  
5.1.2 Glutaraldehyde Protein Cross-linking 
Glutaraldehyde (GA) is a pungent colourless organic compound with the 
formula CH2(CH2CHO)2 [350]. Commercial uses for glutaraldehyde include high 
level disinfection of medical equipment, as an industrial biocide for controlling 
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hazardous microbes and as a fixative in leather tanning applications. It has 
been used in scientific research for several decades as an effective cross-
linking agent for a number of applications, including: fixation for immobilisation 
of enzymes and whole cells [351, 352], cytochemistry and electron microscopy 
[353], protein crystallisation stabilisation for X-ray crystallography [354, 355]. 
Most recently, it has been used as a method for immobilising proteins to 
substrates in SPR studies [356]. The reaction of glutaraldehyde during the 
cross-linking of proteins is dominated by reactions with the ε-amino groups of 
lysine residues [357], although it may react with a number of other functional 
groups present on the protein surface including, thiols, phenols and imidazoles 
[357-360]. A schematic representation of the non-selective cross-linking of 
amine groups on the protein/cell surface with glutaraldehyde is shown in Figure 
5.2. The mechanism for this reaction involves nucleophilic attack on the 
aldehyde groups to form a non-conjugated Schiff base [361]. This reaction 
should be performed at a neutral pH as the reaction is slower due to the 
protonation of the amine groups [362]. At alkaline pH the glutaraldehyde 
monomer can polymerise via a condensation reactions affecting the Schiff base 
formation [363]. This polymerisation gives rise to a mixture of elongated 
species, that can in turn, cross-link intramolecular and intermolecular lysines in 
a nonspecific manner [363, 364]. 
 
Figure 5.2. Cross-linking of cells/proteins with glutaraldehyde. The red lines represent the 
backbone of the glutaraldehyde after reacting with amine groups. 
The majority of proteins contain many lysine residues and because of the 
polarity of the amine group are usually located on the protein surface where 
they are exposed to the aqueous medium [365]. Another advantage of linking 
via lysine residues is that they are generally not involved in the catalytic site, 
this allows moderate cross-linking with preserved protein conformation and thus 
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biological activity [351]: essential when studying antibody-antigen interactions 
[358]. 
5.2 Aims and Objectives 
The aim of this chapter is to: 
Characterise the assays in protein screening arrays on the Array Reader 
platform. 
An array of antibodies will be tethered to the surface using the Fc-region 
specific interaction with PAG, discussed in the previous chapter, to ensure the 
correct presentation of the Fab region for high-affinity binding to target proteins. 
The ideal sensor surface should have a high density of Fab regions aided by 
the multiple binding sites to the PAG itself (up to 6 in solution [215]) to improve 
the maximum surface load and assay limit of detection and dynamic range. The 
surface also needs to be stable to allow regeneration and so re-use of the 
sensor, improving sample throughput. A protein cross-linking method involving 
GA will be optimised to tether covalently the IgG to the PAG binding sites. The 
schematic surface design is shown in Figure 5.3. 
 
Figure 5.3. Schematic representation of the array surface. The numbers 1-3 represent the different 
steps in the proposed method for detecting CRP. (1) is the surface after aCRP has been 
successfully immobilised with GA. (2) is the surface after the primary analyte CRP has been 
injected. (3) is the final step of attaching the detection antibody on top of the primary analyte.  
Au NP
PAG
aCRP
GA
substrate
1 2 3
Primary analyte - CRP
Secondary detection antibody - aCRP
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The performance of the protein screening array will be tested using the target 
protein CRP, as it is clinically important and has a large mass. The performance 
of the CRP assay will be assessed against the assay standards developed in 
Chapter 4, for the total IgG assay, namely: sensitivity, detection limit, accuracy 
and dynamic range. In addition to the initial capture event of the detection 
antibody and CRP, the effectiveness of a secondary amplification binding event 
with a CRP-specific antibody will be studied and the effect on the assay 
performance parameters assessed.  
5.3 Materials 
All materials were used as supplied without further purification unless otherwise 
stated. 3,3′-Dithiodipropionic acid di(N-hydroxysuccinimide ester) (Lomant’s 
reagent), human fibrinogen (Fbr) (60%, with 40% buffer salts; the protein 
content is >80% clottable Fbr), C-reactive protein (CRP) (1 mg/mL) and human 
serum albumin (HSA) (>96%) were obtained from Sigma-Aldrich. Recombinant 
Protein A/G (PAG) (5 mg) was purchased from Pierce UK. Sheep polyclonal 
antibodies to BSA (aBSA) (23 mg/mL, IgG fraction) were supplied by AbD 
Serotec UK and goat polyclonal antibodies to CRP (aCRP) (10 mg/mL) were 
supplied by abcam. 
5.4 Experimental Method 
All experiments were performed on the Array Reader platform as described in 
detail in Chapter 2 and elsewhere [61, 79, 80]. The RI response of each of the 
array elements was calibrated using the change in light intensity for two 
calibration solutions, PBS and 2×PBS from which the RIU was derived. All data 
shown in the subsequent figures are presented as the change in RI, ∆RI with 
respect to control spots functionalised with fibrinogen.  
5.4.1 Surface Preparation 
The array spots were functionalised with proteins: CRP (1 mg/mL), fibrinogen 
and PAG solutions (2 mg/mL), according to the protein key in Figure 5.4. 
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Figure 5.4. Protein functionalisation key. 
Fbr and BSA would act as reference channels; the PAG would provide the 
scaffold for building the CRP-assay surface. 
5.4.2  ‘in situ’ Surface Preparation 
The dry array was installed in the AR and rehydrated with PBS buffer, washed 
with the regeneration buffer (HCl 10 mM) for 4 minutes and finally blocked with 
1.5 µM HSA for 10 minutes. A baseline was then collected before a solution of 
30 nM aCRP was injected for 25 minutes allowing a surface coverage of ≈ 95% 
'& to form based on the global fit procedure. After the injection is completed the 
running buffer is flowed over the surface for 15 minutes to allow any loosely 
bound aCRP to come free from the PAG surface. At this point the GA solution in 
PBS (0.1% w/v) was injected for 4 minutes, followed by a further regeneration 
step. A 4 minute injection time was chosen to limit the exposure time of GA to 
the sensor surface so that the antibody activity was not compromised and also 
to provide adequate cross-linking. Successful preparation of the assay surface 
is then characterised by a permanent shift in the RI associated with the mass of 
aCRP bound to the PAG surface, Figure 5.5.  
Fibrinogen Protein A/GBSA
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Figure 5.5. Example of the cross-linking of aCRP – PAG with glutaraldehyde. Presented here is the 
coverage achieved from a 0.03% GA solution. Coverage equals 48% and was calculated by dividing 
the response at (2), after the regeneration marked with an asterisk; with the response before the 
regeneration (1). 
Figure 5.5 shows how this surface coverage was determined with the 30 nM 
aCRP solution injected at 0-25 minutes, with GA solution injected for 4 minutes 
at 40 minutes to cross-link the aCRP to the immobilised PAG surface. 
Percentage coverage was derived based on the labels in Figure 5.5 using the 
following equation: 
coverage %   mRIUmRIU   100 
Equation 5-1 
The concentration of GA used in Figure 5.5 was 0.03% (w/v); it resulted in a 
percent surface coverage of 48% using Equation 5-1. The concentration of GA 
was varied over the range 0.005% to 0.1% (w/v) (0.125 – 2.5 mM) and the 
resulting percentage surface coverage are presented in Figure 5.6.  
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Figure 5.6. Glutaraldehyde concentration (w/v %) plotted against aCRP percentage coverage 
calculated from Equation 5-1 on protein A/G and fitted with the empirical formula from Equation 
5-2; R2 = 0.999. 
The data in Figure 5.6 were fitted with an empirical formula:  
   A  B
1 , exp x  x0dx 
,  B 
Equation 5-2 
where, : is the minimum asymptote and  is the maximum asymptote, ( is the 
time constant and 0 is the centre point (: ,  2⁄ ); the fit had an R2 value of 
0.999 over the data set. It was determined that maximum surface coverage was 
achieved routinely with 0.1% GA and this was used for all subsequent 
experiments. 
5.5 Results 
With the GA cross-linking optimised a series of CRP protein screening assays 
was performed using concentrations of CRP in the range 0.04 – 10 nM. A 
secondary antibody amplification process was also tested to assess the LOD 
and dynamic range enhancement. Finally, unknown samples of CRP were 
analysed in a blind trial to determine concentrations and access the practicality 
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of the CRP-assay for use in clinical settings using the parameters derived in 
Chapter 2, such as, dynamic and linear range, LOD, CV and the AUC SOP. 
5.5.1 CRP-Assay  
A series of CRP concentrations was studied that followed a 3-fold dilution from 
10 nM. The SOP for the CRP assay was as follows: CRP was injected over the 
surface for 10 minutes (primary association phase), followed by a 6 minutes 
dissociation phase before the secondary aCRP antibody was flowed over the 
surface at a fixed concentration of 20 nM. The secondary antibody 
concentration was optimised at 20 nM aCRP, for 15 minutes, which provided a 
large signal to accurately determine '&. The CRP dilutions were flowed over in 
a random order, to remove any experimental artefacts or concentration bias, 
such as priming the surface [85]. Some of the secondary RI change must be 
due to binding of the secondary aCRP to free sites on PAG rather than the 
target CRP binding sites, Chapter 4. For this reason, the aCRP detection 
antibody was injected with no CRP primary analyte present on the surface, to 
act as a control. The response from PAG – aCRP (secondary) can be 
subtracted during the analysis procedure leaving only the specific CRP – aCRP 
response; this would improve assay specificity and allow the experimental limit 
of detection to be derived. After each assay a regeneration step was performed; 
Figure 5.7 is the trace of a typical assay.  
 
Figure 5.7. An example of the primary capture (CRP) and secondary antibody (aCRP) injection (0-10 
minutes), PBS running buffer (10-16 minutes), detection antibody injection (16-31 minutes). 
Regeneration of the sensor surface is indicated by an asterisk. 
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Once all assays have been performed the responses of both the primary 
analyte, with varied CRP concentration and the aCRP detection antibody, with 
fixed concentration at 20 nM can be plotted as an immuno-kinetic assay, seen 
in Figure 5.8.  
 
Figure 5.8. Immuno kinetic assay of (A) the primary analyte (CRP) 3-fold dilution from 10 nM; and 
(B) the secondary detection antibody (aCRP), with fixed concentration at 20 nM. Trace colour 
signifies the concentration of primary analyte: Black – 10 nM, red – 3.3 nM, green – 1.1 nM, blue – 
0.37 nM, light blue – 0.12 nM, pink – 0.04 nM, dark green – 0 nM. 
The primary analyte capture assay (Figure 5.8A) has a concentration range of 
0.04 – 10 nM that covers ≈ 0.25 mRIU, the LOD of the assay was calculated at 
1 ± 0.5 nM, or 0.1 ± 0.05 µg/mL, calculated as 2σ of the noise above the 
baseline. The response of the secondary detection antibody covers the same 
range in concentration but has a response 4× that of the primary signal (≈ 1 
mRIU), this mean that we have a SNR that is 4× bigger drastically improving the 
assay sensitivity and therefore detection limit to 50 ± 25 pM (7.5 ± 3.8 ng/mL). 
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The blank injection of aCRP (Figure 5.8B - dark green trace) without the primary 
analyte shows a response of ≈ 0.25 mRIU which indicates that some of the 
secondary antibody is still binding to the original PAG surface. The difference 
between the responses seen from the initial aCRP-PAG complex (Figure 5.5) 
compared to the signal of the blank injection is ≈ 6% which corresponds to the 
remaining 5% available surface from the 95% surface coverage reached. A 
calibration curve to the immuno-kinetic assay was derived plotting, AUC 
(defined in Chapter 4) vs standard concentrations, and fitted to five-parameter 
logistic curve (5-PL), shown in Figure 5.9. 
 
Figure 5.9. Standard curves of AUC vs CRP concentration, fitted with the 5-PL equation: (A) 
primary capture response, R2 = 0.977; and (B) secondary detection response, R2 = 0.998. The red 
box represents the AUC calculated from a different sensor chip but calibrated for use in the 
analysis. 
0.01 0.1 1 10
0.2
0.4
0.6
0.8
1.0
AU
C 
(R
IU
 
s)
[CRP] (nM)
0.1 1 10
0.00
0.05
0.10
0.15
0.20
AU
C 
(R
IU
 
s)
[CRP] (nM)
A
B
Chapter 5 
146 
 
The point present at 50 nM, labelled with a red box, was taken from another 
data set and calibrated against the data presented here, to determine the 
saturation point of the initial capture step. Considering first, the primary CRP 
event, the basis of the protein screening array, Figure 5.8A, and the calibration 
curve Figure 5.9A. The dynamic range of primary capture standard curve is ≈ 
0.2 (RIU s), which represents a concentration change of 0.04 – 50 nM (4.7 
ng/mL – 5.7 µg/mL), with no obviously linear range present. The data also does 
not represent the curve well, with significant deviations throughout; R2 = 0.977.  
The secondary detection step, AUC vs CRP calibration curve, shown in Figure 
5.9B, has a better R2 value of 0.998, and the 5-PL curve clearly fits the data 
better: only deviating from the curve at the higher concentrations studied. The 
measured AUC cover a range 5× larger than the initial protein capture assay. 
Therefore suggesting that there is also 5× the mass on the surface and there 
must be more than one antibody binding to each CRP protein from the primary 
step. If scaled for mass (CRP = 118 kDa; aCRP = 150 kDa), this factor is 
reduced to 4×. However, as the secondary antibody was polyclonal then it is 
possible for more than one antibody to bind to each molecule of CRP. 
Especially as it is a pentameric in structure, possibly providing multiple 
epitopes. As CRP is large and has a width of ≈ 9 nm then it is easy to imagine 
more than one antibody binding to CRP. 
5.6 Discussion 
The aim of this chapter was to extend the performance of the AR platform to 
include protein-screening arrays. The target protein was CRP chosen because 
of its large mass for the purposes of assay development. It allows a comparison 
of the performance of the assay with the antibody assays; IgGs have a similar 
mass of 150 kDa. Given the success in screening for antibodies from previous 
chapters, if we can screen for proteins to a similar level of detection and 
accuracy then the AR could become a powerful tool. Applications could 
including the monitoring of many diseases and would not be limited to the 
monitoring of antibody levels, for autoimmune disorders, or vaccine 
development.  
The immuno-kinetic assay presented in the results section confirms that it is 
possible for the AR to monitor CRP to a similar detection level to that of IgG but 
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not the same accuracy, based on the primary response to the antibody capture 
antibodies. The shape of the primary response standard curve is sigmoidal as 
expected, Figure 5.9. However, there is reasonable deviation from the 5-PL 
curve in the mid-range of the concentration range which results in poorer 
accuracy for concentration determination. The extent that the deviation of the 
standard curve (AUC) deviates from the calibration point (AUC) can be 
determined using Equation 5-3: 
deviation  calibration point AUCstandard curve AUC   100% 
Equation 5-3. 
The values calculated from Equation 5-3 are presented in Table 5-1 as 
percentage deviation. It is clear that the standard curve deviates far more from 
the calibration points for the primary capture event compared to the secondary 
detection step, reflecting the SNR in the ∆RI. 
Table 5-1. Percent deviation of the calibration point AUC against the AUC derived from the 
standard curve. 
[CRP]  (nM) Deviation (%) 
Primary Capture Secondary Detection 
3.3 +12 +4 
1.1 -6 0 
0.37 +23 -2 
0.12 -41 0 
0.04 +33 +1 
 
The primary capture event clearly has an unacceptably large error with a mean 
and deviation of 4 ± 29 %. The secondary antibody is significantly better with 
mean and deviation calculated as 0 ± 2 %; this value is very low, giving the 
operator a good level of confidence in their concentration estimation. The 
addition of the secondary detection step improves the accuracy of the assay 
more than 10-fold: 29% compared to 2%. One observation, is the larger error 
associated with higher CRP concentration due to surface saturation, for this 
reason the standard curve deviates from the calibration points at higher 
concentrations (Figure 5.9B), whereas, the curve better represents the data at 
lower concentrations improving the assay accuracy. 
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The performance of the assay and the AUC calibration curves was tested using 
two unknown samples (S1 and S2). Duplicates of each sample were performed 
to calculate the intra-assay variability and the S2 was diluted appropriately, 
owing to the response of the secondary analyte falling at the upper limit of the 
assays dynamic range. Table 5-2 is a summary of the derived concentrations 
and the percent error calculated once the actual concentrations were revealed.  
Table 5-2. Unknown samples with derived concentrations calculated from the standard curve in 
Figure 5.9B.  
Sample Derived [CRP]  (nM) Actual [CRP] (nM) error (%) 
S1 0.16 ± 0.02 0.16 0 
S1 (replicate) 0.18 ± 0.02 0.16 11 
S2 4.45 ± 2.00 6.40 30 
S2 (diluted) 0.58 ± 0.02 0.71 18 
S2 (diluted replicate) 0.63 ± 0.02 0.71 11 
 
The concentration of S1 was 0.16 nM calculated from mass and the data sheet 
accompanying the purified protein. The derived concentrations were very close 
to this value, with the first determined at this exact concentration and the 
second just above 0.18 ± 0.02 nM, which was correct given the error, a value of 
CV can be calculated at 11%. The mean concentration for S1 was 0.17 ± 0.03 
nM, resulting in a CV value of 18%. 
The sample S2 initial response was at the upper limit of the calibration curve, 
where the sensitivity and accuracy are poorer. The dilution was optimised to 
provide a response in the highly sensitive region of the calibration curve. The 
duplicates of S2 both underestimated the concentration that had a revealed 
value of 0.71 nM with the mean concentration for S2 calculated as 0.61 ± 0.05 
nM, with a CV value of 8%. The known concentration was supplied with the 
data sheet and therefore, the assay error can be increased from 8% to 14%. 
The reason for the underestimation of S2 can be seen in the standard curve 
deviations from the calibration points at higher concentrations (Figure 5.9B) 
whereas the curve represents the data at lower concentrations. It is a well 
known effect that the extreme ends of the dynamic range have different 
accuracies. A method to correct for this is to linearise the calibration curve.  
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As the 5-PL fit underestimates the concentration in the upper range of the 
standard curve it is not a function that fits the data set well. The response of the 
assay is essentially linear over 90% of the dynamic range and can be fitted as 
such. Two data points at the extremes of the dynamic range are eliminated 
associated with the low-mass limit and the saturation of the number of available 
sites on the surface, Figure 5.10. 
 
Figure 5.10. Standard curve for CRP concentration vs AUC. The data are fitted with a line and the 
upper and lower points excluded from the fit procedure (shown in red). The equation of the line is y 
= 0.72 + 0.32x; R2 = 0.999. 
The linear fit of the AUC over the concentration range 0.04 – 3.3 nM (4.7 – 376 
ng/mL) has an R2 value of 0.999 covering ~2 orders of magnitude. It means that 
the assay has a constant sensitivity over 90% of the dynamic range. The 
concentrations of the two unknown samples were recalculated with the new 
standard curve (Figure 5.10); the values are presented in Table 5-3. 
Table 5-3. S1 and S2 concentration derived from the standard curve in Figure 5.10. 
Sample Derived [CRP] (nM) Actual [CRP] (nM) Error (%) 
S1 0.17 ± 0.02 0.16 6 
S1 (replicate) 0.19 ± 0.02 0.16 16 
S2 n/a 6.40 n/a 
S2 (dilution) 0.66 ± 0.02 0.71 9 
S2 (dilution replicate) 0.71 ± 0.02 0.71 0 
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The individual values derived for S1, in Table 5-3, are correct given the 
associated error. The mean value, in this case, is 0.18 ± 0.03 nM, with a CV 
value of 17%. S2, before the dilution step, was outside of the assays dynamic 
range but with the dilution optimised, were in the middle of the linear range. The 
mean concentration for S2 was 0.69 ± 0.05 nM, with a CV value of 7%. This is a 
better estimate of concentration compared with the initial standard curve, with 
both unknowns determine correctly within the error. 
The performance of nine-automated hs-CRP assays has been reviewed [366] 
comparing results across platforms and manufacturers. They studied 388 serum 
samples and tested parameters such as LOD and dynamic range, compared to 
what was quoted on the supplied data sheets. It was found that all methods 
showed a linear response in the CRP concentration range, 0.3-10 mg/L, with 
five out of nine having a CV value of less than 10%, over all concentrations 
tested. This linear range is much larger than that of the AR and is not as large a 
range in terms of order of magnitude.  
 
Table 5-4 is a summary of the performance of three types of CRP assay 
compared against the AR platform; it includes the two most common clinically 
used techniques and ELISA-assays used regularly for research purposes.  
Comparison of the AR performance with the secondary step suggests the AR 
CRP-assay to be comparable in terms of the parameters discussed. The LOD 
for the AR was approximately two orders of magnitude more sensitive than both 
the nephelometric and turbidometric assays but was not as sensitive as the 
ELISA assay. The dynamic range of the assays, all cover more than two orders 
of magnitude. The ELISA assay working range is three orders of magnitude 
lower than the AR but six orders of magnitude lower than the nephelometry and 
turbidometric assays; this suggests that the ELISA is more suited for hs-CRP 
assays. Whereas, nephelometric and turbidometric assays would be more 
suited for measuring standard CRP levels as a marker of inflammation or 
conditions such as sepsis, when CRP is present at a concentration of more than 
1 µg/mL [367]. 
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Table 5-4. Comparison of CRP-assay parameters based on different techniques. The nephelometry 
assay is based on reagents purchased from Dade Behring, analysed on the BN II. The 
turbidometric assay is based on reagents purchased from Kamiya using the Hitachi 917 analyser. 
The ELISA-assay is based on the human CRP ELISA Kit purchased from Abcam. 
 Array Reader Nephelometry Turbidometric ELISA 
LOD 7.5 ng/mL 0.2 µg/mL 0.1 µg/mL 2 pg/mL 
Dynamic range 
4.7 – 1140 
ng/mL 
0.17 – 11 µg/mL 0.1 – 20 µg/mL 
2 - 600 
pg/mL 
Linear range 
4.7 – 376 
ng/mL 
0.17 – 11 µg/mL 0.1 – 20 µg/mL 
2 - 100 
pg/mL 
CV % < 20% < 10% < 10% < 10% 
Assay time 40 mins 40 mins 40 mins 6 hrs 
 
Comparison of the linear range, again show similarities between the assays, the 
turbidometric assay has the largest range, with the ELISA having the smallest. 
The AR CRP-assay covers 1.65 orders of magnitude; this is closer to the 
nephelometric assay than the ELISA. The measurement accuracy (CV) 
associated with the assay however, show that the others do out-perform the AR 
but with better quality assurance the CV of 20% is likely to decrease to a similar 
value to the rest. 
The assay time for the AR is similar to the nephelometric and turbidometric 
assays, at ≈ 40 minutes, to calculate the concentration of CRP from an 
unknown sample. However, both nephelometry and turbidometric techniques 
are able to screen multiple samples simultaneously whereas the AR platform 
screens samples individually, therefore the AR is not capable of high throughput 
screening, unless a separate flow cell system were to be designed. An 
advantage of the AR however, is the option for other assays present on the 
same array, suggesting that the CRP assay could form part of a multiplex array.  
The clinically relevant range for CRP for inflammation and sepsis is between 1 
and 500 µg/mL. Therefore, the calculated dynamic range of 4.7 – 1140 ng/mL, 
lies just below this level, allowing a sample dilution of up to 250-fold for a CRP 
concentration of 1 µg/mL to still be detected. This dilution would remove any 
effects associated with high serum concentration, such as matrix effects and 
NSB; providing an assay suitable for the detection of CRP. However, the data 
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presented in this chapter were performed in buffered solutions rather than 
serum but allowing for the required dilution the differences in assay 
performance would most likely be minimal.  
In the introduction to this chapter, a study by Hu et al. [349], was mentioned 
who used a similar experimental design on their SPR platform by building up a 
layer of Protein G and aCRP to use as a detection system for CRP. However, 
with no method of cross-linking the aCRP to the protein G the assay is not re-
usable, with the protein G surface needing to be functionalised before each 
sample. They also did not use a secondary detection antibody, which may have 
increased the assay sensitivity. However, it is clear that our assay offers several 
advantages over theirs both in detection limit: 1 µg/mL compared to 7.5 ng/mL 
(more than a 100-fold increase); and also in the use of GA allowing higher 
sample throughput on the AR. These advantages make our assay far more 
practical in a clinical setting than other current SPR-based CRP-assays. 
A method of improving the AR CRP-assay would include optimising the protein 
printing SOP. If the PAG surface could be functionalised with aCRP during the 
printing process then the assay would not be limited to a single target. Attempts 
were made to print both the aCRP and GA solutions directly onto the spot as a 
single mixture and individually, however, both methods failed to perform 
sufficiently. By flowing the aCRP over the surface we can maximise the 
coverage which was not possible from direct printing. Further work to increase 
the aCRP surface density via printing would allow multiplex protein screening, 
giving the AR a significant advantage over the other assays in Table 5-4. A 
problem also remaining with the use of the secondary detection antibody, again 
by increasing the surface density of aCRP the need for the secondary detection 
step could be removed. 
The main issue with screening for proteins is the low-mass detection limit; CRP 
provided a good target with its high mass but the LOD would need to be 
significantly increased to detect protein with lower mass. The bio-stack 
amplification process could aid in the screening of such targets, this method 
was not required for CRP but could improve our LOD if necessary. The current 
CRP LOD is 7.5 ng/mL (60 pM), cytokines have a molecular weight of 
approximately 20 kDa and could therefore, have a detection limit of 360 pM with 
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a secondary detection step. In serum, cytokines have a concentration in the pM 
range and would be just be outside of our LOD. With the bio-stack amplification 
process this LOD could be decreased by approximately 30-fold, to allow the 
possible screening of many other disease biomarkers that are present at a 
similar serum concentration.  
5.6.1 Conclusion 
The objectives of this chapter were to address protein screening assays and 
determine the extent of the AR sensing capabilities when targeting proteins 
from solution. Current protein screening assays on the AR do not produce the 
same LOD as antibody screening due to the surface density of the capture 
antibody and issues with the low-mass detection limit. However, with the use of 
a secondary detection antibody, effectively making this a sandwich assay, the 
LOD and accuracy can be vastly improved and can compete to a similar level 
as CRP ELISA assays. The aCRP capture antibody immobilisation worked well 
with PAG as did the GA cross-linking step, creating a re-useable surface for 
multiple sample screening.  
If a dedicated chip, pre-printed and functionalised before installation could be 
created then multiplex protein screening would be possible. For example, to 
monitor cardiovascular conditions alongside markers such as apolipoproteins 
[368], or for monitoring sepsis with other markers such as IL-6, procalcitonin 
and neopterin, shown to correlate with sepsis [367]. These markers have the 
same, or similar mass to cytokines and therefore could be detected using the 
bio-stack method.  
The AR can now perform both antibody and protein screening assays with the 
LOD in the ng/mL range. Currently, antibody screening arrays are already 
optimised for multiplex high-throughput arrays, with PAG used as an assay for 
total IgG rather than providing a scaffold for protein screening assays. Antibody 
screening arrays have been used to characterise Fab and Fc affinities and we 
will develop this further in the next chapter in the assessment of new vaccine 
efficiencies. The vaccine screen will combine all of the SOPs derived thus far, 
including the global fit and the array preparation and is close to a complete 
screening technology.  
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6 Evaluating the Immune Response of a Yersinia 
pestis vaccine in a Macaque Animal Model 
6.1 Introduction 
A novel application of the AR antibody screening arrays is to evaluate the 
efficacy of vaccine candidates, deriving new information to assess the 
performance of vaccines and maximising the data extracted from animal model 
screening. The PAG assay can be applied to monitor total IgG response and 
immunogen spots for the specific antibody concentrations and affinities raised 
to vaccine components. Combined on a single array, this could play a key role 
in reviewing vaccine efficacy. Passive immunity can be studied by assaying the 
affinity and interaction of monoclonal antibodies (mAbs) with antigens identified 
as vaccine candidates, followed by the screening of serum from vaccinated 
animals. The pathogen, against which the vaccine has been raised, causes one 
of the most notorious diseases throughout history, the plague. 
The most famous plague pandemic was the Black Death which originated in 
China killing half of their population and then spread to Europe, killing one third 
[369-371]. The Black Death and subsequent epidemics helped initiate many 
new policies in medical education and practice including the advent of clinical 
research and surgery in medical education [372, 373]. Plague continues to be a 
major health problem and remains endemic in parts of Asia, Africa and the 
Americas, with approximately 3000 cases reported annually [374]. Three forms 
of the disease exist which are dependent on the route of transmission of the 
bacteria; bubonic, septicaemia and pneumonic [375]. A bite from an infected 
flea can result in bubonic plague and can occasionally progress to a 
septicaemia form of the disease, secondary pneumonic plague can develop 
from either of these forms in approximately 12% of cases [371]. Primary 
pneumonic plague is usually fatal even when treated with antibiotics and occurs 
following inhalation of the Yersinia pestis (Y. pestis) bacteria [376, 377]. Y. 
pestis is a Gram-negative and rod shaped bacterium belonging to the Yersinia 
Genus within the Enterobacteriaceae family [371]. It is thought to have evolved 
from the enteropathogen, Y. pseudotuberculosis becoming a flea-vectored 
pathogen lethal to man [378, 379]. Y pestis has a number of virulence factors 
that enable it to survive in humans by causing damage to host cells, facilitating 
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use of host nutrients and avoiding phagocytosis and other host defence 
mechanisms [377, 380]. Y.pestis contains a trio of plasmids which encode for a 
number of virulence factors. There is a 70 kb plasmid (pYV/pCD1) which 
encodes for the V-antigen and type III secretion system (T3S), a larger plasmid 
at 100 kb termed pFa/pMT1 which encodes for Fraction 1 antigen (F1-antigen) 
and a murine toxin and finally a smaller plasmid at 9.5 kb termed 
pPst/pPCP1/pPla which encodes for a number of proteins which help 
disseminate insect transmitted Y. pestis in the mammalian host [378, 381-383]. 
Y. pestis is an intracellular pathogen which, upon infection, gains entry and 
grows in host macrophages [378]. Inside the macrophage it is transported to the 
lymph nodes [384]. Upon apoptosis of the infected macrophage it becomes 
extracellular colonising major organs and deploying its virulence mechanisms 
and immune evasion strategies causing potentially fatal systemic disease [378]. 
Current strategies for treating Y. pestis infection involve an intensive course of 
antibiotics, specifically streptomycin, chloramphenicol and tetracycline [385]. 
However, with the widespread emergence of multi-drug resistant strains 
antibiotic treatment is not always successful [386]. There is therefore a great 
need to develop safe and effective vaccines against this pathogen. 
To date, a number of vaccines have been used against plague, however it is 
difficult to assess their efficacy given the sporadic nature of plague outbreaks 
and the diseases versatility. The US FDA have licensed a formaldehyde-killed 
whole-cell vaccine (KWC) but this was discontinued by its manufacturers in 
1999. The vaccine demonstrated efficacy in preventing bubonic plague but it did 
not prevent the development of primary pneumonic plague [387, 388]. The fact 
that inhalation of the bacterium can be so fatal causes much concern for the 
use of plague as a bioterrorism agents and it is considered to be among the top 
five potential biological weapons [377]. Intentional dissemination of plague 
would most probably occur via an aerosol and the mechanism has been shown 
to produce disease in non-human primates [389]. Live attenuated vaccines 
have been used in several countries but due to considerable reactogenicity 
associated with these vaccines they have not been licensed in the US [390]. 
Much of the effort to develop a new plague vaccine has been focused primarily 
on the F1 capsular and V virulence proteins, administered together (F1 + LcrV) 
or as a fusion protein (F1V). The F1 antigen forms a protein capsule-like 
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structure on the bacterial surface that is believed to inhibit phagocytosis [391] 
and bacterial adhesion to epithelial cells; both having a role in bacterial 
transmission [392]. The gene for V antigen (LcrV) is part of the lcrGVH operon 
[393], which is located on a 70-kb low-calcium response (Lcr) plasmid 
(pYV/pCD1) [394]. For the vaccine to be produced a live bacterial vector is 
required, which is generally attenuated Salmonella or E. coli. Interestingly, 
some authors have noted that immunisation with attenuated Salmonella alone 
provides low-level protection probably due to common surface moieties [395-
397]. E. coli is the vector used for all vaccines studied in this chapter, although 
numerous studies have been performed with Salmonella where strains were 
constructed to produce F1-V fusion protein [398], LcrV [399] and F1 capsule on 
the surface of the cell [395]. The crystal structure of LcrV and F1 is presented in 
Figure 6.1. A range of virulence factors have previously been studied and are 
summarised in a paper published by Williamson and Oyston [378]; only V and 
F1 antigens offer significant protection against both bubonic and, more 
importantly, pneumonic plague. 
 
Figure 6.1. Crystal structure of the vaccine antigens: (A) LcrV antigen, V protein, which has 
approximate dimensions of 7 × 3.5 × 2.5 nm (PDB = 1R6F); (B) F1 antigen with has approximate 
dimensions of 6 × 4.5 × 3 nm (PDB = 1Z9S). 
As far back as 1953 the protective efficacy of the F1 antigen has been known 
[400], with human volunteers immunised with F1 producing a protective immune 
response assessed by passive transfer into mice [401]. When infected with the 
whole Y. pestis bacteria the majority of antibodies are raised against F1 [402] 
suggesting that this is a good vaccine candidate for protection against the 
A B
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bacterium. Another good candidate is LcrV, due to the fact that it is a virulence 
factor and therefore present on the bacterial surface is involved in the 
pathogenesis of the organism [403, 404]. Alhydrogel is the only FDA approved 
adjuvant (discussed in Chapter 1) and is often used in the administration of the 
subunit antigens to increase the vaccine immunogenicity. Alhydrogel is an 
aqueous aluminium hydroxide suspension that has been widely used as a 
protein-binding vaccine adjuvant for many years [405]. Both F1 and LcrV have 
been shown to cover the alhydrogel surface almost to saturation, which is 
thought to enhance the immune response to the vaccine [405]. By combining F1 
and LcrV antigens along with the alhydrogel in a single vaccine it is hoped to 
provoke a larger immune response than either antigen alone. It should offer 
better protection against weaponised pneumonic plague, a real concern for 
today’s world, by directly recognising the virulence factor of LcrV. The 
pathogenesis of the bacteria will be inhibited as a consequence and the 
pathogen cleared via the stimulated immune response to F1. 
Fab and Fc regions are critical to the efficacy of the immune response and a 
quantitative measure of both would be useful for developing and screening 
vaccines and understanding the immune response. Determining the affinity of 
mAbs produced in mice to both the Fc and Fab regions will be beneficial in 
selecting the optimal antibody for passive immunisation where a fast immune 
response is required. A high affinity on the Fab region will mean more effective 
recognition of the target pathogen whereas a high affinity at the Fc region will 
result in a highly stimulated immune response, specifically in the clearance of 
bacterial pathogens by mediating antibody-dependent and complement-
dependent cytotoxicity. During opsonophagocytosis several antibody molecules 
bind to the pathogen via the Fab region presenting the Fc region to the immune 
system (Figure 6.2A). Fc receptors expressed on surfaces of neutrophils and 
macrophages can then form high affinity complexes with the antibody Fc 
regions (Figure 6.2B). The phagocyte can then extend its plasma membrane 
around the attached microbe and ingests the microbe into a vesicle called a 
phagosome (Figure 6.2C). Therefore, phagocytosis could occur more rapidly, 
clearing the pathogen more effectively if an antibody used for passive 
immunisation was raised against a common surface epitope with high affinity. 
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Figure 6.2. Schematic representation of phagocytosis: (A) Antibodies bind to pathogen surface 
epitopes on the pathogen; (B) phagocyte surface receptors interact with the antibody Fc regions; 
(C) Plasma membrane extends around the pathogen eventually forming a phagosome. 
As well as the production of mAbs in mice, the vaccine can also be tested in 
cynomolgus macaques (Macaca fascicularis). Evaluation in animal models is 
required to generate the preclinical data upon which application for approval for 
human testing of a new vaccine will be based. A rational model should include 
vaccination in a manner suitable for use in humans (including route, adjuvant, 
dose, etc.) [406]. Mouse models have the advantage of low costs and large 
supplies of laboratory animals necessary for early testing. However, the murine 
respiratory tract and immune system differ significantly from those of humans 
[407]. Non-human primates, in this case macaques, are considered the most 
appropriate for characterising the plague model as they share the most 
homology with humans. However, the use of primates is expensive and there 
are many ethical points to consider when carrying out animal studies. Using the 
AR to quantitatively profile the immune response from animal sera could 
minimise the number of animal required for further study. 
A
B
C
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The AR platform is ideally suited to evaluate the efficacy of vaccines given its 
ability to measure the affinity of antibody – antigen interactions, with low sample 
volume and minimal preparation steps required. In general, the affinities of 
antibodies produced after vaccination are not measured but by doing so could 
help screen vaccines for future studies, speeding up the vaccination trial 
process, saving money, and reducing the number of animals required before 
the vaccine can move on to trails involving humans participants. 
6.2 Aims and Objectives 
The aim of this chapter is to: 
Address the application of antibody screening arrays to assess the efficacy of a 
two-component (F1 + LcrV) vaccine and the associated subsequent 
immunological response in naive macaque monkeys. 
The objectives are to design an array containing the PAG-assay, to quantify 
total IgG, and the immunogens F1, LcrV and the F1V fusion protein, to measure 
specific antibody concentrations and to characterise their Fab affinity. The array 
will be used to characterise the Fab and Fc affinity of mAbs raised against LcrV. 
Seven macaque serum samples are then studied that were immunised with a 
two-component vaccine (F1 + LcrV) against Y pestis. In each sample, we will 
determine the concentration of the antibodies raised specifically to the vaccine 
components and determine their Fab affinity. We will then calculate the 
percentage of the specific antibodies as a function of the total antibody 
concentration. The results will be compared with those obtained by Willianson 
et al. [408], with the role of the antibody arrays for screening potential vaccine 
candidates discussed. 
An acknowledgement is made to DSTL (Porton Down, UK) for supplying the 
samples and special thanks to Dr Di Williamson for her help and advice 
throughout the study. 
6.3 Materials 
Self-assembling monolayer (SAM) components: HS-(CH2)17-(OC2H4)3-OH (used 
as a ‘spacer’) and HS-(CH2)17-(OC2H4)6-OCH2COOH (used as a ‘linker’), were 
obtained from ProChimia Surfaces (Poland). N-(3-Dimethylaminopropyl)-N'-
ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), 16-
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mercaptohexadecanoic acid (MHDA), bovine serum albumin (BSA) (98%), 
human fibrinogen (FBR) (60%, with 40% buffer salts; the protein content is 
>80% clottable FBR) and human serum albumin (HSA) (>96%) were obtained 
from Sigma-Aldrich. Recombinant Protein A/G (PAG) was purchased from 
Pierce. Sheep polyclonal antibodies to BSA (aBSA) (23 mg/mL, IgG fraction) 
were supplied by AbD Serotec. Human Serum (HS) (male AB) was obtained 
from Biosera. For the secondary antibodies, all were polyclonal and produced in 
Goat with aIgG (H+L) purchased from Bethyl labs at a concentration of 1 
mg/mL. 
6.3.1 Sub-unit Antigens and IgG mAbs 
All Macaque related materials were supplied by DSTL based at Porton Down 
(UK). Both F1 and LcrV antigens were produced in E. coli BL21. Recombinant 
LcrV protein (200 mg/mL) of Y. pestis (strain GB) was produced as a fusion with 
glutathione-s-transferase and purified as previously described [409]. 
Recombinant F1 protein (1.4 mg/mL) was expressed and purified in E.coli from 
a culture supernatant [410]. The final antigen was the fusion protein F1V (160 
µg/mL) which has previously been described [387]. In all cases, the 
recombinant proteins were formulated for use by coadsorption to alhydrogel 
(Brenntag Biosector, Frederikssund, Denmark) in phosphate buffered saline 
[411]. All Mabs used were raised in mice against LcrV, details of the antibody 
production are available [412]. 
6.3.2 Animals and Immunogenicity Studies 
All serum used in the study were derived from adult male and female 
cynomolgus macaques from a previous study [408]. Immunisation was effected 
intra-muscularly with 0.5mL of the F1+LcrV vaccine adsorbed to alhydrogel 
(alum content 0.65 mg) on days 1 and 21. This process was performed with the 
macaques divided into five groups such that group 1 received 5 mg F1+5 mg 
LcrV (serum samples 325 and 327), group 2 received 10 mg F1+10 mg LcrV 
(serum samples 330 and 331), group 3 received 20 mg F1+20 mg LcrV (serum 
sample 336), and group 4 received 40 mg F1+40 mg LcrV (no serum samples 
tested). Group 5 received a single dose of 40 mg F1+40 mg LcrV (serum 
sample 341).  
A further pooled positive control serum (macaque reference serum (MR)) 
derived from macaques that showed a high immune response following 
Chapter 6 
161 
 
vaccination is studied. Two negative control samples from macaques that were 
not immunised are used for comparison, along with human serum to act as a 
third negative control.  
6.4 Experimental Methods 
All experiments were performed on the Array Reader platform as described in 
detail in Chapter 2 and elsewhere [61, 77, 80].  
6.4.1 Surface Preparation 
Unfunctionalised Au arrays were taken from storage and cleaned with water 
and iso-1-propanol (IPA). They were then functionalised with 1:10 
(linker:spacer) mixture of the SAM and activated with EDC/NHS for 1 hour. The 
activated arrays were then functionalised with proteins by printing BSA, CRP, 
fibrinogen (1 mg/mL), PAG (2 mg/mL), F1 (1.4 mg/mL), LcrV (1 mg/mL) and the 
F1V fusion protein (625 µg/mL) from solutions in PBS directly over the 
nanoparticle containing array spots, according to the protein key in Figure 6.3.  
 
Figure 6.3. Protein functionalisation array key.  
Recombinant proteins LcrV, F1, Fusion and PAG were all specific assays 
designed to capture target antibodies from buffered solutions and serum. 
Fibrinogen and BSA would act as a negative control and a reference surface 
throughout the course of experiments.  
Fibrinogen
PAG
BSA F1
LcrV Fusion
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6.4.2 aLcrV Monoclonal Antibody Profiling  
After installation, the functionalised arrays underwent the standard protocol of 
washing with regeneration buffer and blocking with HSA solution. There were 
five mAbs studied in total, referenced as: mAb7.3, mAb12.3, mAb29.3 mAb36.3 
and mAb46.3. Each mAb was tested individually following the SOP described in 
Chapter 2. All solutions were prepared following a 2-fold dilution protocol 
starting at 20 nM. A 4 minute baseline was first collected, this was followed by a 
10 minute association phase and a 15 minute dissociation phase before the 
surface was regenerated; this process was repeated for all concentrations and 
all mAbs. Each mAb assay was also calibrated at the start and end of the data 
set with a mAb7.3 10 nM injection, to allow for any loss in response over the 
time course of the experiment to be accounted for. 
6.4.3 Macaque Sera Specific IgG Profiling 
An unused functionalised array was installed for each serum sample. The array 
was cleaned with regeneration buffer and blocked with both HSA and human 
serum (1:5 serum:PBS) to account for the complex nature of the sample. The 
same SOP was followed for the serum sample assay. All samples were stored 
at -20 °C until needed. 
The samples were diluted depending on the observed signal with dilutions at 
1:25, 1:50, 1:100, 1:250, 1:500, 1:1,000, and 1:2,000. The assay response was 
calibrated with a solution of mAb 7.3 10 nM, a solution of aF1 mAb was used 
before and after the assay for array-to-array calibration and to allow for any loss 
in response over the time course of the experiment. 
6.4.4 Total IgG Determination 
Total IgG was determined for each serum sample following the SOP devised in 
Chapter 4. Assays were performed by using the PAG assay SOP with dilutions 
of 1:2,500, 1:5,000 and 1:10,000 with duplicates. These were calibrated with the 
same human serum (HS) as used in Chapter 4. 
6.4.5 Constructing the Standard Curves 
Standard curves were needed for the specific analytes and the total IgG 
quantification. Purified samples of mAb 7.3 for LcrV, aF1 mAb for F1 supplied 
by DSTL and HS for the PAG surface were used to form the standard curves. 
Concentrations were used to cover the full dynamic range of the assay with 
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AUC determined for each concentration and plotted as described in Chapter 4 
using the 5-parameter logistic fit. 
 
Figure 6.4. Standard curves used for calculating either specific or total IgG from serum. For panels 
(A-C) the black line is the 5-PL fit, the red line are 95% confidence limits: (A) aF1 standard curve, R2 
= 0.999; (B) mAb 7.3 standard curve, R2 = 0.999; and (C) HS standard curve for determining total 
IgG, R2 = 0.999. 
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Panels (A-C) of Figure 6.4 all produce a highly accurate method of determining 
concentrations given the R2 value of 0.999 for all three curves. From these plots 
the assays limits can be derived such as the dynamic range and sensitivity; 
these are summarised in Table 6-1.  
Table 6-1. Characteristics of the standards curves derived for each antigen.  
Property F1 (nM) LcrV (nM) Human serum [IgG] (µg/mL) 
Dynamic range 0.625 – 100 0.3 – 100 0.02 – 566 
Linear range 2.5 – 40 5 – 40 0.5 – 56 
Detection limit 1.5 ± 0.5 1.3 ± 1.0 0.08 ± 0.05 
 
The standard curve for F1 has a dynamic range of 0.625 – 100 nM with linear 
range of 2.5 – 40 nM and a detection limit of 1.5 ± 0.5 nM. The detection limit is 
within the expected performance of the AR with concentrations above the linear 
range often showing a poor quality of fit to the 1:1 binding interaction model, so 
these values are as expected for this assay. The same can be said for the LcrV 
assay which has a dynamic range of 0.3 – 100 nM with a linear range of 5 – 40 
nM, so again reaching a maximum of 40 nM, the detection limit is comparable to 
F1 at 1.3 ± 1.0 nM. The PAG-assay for total IgG was described in great detail in 
Chapter 4 and again offers a large dynamic range covering more than 4 orders 
of magnitude, with a detection limit of 0.08 ± 0.05 µg/mL, corresponding to 0.5 ± 
0.3 nM. 
6.5 Results 
The results presented in the following section aim to address the application of 
antibody screening arrays to assess the efficacy of a new vaccine. The study 
was separated into two parts; the first part was designed to determine the 
affinity of the interactions between mAbs raised in mice against the Fab region 
(LcrV antigen) and Fc region (PAG). Identifying high affinity antibody-antigen 
interactions may aid the selection of antibodies able to elict passive immunity. 
The second part of the study used sera samples from seven immunised 
macaques, exposed to the Y. pestis bacterium. The concentration of specific 
and total IgG can be determined using the high quality standard curves 
presented in the Methods section. 
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6.5.1 aLcrV mAb Profiling  
The response of each mAb (ID: 7.3, 12.3, 29.3, 36.3 and 46.3) was measured 
against the recombinant LcrV antigen and PAG, to characterise the affinity 
constant of the mAbs interacting with both the Fab and Fc region, respectively. 
All the responses are presented in Figure 6.5 with concentrations starting at 20 
nM and following a 2-fold dilution. Both mAb12.3 and mAb36.3 showed no 
response to LcrV compared to the reference channel but they show specific 
binding to PAG indicating the epitope for the Fab region must be not be 
accessible. All mAbs profiled showed no signs of NSB with the reference 
channels. The specific responses were subtracted from the Fbr reference and 
plotted as ∆RI. 
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Figure 6.5. Collected data for the mAbs binding to both LcrV and PAG antigens fitted with the 1:1 
binding interaction model. All concentrations followed a 2-fold dilution from 20 nM. The black 
traces represent the collected experimental data; the red traces represent the fitted model. 
All of the PAG data showed an interaction that reached near saturation '& apart 
from mAb7.3 which had a response ≈ 50% of that of the others, suggestive of a 
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slower association phase. The statistical analysis of the global fit is presented in 
Table 6-2.  
Table 6-2. Statistical analysis of the 1:1 binding interaction model applied to the collected mAb 
data presented in Figure 6.5. 
mAb protein R2 χ2 
Residual 
(µ ± σ) (µRIU) 
7.3 LcrV 0.999 60 1 ± 11 
7.3 PAG 0.997 28 1 ± 17 
46.3 LcrV 0.994 15 0 ± 16 
46.3 PAG 0.999 159 1 ± 23 
29.3 LcrV 0.995 91 0 ± 15 
29.3 PAG 0.999 56 2 ± 21 
12.3 PAG 0.997 54 -2 ± 16 
36.3 PAG 0.999 17 0 ± 10 
 
From Table 6-2 all values of R2 are 0.99 or better with χ2 consistently below 
100, except mAb46.3 - PAG. All statistical values are indicative of a good fit for 
the 1:1 binding interaction model. Correlation matrices for all mAb global fit 
procedures can be found in Appendix B. 
6.5.2 Macaque Sera Study  
The data collected with the supplied macaque serum were more complicated to 
analyse, reflecting the complexity of the whole serum and associated matrix 
effects and NSB. A dilution of at least 1:50 (sera:PBS) was necessary to 
minimise the effect of the background proteins and at least five dilutions were 
studied for each sample. However, despite the dilution precautions, additional 
binding proteins contributed to the immuno-kinetic assay and gave rise to extra 
features in the collected data, effectively forming a two-process interaction [83, 
164]. All values of χ2 for the 1:1 interaction exceeded the 300 cut-off value 
determine in Chapter 2 by quite a margin. Therefore, additional terms were 
added to the 1:1 binding model to account for the variations. The new 
interaction model allowed for two adsorption events (Equation 6-1). The two-
process binding interaction model, would allow both the high-affinity antibody 
interaction and a low-affinity complex with a rapid dissociation rate to be 
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measured. An additional term to the analytic solution of the Langmuir equation 
can be added which allows for second process to also be monitored: 
%  ''&  
"#,)*+"#,)*+ , "$, 1  exp "#,)*+ , "$,

, 1 –   "#,!)*!+"#,!)*!+ , "$,! 1  exp "#,!)*!+ , "$,!
 
Equation 6-1 
Where % is the surface coverage, a fraction of the occupied binding sites and ' 
refers to the experimental observed surface coverage;  is the fraction of the 
surface occupied by species 1 and ranges within 0 – 1, the surface occupied by 
species 2 is 1- ; )*+ is the concentration of protein in solution; and "# and "$ 
are the adsorption and desorption rate constants, respectively. For the model to 
work correctly the two processes must be significantly different in rate for them 
to be identified. 
The data collected are presented in Figure 6.6 and Figure 6.7 and show the 
response of the macaque sera to the antigens rLcrV and rF1. There was no 
response to the printed fusion protein significantly above the noise, likely due 
protein degradation effecting the epitope site conformation of the printed 
antigen and is removed from the rest of the chapter. 
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Figure 6.6. Macaque sera samples binding to both LcrV and F1 antigens fitted with the two-process 
binding interaction model. Sera dilutions range 1:50 – 1:2000 (serum:PBS): black trace – 
experimental data; red trace – two-process global model. 
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Figure 6.7. Macaque sera samples binding to both LcrV and F1 antigens fitted with the two-process 
binding interaction model. Sera dilutions range 1:50 – 1:2000 (serum:PBS): black trace – 
experimental data; red trace – two-process global model.  
The PAG-assay was performed following the SOP devised in Chapter 4. The 
PAG binding is not sensitive to the Fab affinity and therefore binds all antibodies 
irrespective of their specificity. For this reason, the Fc binding of the target 
specific analytes were not distinguished, this could have been studied if a 
purification step was used to isolate the vaccine specific IgG. However, the 
PAG assay did allow the ratio IgG (specific) to IgG (total) to be measured. The 
addition of the second exponential function to the model allowed a good fit to 
the data with the statistical analysis improved significantly. The model allowed 
for a fast and slow association and dissociation phases due to one highly 
specific interaction and another with a weaker affinity. The statistical values 
calculated from the global fit model are presented in Table 6-3. 
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Table 6-3. Statistical analysis of the two-process binding interaction model applied to the collected 
data from the sera samples presented in both figures Figure 6.6 and Figure 6.7. 
Serum 
LcrV F1 
R2 χ2 
Residual 
(µ ± σ) (µRIU) R
2
 χ2 
Residual 
(µ ± σ) (µRIU) 
MR 0.995 43 1 ± 32 0.991 101 1 ± 31 
MS325 0.999 324 1 ± 32 0.998 198 5 ± 25 
MS327 0.985 253 3 ± 41 0.974 54 -1 ± 40 
MS330 0.999 298 5 ± 38 0.992 179 2 ± 21 
MS331 0.998 87 1 ± 20 0.991 154 -2 ± 31 
MS336 0.999 285 4 ± 25 0.998 274 2 ± 26 
MS341 0.995 384 0 ± 32 0.995 209 -1 ± 17 
 
All serum samples show good fit to the two-process model with R2 greater than 
0.99; apart from serum samples MS327 with R2 of 0.98 and 0.97 for LcrV and 
F1 data, respectively. χ2 values were all below the 300 cut-off mark except for 
MS325 and MS341 owed to the complexity of the two-processes being 
modelled and no new statistical measure of a suitable χ2 cut-off value. 
Correlation matrices for all two-process global fit procedures can be found in the 
Appendix B. 
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Figure 6.8. LcrV and F1 response to negative macaque sera samples after fibrinogen reference 
subtraction. Samples MS209 and MS211 are negative control macaque sera following no 
immunisation; HS is the negative control using human serum. Serum sample dilutions studied: 
black trace – 25-fold; red trace – 50-fold; and green trace – 100-fold. 
Serum samples from the negative control animals and human serum also 
studied: the results are shown in Figure 6.8. Higher concentrations were used 
given no specific antibody present. All data show a small response that arrive 
and leave quickly indicative of non-specific binding, however the quality of the 
data was not enough to confidently derive the affinities using the global fit 
model.  
6.5.3 IgG Calibration of the Serum Sample Data with Monoclonal IgG: the 
Epitope Density Factor 
The sera data were calibrated using the mAbs as the standards, however the 
antibodies present in sera are polyclonal in nature. A polyclonal antibody 
sample can bind to more than one epitope of a protein molecule due to the 
spectrum of IgG with Fab affinities present to a number of epitopes. The 
number of the antibodies a single antigen is capable of bindings is limited by 
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steric factors, as available epitopes will be masked upon antibody binding. Even 
so, there will be an epitope density factor that needs to be determined. 
A study was proposed to determine the number of antibodies capable of binding 
to LcrV by producing a pseudo-polyclonal antibody mixture based on a 
combination of mAbs. From Figure 6.5, three mAbs successfully interacted with 
the LcrV protein, with each binding to a different epitope location. Pseudo-
polyclonal mixtures of two and three mAbs were prepared and the ratio of these 
was based on their association rates ("#), which were 2.63, 1.17 and 0.66 × 105 
M-1s-1 for mAb7.3, mAb29.3 and mAb46.3, respectively, resulting in the ratio 1 : 
2.25 : 3.95, which would form a total concentration of 40 nM. This ratio would 
allow the antibodies to interact at the same rate with the surface and prevent 
one mAb filling the surface quickly potentially blocking the remaining mAbs from 
binding with the LcrV. The kinetic assay data are presented in Figure 6.9. 
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Figure 6.9. Pseudo-pAb study based of a mixture of mAbs, all assays followed an association 
phase 0 – 10 minutes and have a total Ab concentration of 40 nM: (A) Individual mAbs; black trace 
– mAb7.3; green trace – mAb29.3; red trace – mAb46.3. (B) Two-way mixture of mAbs; black trace – 
mAbs7.3 + mAb29.3; red trace – mAb7.3 + mAb46.3; green trace – mAb29.3 + mAb46.3. (C) Three 
way mixture of mAb7.3 + mAb29.3 + mAb46.3 – black trace. 
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The kinetic data presented in Figure 6.9 follow a typical 1:1 binding interaction. 
From Figure 6.9A it can be seen that mAb7.3 (black trace) interacts faster with 
the surface resulting in a quicker association rate than the other mAbs. In 
Figure 6.9B the mixture of mAb7.3 and mAb29.3 has a lower response which 
may indicate competitive binding leading to steric effects resulting in a lower 
value of '&. In Figure 6.9C the mixture of all three mAbs produces a response 
similar to that of the two-way mixtures. 
6.5.4 Secondary Detection Analysis of the Serum Samples with aIgG 
Secondary amplification was used to determine the nature of the second 
process. Human aIgG detection antibodies raised in a mouse were introduced 
to quantify the surface concentration of IgG. Analysis of the detection antibody 
was performed on the serum data at different time points during the dissociation 
phase to confirm whether the fast association/dissociation process was owing to 
NSB. Three repeats of the MR serum at a dilution of 1:50 were performed with 
the secondary aIgG injected at time points (12, 15 and 30 minutes) seen in 
Figure 6.10. 
 
Figure 6.10. Secondary analysis to determine the origin of the two-process binding interaction. 
After MR serum was injected at a 50-fold dilution for 10 minutes, aIgG was injected at 12 minutes 
(black), 15 minutes (red) and 30 minutes (green) to compare the secondary responses: (A) is the 
total responses of the LcrV antigen; (B) is the secondary responses of the LcrV antigen aligned to 
0 mRIU and t=0; (C) is the total responses of the F1 antigen; (D) is the secondary responses from 
the F1 antigen aligned to 0 mRIU and t=0. 
0 10 20 30 40 50
0.0
0.5
1.0
1.5
2.0
2.5
∆R
I (m
RI
U)
time (min)
0 5 10
0.0
0.5
1.0
1.5
∆R
I (m
R
IU
)
time (min)
DC
0 10 20 30 40 50
0.0
2.5
5.0
7.5
∆R
I (m
R
IU
)
time (min)
0 5 10
0
1
2
3
4
∆R
I (m
R
IU
)
time (min)
BA
LcrV
F1
Chapter 6 
176 
 
The secondary antibody introduced to the surface at 12, 15 and 30 minutes 
showed a slight increase in '& with allowed dissociation time (Figure 6.10 B, D), 
suggesting that the antibodies present on the surface after 12 minutes are still 
there after 30 minutes. If the process on the surface responsible for the faster 
association and dissociation was IgG then the '& values for the aIgG 
introduced at 30 minutes would have a '& value lower than that of 12 and 15 
minutes, consistent with the fast dissociation of IgG in the assay time range of 
10 – 15 minutes. Since this is not observed the experiment provides evidence of 
NSB on the assay surface interfering with the specific IgG signal. 
6.6 Discussion 
The study has successfully profiled the association, dissociation and binding 
affinities of a number of purified antibodies and serum samples containing 
antibodies raised against recombinant LcrV and F1 present in a trial vaccine 
supplied by DSTL (Porton Down, UK). The study takes advantages of the key 
areas where the AR can outperform other sensors; specifically multiplex 
antibody screening assays capable of characterising antibody – antigen 
interactions. 
The study was performed in two parts; the first was an investigation of mAbs 
raised against LcrV in mice to measure their affinity values and to understand 
the mAb – LcrV interaction. Of the five mAbs tested three showed a good 
binding response via their Fab (LcrV) and Fc (PAG) region; while the remaining 
two only showed a response to the Fc region. The second study involves 
screening serum from seven macaques following vaccination with the two-
component vaccine. From the assay data collected the specific concentrations 
of IgG against F1 and LcrV measured with their affinity value determined. The 
PAG assay, present on the same array, allowed the total IgG to be determined 
for each serum sample. 
A good immunogenic protective response should contain a high titre of specific 
antibodies able to mount a quick response identifying and coating a pathogen 
surface. The high Fab affinity may aid this interaction by forming a stronger 
interaction with the pathogen. One theory is that of antibody maturation [413]; 
where early stage antibodies show a wide frequency spectrum for antigens and 
are polyspecific. After affinity maturation the antibody shows a very narrow band 
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spectrum and the antibodies become monospecific; after a booster dose for 
example. The Fc region affinity for the Fc receptors on immune complexes is 
critical to clearing the infection – it does however compete with the Complement 
clearance process and here C1q and C3b binding is also essential. A higher 
affinity may promote faster clearance via opsonophagocytosis, particularly 
important for passive immunisation were a smaller spectrum of antibodies may 
be present resulting in fewer antibodies binding to the pathogen [414]. If fewer 
antibodies are bound then they may require a stronger affinity to promote a 
similar immune response. The following discussion will address these points 
and assess the contribution the AR could have on vaccine development using 
the SOP and analysis techniques discussed throughout this thesis.  
6.6.1 Monoclonal Antibody Study 
The values calculated for the mAb data are presented in Table 6-4 for the 
affinity of the antibodies binding to the LcrV antigen (Fab affinity) and the PAG 
surface (Fc affinity). The LcrV – mAb affinity could only be calculated for three 
of the five antibodies: two antibodies (mAb12.3 and mAb36.3) showed no 
significant specific or non-specific binding. The reason for these antibodies 
showing no response could be related to the epitope on the protein being 
masked due to its surface orientation during the functionalisation process or 
steric effects from the conformational structure of LcrV masking the epitope. 
Alternatively, the mAbs may have degraded resulting in loss of Fab activity, 
however due to the PAG response the Fc epitopes must still be intact.  
Table 6-4. The affinity constants, KD, derived for the mAbs against LcrV and PAG antigens. 
Monoclonal 
Antibody 
34 (pM) 
LcrV (Fab binding) PAG (Fc binding) 
mAb7.3 80 ± 7 1035 ± 60  
mAb29.3 399 ± 27 666 ± 9 
mAb46.3 865 ± 61 201 ± 5 
mAb12.3 no response 382 ± 5 
mAb36.3 no response 120 ± 4 
 
Between the three mAbs which did show a response there was a 10-fold 
difference in 34, with mAb7.3 having an affinity as low as 80 pM. A number of 
studies [408, 415, 416] have found mAb 7.3 to be of further interest as it is the 
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only mAb which has shown protection against Y. pestis in mice and has 
exclusive specificity for the Y. pestis LcrV antigen [415]. The protection shown 
by mAb7.3 has been attributed to the LcrV epitope. The epitope position was 
studied in great detail by Hill et al., [415] and it was discovered to be present on 
the coiled coil region of LcrV specifically on residue N255 which is located near 
the α7 helix at the end of a β-sheet (β6); seen in Figure 6.11. 
 
Figure 6.11. Crystal structure of the LcrV protein. (A) is a portion of the LcrV protein with labelled 
structures, the black box represents the proposed position of the mAb7.3 epitope at the residue 
N255; (B) N255 region magnified. Figure adapted from Hill et al. [415]. 
Hill et al. [415], suggest that it mediates protection against Y. pestis by binding 
proteins involved with the type III secretion system (T3SS). The T3SS is 
employed by a number of Gram negative bacterial pathogens to inject toxins 
into host cells [417], the major extracellular component of the T3SS is a needle-
like structure [418] that extends from the outer-membrane portion of the 
apparatus and through which runs a channel used to transport these toxins 
[419]. The needle is formed by a helical assembly of multiple copies of LcrV 
[420]. Therefore, disrupting the LcrV – LcrV multimerisation in vivo inhibits the 
A
B
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formation of the type III secretion system and LcrV – host interactions, as the 
needle tip cannot form.  
The antibodies mAb29.3 and mAb46.3 had significantly lower values of affinity 
compared to mAb7.3 of 400 and 865 pM, respectively, although on the 
spectrum of antibody – antigen complex stability, the 34 values are still high 
compared with 1 nM observed for the aCRP-CRP observed in Chapter 4. The 
improved mAb7.3 affinity of 80pM could be a sign of the antibody maturation 
process [421] and indicates that this mAb is best suited for use as a capture 
antibody in ELISA assays for protein quantification compared with the weaker 
affinity mAbs. 
The affinity of the Fc region determined by PAG showed some variation, with 
affinity values in the range of 120 – 1035 pM. These values are consistent with 
Chapter 4 where PAG was shown to have a high affinity for PAG with 34 values 
against SPG and SPA in the low pM range. The strongest interaction was 
between the mAb36.3 – PAG complex followed by mAb46.3, interestingly even 
though mAb7.3 has been shown to provide protection in mice via passive 
immunisation [412] it had the lowest affinity with the Fc region at 1 nM, 
suggesting that its epitope location on LcrV plays the most important role in 
providing protection in vivo. However, measuring the Fc affinity via PAG is only 
a proxy for the important Fc – Fc receptor interaction so it may not represent the 
true affinity but it does provide an estimate. The mAb responses to LcrV antigen 
and PAG are plotted against each other capturing both properties 
simultaneously, Figure 6.12. 
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Figure 6.12. Affinity values for the mAb-LcrV (x-axis) vs mAb-PAG (y-axis) interactions. Black 
points represent the mAbs that interacted with both proteins; red points represent the mAbs that 
showed no affinity to LcrV. 
There is a negative correlation between the affinities to each protein. However, 
this relationship is likely to be accidental and not statistically significant given 
three data points. Although, it does provide an initial estimate and suggest that 
mAbs in the lower right corner of Figure 6.12 may provide the best protection. A 
larger mAb cohort would allow more points to be plotted, if this relationship 
continued to show negative correlation this could prove to be a valuable tool in 
studying antibody Fc and Fab relationship.  
This method of screening the Fab and Fc affinity for mAbs can aid in the 
development of therapeutic antibodies as well as vaccines. Twenty-eight 
recombinant mAbs are currently approved for therapeutic use by the FDA and 
with over 200 new candidates entering into clinical trials, the field of mAbs is 
becoming an extremely competitive field [422]. The optimum therapeutic 
antibody is highly potent, long-acting, stable and non-immunogenic antibody 
molecule [423]. The AR is ideally suited to measuring antibodies cross-reactivity 
with similar species identifying the level of immunogenicity. A high level of 
affinity at the Fab region is important for antigen recognition and the 
assessment of antibody maturation. The Fc region binds to a number of 
receptors so the correct engineering to provide the strongest interactions is 
important to provide a strong immune response and to avoid clearance. 
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Tang et al., described a positive relationship between the Fab-affinity of IgG 
antibody and antibody-dependent cellular cytotoxicity (ADCC) [424]. Another 
study, by Kyriakos et al. [425], based on the affinity of anti HER2 antibodies 
found that the lowest-affinity antibody exhibited the least catabolism by the 
target cells, whereas the highest-affinity antibody exhibited the most. Increasing 
the affinity to the antigen appeared to have a negative effect on target mediated 
clearance (cleared along with the pathogen via phagocytosis) but, like Tang et 
al., a positive effect on ADCC activity. 
6.6.2 Macaque Serum Study 
The same antibody screening array was used to screen the serum from seven 
macaques vaccinated with the two-component vaccine (F1 + LcrV) against Y. 
pestis. The study required standard curves to quantify the immune response. 
However, the standard curves (Figure 6.4) were not complete and the epitope 
density needed to be determined accurately to allow for a population of binding 
sites on the surface (polyclonal serum = mAb1 + mAb2 + mAb3 etc). 
A study was proposed to identify the poly-to-mono antibody calibration factor by 
producing a pseudo-polyclonal mixture of the three mAbs that recognised the 
LcrV antigen (mAbs 7.3, 29.3 and 46.3) discussed in the results, section 6.5.3. 
Each mAb mixture was injected at 40 nM, first individually and then as a pair, 
based on the ratio of the "# values; the '& values are summarised in Table 6-5.  
Table 6-5. Values of ϑm calculated from a single exponential fit for each bind from the pseudo-
polyclonal experiment. (*) indicates the expected ϑm values of the pair mixture calculated by adding 
the single values of ϑm together. 
mAb 
mAb 
(single) 
mAb 
mAbs (pair-wise mixtures) Mixture response 
%  
('& measured / '& predicted) 
'& 
(mRIU)  
'& (mRIU) 
(measured) 
'& (mRIU) 
(predicted)* 
7.3 0.49 
7.3 + 
29.3 
0.50 1.04 48% 
29.3 0.55 
7.3 + 
46.3 
0.75 1.07 70% 
46.3 0.58 
29.3 + 
46.3 
0.73 1.13 65% 
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Initially the '& values of the single mAbs were compared to the pair mixtures, in 
theory, given that independent epitopes for each mAb are present on the 
surface then the total '& of the single injections when added together should be 
the same as the '& values of the pair mixture injections (Equation 6-2). 
'&mAb1 ,  '&mAb2    '&mAb1 , mAb2 
Equation 6-2 
All observed values were lower than predicted indicating close epitope proximity 
on the protein surface and consequent interference in the kinetic binding 
processes. The LcrV protein has the approximate dimensions of 7 × 3.5 × 2.5 
nm (Figure 6.1) indicating that it may not be sterically possible for two 
antibodies to access both epitope sites simultaneously; one will be obscured so 
the association kinetics become co-operative [426].  
The ratio of this calculation is rather interesting as it could provide insight into 
the antigens epitope location. It has already been mentioned that mAb7.3 is 
located around the coiled-coil region and the fact that the calculated mixture 
response, Table 6-5, is only 48% when combined with mAb29.3 suggests that 
this antibody could have a similar epitope location. Whereas mAb46.3 has a 
more distinct epitope location from the mAb29.3/7.3 epitopes, given the higher 
mixture responses, 65% and 70%; a simple schematic representation of the 
predicted epitope locations is presented in Figure 6.13. 
 
Figure 6.13. Schematic representation of the suggested mAbs epitope locations on the LcrV 
protein.  
The data also show that the 3-way mixture had a similar '& value as the 2-way 
mixtures; this is visible in Figure 6.14. To determine the calibration factor, the 
29.3
46.3
7.3
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mean '& value for the 3-way mixture can be divided by the mean '& value for 
the single mAbs: 
calibration factor   '&3  way mAb mixture'&mean mAb single  
Equation 6-3 
The calibration factor was calculated to be 1.4 from Equation 6-3. In the serum 
samples however there will be many more antibodies produced with a range of 
epitopes on the LcrV surface meaning that this factor could be greater. Given 
that a 3-way pseudo polyclonal mixture was the upper limit that could be tested 
the factor of 1.4 was used for all further data analysis. 
 
Figure 6.14. Mean and standard deviation of calculated ϑm values for all possible combinations of 
mAbs. 
The study was an example of possible epitope mapping investigations that 
could be an application of the AR and could act as a companion study for 
therapeutic antibody screening if more than one mAb have been raised. It does 
assume however, that the epitopes are on the same protein whereas this will 
not always be the case and a portion of the signal will be from binding to 
separate proteins. Using this method the epitope sequence cannot be 
determined but it could be useful, as shown here, in identifying the epitopes for 
mAbs that could present cooperative binding, or compete for similar sites. mAbs 
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could be chosen that have antigen epitope binding sites at the optimum 
distance from each other to promote more effective interactions, for passive 
immunisation this could be of benefit as with more antibody present on the 
pathogen surface the processes such as opsonophagocytosis and Complement 
activation could be triggered earlier. 
The best estimate of the calibration factor for the epitope distribution on the 
sensor surface is 1.4 from which the specific antibody concentrations in serum 
samples can be determined, using the same method as for PAG-assay based 
on AUC. The mean and standard deviation of the specific IgG concentrations 
are presented in Table 6-6, along with the total IgG calculated from the PAG 
response. 
Table 6-6. Specific and total IgG concentrations calculated from the macaque sera samples. 
macaque 
serum 
(immunisation 
group) 
IgGspecific (µg/mL) 
IgGtotal 
(mg/mL) 
IgGspecific / IgGtotal (%) 
aLcrV aF1 aLcrV aF1 
MR (0) 803 ± 56 43 ± 15 5.9 ± 0.3 13.6 ± 1.7 0.7 ± 0.3 
MS325 (1) 70 ± 4 16 ± 5 6.1 ± 0.5 1.2 ± 0.2 0.3 ± 0.1 
MS327 (1) 157 ± 9 115 ± 14 6.1 ± 0.5 2.6 ± 0.4 1.9 ± 0.4 
MS330 (2) 181 ± 55 49 ± 9 4.7 ± 0.4 3.9 ± 1.6 1.0 ± 0.3 
MS331 (2) 216 ± 47 23 ± 4 6.2 ± 0.3 3.5 ± 1.0 0.4 ± 0.1 
MS336 (3) 398 ± 49 19 ± 1 5.2 ± 0.2 7.6 ± 1.3 0.4 ± 0.1 
MS341 (5) 92 ± 10 17 ± 4 6.1 ± 0.5 1.5 ± 0.3 0.3 ± 0.1 
 
All the macaques responded to immunisation with a specific IgG concentration 
to F1 and LcrV. All titres are within the µg/mL range with aLcrV ranging 70 – 
800 µg/mL (µ ± σ = 274 ± 257 µg/mL) and aF1 having a lower concentration, 
ranging from 16 – 115 µg/mL (µ ± σ = 40 ± 35 µg/mL). The concentration of 
aLcrV is significantly larger than aF1 for all samples tested. In contrast, 
Williamson et al. [408] found aF1 to have a higher titre than aLcrV over all time 
points studied, with the concentrations: aF1, 4 – 40 µg/mL compared with 
aLcrV, 2 – 26 µg/mL. Reasons for the differences in concentration could be due 
to NSB present in the data polluting the derived concentrations and also the fact 
that the epitope calibration factor is not precisely known, with only the lower limit 
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calibration factor used. Another reason could be that the results of the ELISA 
assays performed by Williamson et al. depend on the epitope integrity of the 
detection antibody. If the epitope presentation were to be hindered by the 
capture process then this would result in a lower concentration of IgG detected. 
As the process described here measures the primary response then masked 
epitopes do not present a problem, providing a higher calculated specific IgG 
concentration.  
The calibration factor determination for the epitope population is a concern that 
affects all the serum analysis, firstly the concentration, as seen above, and 
secondly, the affinity determination which is directly linked to concentration 
(Equation 6-1). For instance, if the calibration factor was increased by two then 
the affinity values would become twice as weak. Using the mean concentrations 
determined in this study and those determined by Williamson et al. [408] an 
estimate of the calibration factor required to repeat these results would be ≈ 3 
for the aF1 but ≈ 15 for the aLcrV. The calibration factor for aLcrV is not a 
realistic factor as it would require 15 antibodies to be able to bind to the single 
LcrV protein surface and due to the protein size this is not physically possible. 
The following analysis is performed using the estimated lower limit of the 
calibration factor, 1.4. 
The serum data collected in this study has been grouped by immunisation dose 
received, presented in Figure 6.15. To recap, the macaques were divided into 
five groups such that group 1 received 5 mg F1+5 mg LcrV (serum samples 325 
and 327), group 2 received 10 mg F1+10 mg LcrV (serum samples 330 and 
331), group 3 received 20 mg F1+20 mg LcrV (serum sample 336), and group 4 
received 40 mg F1+40 mg LcrV (no serum samples tested). Group 5 received a 
single dose of 40 mg F1+40 mg LcrV (serum sample 341). Group 0 refers to the 
pooled MR serum as a positive control. 
The study by Williamson et al. [408], showed little correlation between F1 + 
LcrV vaccination concentration and specific IgG concentration. The 
concentration of the MR serum is high in both cases as expected. The aLcrV 
data appears to follow a weak positive trend for Groups 1 – 3, as Group 5 only 
received a single dose the lower value could be expected. aF1 however, does 
not follow this same trend when the data are averaged and actually has a 
negative correlation. With the Group 5 macaque the concentration of aF1 is 
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again lower than the other immunisation groups due to the single immunisation 
dose. The result is in line with findings from the Williamson et al. study which 
also demonstrated the need for the booster immunisation in the macaque 
species. 
 
Figure 6.15. Specific IgG assay results for aLcrV (red) and aF1 (green) organised into their 
respective immunisation groups. Group 0 is the positive control MR serum. Groups 1 – 4 received 
two injections, vaccination + booster; group 1 received 5 mg F1+5 mg LcrV (serum samples MS325 
and MS327), group 2 received 10 mg F1+10 mg LcrV (serum samples MS330 and MS331), group 3 
received 20 mg F1+20 mg LcrV (serum sample MS336), and group 4 received 40 mg F1+40 mg LcrV 
(no serum samples tested). Group 5 received a single dose of 40 mg F1+40 mg LcrV (serum sample 
MS341). 
The concentration of total IgG was determined via the PAG-assay (Table 6-6) 
and it allows the specific IgG concentrations to be expressed as a percentage of 
the total concentration, Figure 6.16A. The total IgG over all serum samples had 
a mean value of 5.8 ± 0.6 mg/mL and was quite consistent over all samples, 
with the levels showing no trend between immunisation groups. As the specific 
IgG concentration was larger from aLcrV compared to aF1 this was also true for 
the percentages, with aLcrV and aF1 in the range 1.1 – 13.6% and 0.3 – 1.9%, 
respectively. 
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Figure 6.16. Specific IgG and total IgG concentration comparison; in both panels, red is aLcrV, 
green is aF1. (A) IgGspecific / IgGtotal (%) against serum sample; (B) ratio of aLcrV to aF1. 
A review of the literature found no expected range for the percentage of a 
specific IgG compared to total IgG. The MR serum, however could be used as 
an estimated standard and had the highest ratio of aLcrV:IgG(total) of ~ 10% 
and an above average value of ~ 0.7% for the aF1 ratio. Serum MS327 showed 
consistently high values for each and could be suggest a better level of 
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protection as there will be fewer other IgGs inhibiting the binding of the specific 
IgG.  
Serological isotyping of the serum was performed in the study by Williamson et 
al. and it was discovered that the response was predominantly IgG2 for both 
antigens with only LcrV inducing a small response from IgG1. Naive serum 
contains more IgG1 than IgG2, with IgG1 accounting for 60 – 70% of total IgG, 
whereas IgG2 only accounts for 20% [427]; further evidence for the lack of 
correlation between specific and total IgG. The ratio of aLcrV to aF1 is plotted in 
Figure 6.16B with the average value of 9. There also, is a clear positive trend in 
the ratio and immunisation group similar to that seen with the concentration of 
aLcrV but the trend is amplified due to the decreasing trend seen for aF1 
concentration. The MR serum does have a large ratio of aLcrV:aF1 suggesting 
aLcrV antibodies provide a better level of immunity to aF1.  
With the specific antibody concentrations known, the affinities can be 
determined using the two-process binding interaction model. The kinetic 
constants calculated from the fit, according to Equation 6-1, include two values 
for "# ("#,, "#,!) and "$ ("$,, "$,!). Also in the output is a value gamma (γ) 
ranging from 0 – 1 and is the fraction of the surface occupied with protein 1. The 
model allows for two association and two dissociation processes (rates) each 
with a rate constant. For all values determined there is a slow interaction 
process and a fast one, the slow process is indicative of an antibody:antigen 
binding event (34,), while the fast one is typical of NSB (34,!). For the NSB fast 
interaction the total protein concentration, measured using a Nanodrop (Thermo 
Scientific Nanodrop 2000c) device, was used to determine the second affinity 
constant. The calculated values for affinities are presented in Table 6-7.  
The 34, values for LcrV show a negative trend according with immunisation 
group and antibody concentration. The negative trend suggests that a smaller 
immunisation dose may actually promote an antibody with a better affinity, or 
perhaps a smaller range of more highly specific antibodies present in the 
polyclonal IgG. F1, on the other hand, does not show any signs of correlation 
and like the concentration seem to be immunisation dosage independent, these 
trends can be seen in Figure 6.17A. 
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Table 6-7. Summary of the calculated affinity constants KD for the macaque sera IgGs against LcrV 
and F1 antigens. 
Macaque Sera 
LcrV F1 
34, (nM) 34,! (µM) 34, (nM) 34,! (µM) 
MR 1.20 ± 0.08 0.25 ± 0.02 0.86 ± 0.31 1.36 ± 0.49 
MS325 1.40 ± 0.07 32.62 ± 1.66 0.17 ± 0.05 0.27 ± 0.09 
MS327 3.45 ± 0.21 1.23 ± 0.07 0.67 ± 0.08 0.48 ± 0.06 
MS330 3.23 ± 0.98 32.54 ± 9.87 1.44 ± 0.26 0.76 ± 0.14 
MS331 5.87 ± 1.29 0.28 ± 0.06 0.22 ± 0.04 0.07 ± 0.01 
MS336 8.40 ± 1.04 1.66 ± 0.20 0.30 ± 0.02 0.10 ± 0.01 
MS341 1.09 ± 0.12 27.59 ± 2.92 0.09 ± 0.02 0.21 ± 0.04 
 
34,! values are presented in Figure 6.17B, there are no trends present in the 
data which is expected as total protein content will be independent of the 
immune response after vaccination, affecting proteins not present at high 
concentrations compared to albumin for example. 
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Figure 6.17. Affinity constant (KD) values. (A) Affinity constants for KD,1; (B) Affinity constants for 
KD,2. Red is aLcrV; green is aF1. 
In the mAb study discussion it was suggested that mAb7.3 was more protective 
because of its epitope location which affected the T3SS [415]. By measuring the 
affinity of antibodies present in macaque serum after vaccination we have 
identified macaques that may possess antibodies directed against LcrV and 
therefore, more capable of inhibiting the virulence effects of the pathogen. The 
MR serum had the strongest affinity for LcrV along with MS325 and MS341. So 
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it could be said that these samples contain better neutralisation antibodies and 
would therefore be more protected against a Y. pestis infection. 
Most bacteria toxins, including Y. pestis, are active at nanomolar 
concentrations; a single molecule of diphtheria toxin can kill a cell [428]. To 
neutralise toxins, therefore, antibodies must be able to diffuse into the tissues 
and bind the virulence factor, or toxin, rapidly and with high affinity. The fact that 
IgG antibodies can diffuse easily throughout the extracellular fluid and their high 
affinity make an ideal candidate to neutralising toxins. For the same reason it 
could also be said that the affinity of aF1 is not as important, as F1 is not a 
virulence factor and as long as the aF1 affinity is in the low nanomolar range 
and it is present at a high enough concentration, then it may not be possible to 
improve protection any further. 
The MR serum provided a positive control to compare all further serum samples 
against. There are a number of parameters therefore that we have measured 
that could influence the level of protection offered by the vaccine, including: 
specific IgG, the percent specific IgG of total IgG and affinity. Quantification of 
specific IgG found the MR serum to have greater than twice the concentration of 
aLcrV compared to all other samples. The trend was not so pronounced with 
aF1 but the MR serum did have a concentration over the mean value of aF1. It 
is clear that an animal will benefit from a higher titre of specific IgG as more 
antibodies are available for recognition of the pathogen. MS336 had the highest 
titer of aLcrV after MR and suggests that this animal may have a good level of 
protection, with antibodies raised against the virulence factor LcrV.  
The percentage of antigen-specific IgG: total IgG is an interesting measure and 
one that is not often quoted, however higher titres of antigen-specific IgG are 
essential for assisting in the recognition and removal of pathogens. The MR 
serum had the largest ratio along with MS336 for aLcrV, further evidence that 
this parameter may offer evidence for level of protection. Both MR and MS336 
had the largest ratio for aLcrV:aF1 suggesting again that it is the aLcrV IgG that 
promotes protection with the F1 immunogen initially provoking the immune 
system response. The affinity value for MR is the lowest for LcrV, therefore 
having the strongest interaction of all serum samples tested. In contrast to 
MS336 correlating best with MR in terms of quantifying specific IgG, the value 
of 34 was actually the highest, therefore showing the weakest interaction with 
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LcrV. As the concentration of LcrV-specific IgG was greater, it could be argued 
that the affinity is not as important, although with the MR having a strong 
affinity, this suggests otherwise. 
The positive control MR serum sample consistently showed a higher 
concentration of antigen-specific IgG, a larger ratio with total IgG and a stronger 
affinity to the other samples; especially towards the virulence factor LcrV. These 
trends suggest that there is a relationship between the discussed parameters 
and level of protection provided. This screening method could therefore aid in 
vaccine development, with an immune response requiring a high concentration 
of antigen-specific IgG (> 500 µg/mL) and a large ratio of specific IgG against 
total IgG (> 5%), and finally a strong level of affinity (< 1 nM). 
6.7 Conclusion 
The antibody screening arrays have been successfully used to characterise the 
Fab and Fc regions of purified mAb to characterise the affinity values. A strong 
affinity with the Fab-region is suggested as a requirement for mAbs used in 
therapy and passive immunisation with the mAbs ideally raised against a 
virulence factor. 
Fab affinities were measured for serum samples from vaccinated macaques 
and a suggested screening protocol was developed based on affinity, titre and 
ratio (IgG(specific)/IgG(total)) of the antibodies raised. The Fc affinity of the 
antibodies was not measured and this region is important in registering the 
attack with the immune system. Measuring the Fc affinity value would not be 
possible without firstly purifying the antibody samples to avoid polluting the PAG 
surface. The affinities could then be measured providing more data on the 
produced antibodies. 
The proposed screening method could speed up the vaccination trial process 
and reduce costs by combining a number of assays in one; including total IgG 
concentration, specific IgG concentration and the affinity constants against their 
respective antigen. A second consequence is improved ethical practice, as a 
more detailed interrogation of the efficacy of antibodies could allow better 
scrutiny of antibodies before further animal testing is needed. The focus of this 
study was an ideal application taking advantage of the AR strongest attributes, 
multiplex antibody screening using small sample volumes of serum required. 
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7 Conclusions and Future Work 
The aim of this thesis was to evaluate the Array Reader as a possible point-of-
care platform for real-time, label-free, high-throughput proteomic profiling with 
applications in the fields of personalised patient care and differential disease 
diagnosis. I believe that the work presented has made a good start at 
addressing this aim, with the platform performance optimised and a number of 
applications tested for both antibody and protein screening assay. 
The global fit model proved highly successful in characterising binding 
interactions. It also highlighted the quality of the data produced and its 
reproducibility. Goodness-of-fit tests scrutinised the model in detail and 
provided a source of identifying problem areas with the model, pointing towards 
new information about the underlying kinetic processes. An SOP was 
developed to provide optimised dynamic range, sensitivity, reproducibility and 
limit of detection of immuno-kinetic assay. These were referred to frequently 
and provided a method of assay comparison with current commercially 
available assays. 
The first on-array assay designed for the AR involved protein A/G which was 
used extensively throughout this study. Protein A/G binds IgG specifically via 
the Fc region and was readily used to functionalise the particle plasmon SAM 
surface. The resultant surface had a large binding capacity and provides a 
highly specific, homologous and active surface for studying binding interactions 
directly or acting as a support. The first application was a total IgG assay used 
to quantify IgG from serum samples. Hospitals measure IgG levels routinely and 
several studies indicate that IgG deficiencies may be associated with a number 
of complications, including: immuno-deficiency disorders [242], respiratory tract 
infections such as bronchiectasis [307] bronchitis [243] and at the onset of 
sepsis [308]. In contrast, patients suffering from pneumonia [309] or various 
autoimmune disease [310] may have increased levels of IgG. 
PAG also provided a platform for protein screening assays, by tethering 
antibodies to the surface via the Fc region, which allowed the antigen binding 
site to remain available for the target protein; a requirement for antibodies to 
retain their activity. The CRP-assay performed to a good standard but required 
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the use of a detection antibody, improving the LOD to 7.5 ng/mL. However, it 
did prove that protein screening assays were possible and could have a similar 
LOD to antibody screening assays, given a suitable target, with the bio-stack 
amplification approach, discussed in Chapter 3, potentially enhancing the 
capabilities by up to 30-fold, extending the assay to screen for low-mass, or low 
abundant biomarkers of disease. The penetration depth of the plasmon field 
was also measured for the first time using the same bio-assay technique. By 
measuring the penetration depth it is possible to tailor the sensing region for a 
specific assay, decreasing the range if necessary when studying complex 
samples. Protein screening arrays still have some way to go for the generalised 
applicability but there is room for the optimisation of the PAG surface to 
increase the surface load and form multiplex arrays. 
The ability of the AR to screen the affinity of binding events at both the IgG Fc 
and Fab region allows antibody interactions to be interrogated. Profiling the 
binding affinities of both regions for a complete antibody characterisation is 
potentially very important. While the PAG-Fc binding affinity is a proxy for the 
Fc-FcR affinity it does allow the integrity of the Fc region to be compared and 
parameterised. Immediate applications include the routine screening of both the 
Fc and Fab regions of humanised antibodies designed for immunotherapy of 
cancer for example, where, in a relatively short space of time monoclonal 
antibodies have entered mainstream cancer therapy and this trend will likely 
grow with the discovery and development of new mAbs. 
Another field that could benefit from measuring Fc and Fab affinity is for vaccine 
development, the subject of Chapter 6. We performed an efficacy screen of a 
two-component vaccine to Y. pestis and profiled the properties of five 
monoclonal antibodies to the virulence factor LcrV. The immune response of 
seven macaques to the vaccine was evaluated with a number of parameters 
and compared against a positive control macaque that showed protective 
immunity. The affinity measurements and kinetic parameter set started the 
process of identifying suitable antibody properties that trigger a strong immune 
response activating opsonophagocytosis. An interesting side study to this 
involved the beginnings of an epitope mapping application, by measuring the 
mass of mAb mixtures, antibodies that compete for similar epitopes could be 
identified. This mapping process will also help with passive immunisation, by 
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providing a mAb cocktail that will not compete for similar epitopes, or 
alternatively, mAbs that have similar epitope locations and could therefore 
promote Complement activation via the binding of C1q [429]. The serum 
samples were also used to measure the specific antibody titre against their 
respective immunogens and calculate the values of affinity. The process 
resulted with a number of potential cut-off parameters, for which raised 
antibodies could be screened against. It could help identify better dose regime 
and limit the number of animals required for testing: ethically speaking this 
could have large implications in the field. The potential of the AR in antibody 
screening arrays is now well established and only the number of in-array assays 
and their design is required for this to become a routine screening platform. 
With some further developmental work, the AR instrument could become a 
commercially available platform. Initial design, development, automation and 
manufacturing costs of the AR would be large, at around $1 million to develop 
the first commercial device that had regulatory approval. However, a realistic 
commercial price tag for the platform would be ~ $30,000 with the cost of 
forming the instrument closer to $5,000. This price tag is significantly cheaper 
and the device more user friendly than a number of competitors, such as 
BIAcore. Commercialised BIAcore SPR instruments can cost from £100,000 up 
to £600,000, with supplies for each experiments costing £100 - £1,000; for 
example, the popular commercialised CM5 chip cost £60 - £100 each. With a 
focus on miniaturisation and pre-assay array assembly then the cost associated 
with the AR would be significantly less given the simple nature and the relatively 
cheap consumables required to build the platform. 
A potential application of the platform at this stage, continuing with the vaccine 
theme, would be the screening of therapeutic antibodies; recently there has 
been renewed optimism for an HIV-1 vaccine used for immunotherapy. An 
effective HIV-1 vaccine would need to induce antibodies that target a large 
number of strains [430], as HIV is constantly evolving [431]. Thus, a vaccine to 
this pathogen would have to induce high-affinity antibodies to a multitude of 
epitopes. The principle that antibodies in serum could be protective against HIV-
1 was established by passive transfer of pooled human serum to chimpanzees, 
which were then protected from infection with HIV-1, by Eichberg [432] in 1992. 
However, efforts to characterise the protective antibodies in human sera were 
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halted by the technology. If the antigens were to form a multiplex array then this 
assay is perfectly suited to the AR platform. 
Another potential application of the platform is for autoimmunity studies. 
Autoimmune diseases are rare and involve a humoral and/or cellular immune 
response against tissue-derived self-antigens [433], with a prevalence of 3% - 
5% of the European population [434]. Autoimmune disorders are generally 
diagnosed by detecting high-affinity autoantibodies in serum, which can 
precede the clinical symptoms of the disease by years, such as rheumatoid 
arthritis that cause joint mutilations. It is easy to imagine an autoimmune array 
containing a number of clinically significant autoimmune disorder assays that 
could form a panel of markers to diagnosis autoimmunity in patients. 
Work was started during my PhD to create an autoimmunity array which aimed 
to identify potential autoimmune targets for chronic obstructive pulmonary 
disorder (COPD), a disease which is not well understood but there are strong 
implications that it is related to autoimmunity [435-437]. However, due to the 
complex nature of this disease and the serum concentration of the 
autoantibodies not well known, the study was put on hold for the time being. 
The applications for antibody screening could be achieved using the current 96-
spot array configuration set-up. However, the number of spots could be 
increased by a factor of 10, providing up to 50 potential assays on a single array 
chip. We have previously demonstrated a 1,500 spot array with similar 
sensitivity, only limited by the number of pixels in the camera [438].  
One application with the larger array format could be for food allergies, which 
continues to rise in the USA and Europe. A paper of diagnosing peanut allergy 
was recently published from our laboratory [78]. Peanut allergy sufferers 
produce the largest group of allergy-related fatalities [439, 440]. In the USA, as 
many as 2% of children are peanut allergic, often having multiple allergies, 
leading to a disproportionately large number of deaths [441] and prompting 
some scientists to consider an approaching peanut allergy epidemic [442]. The 
exact cause of this allergy is unknown but by printing a large array of 50 food 
allergens then sera could be screened to measure the extent of allergy in 
patients. 
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George Poste has written about the ‘fragmented research on disease’, and 
notes how although there are over 150,000 papers documenting thousands of 
different biomarkers for disease, only about 100 biomarkers are routinely used 
in the clinic [443]. By scaling up the array screening capabilities it may be 
possible to print an array able to screen for these 100 markers. An even better 
target however, would be the entire serum proteome leading to systemic 
diagnosis of co-morbidities. With the current population growth and increased 
longevity are leading to a rapid demographic change. There is now a real need 
for the healthcare system to adapt and identify useful markers of disease. 
Projections indicate that the annual number of deaths due to cardiovascular 
disease will increase from 17 million in 2008 to 25 million in 2030, with annual 
cancer deaths increasing from 7.6 million to 13 million [444]. An assay capable 
of whole proteome screening with the goal of personalising medicine to the 
individual could be what the future healthcare system requires. 
We may currently be a long way off the goal of personalised medicine but the 
work presented in this thesis is a small step in the right direction and we have 
demonstrated real potential for blood proteome screening. Multiplex assays will 
be required initially to identify possible biomarkers and secondly the associated 
disease state. Links between disease biomarkers are vital and the success of 
multiplex assays will contribute to this, rapidly accelerating the throughput, 
saving money and lives in the process. 
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9 Appendices 
9.1 Appendix A 
 
Table 9-1. Correlation matrix for the global fit model to aBSA – PAG formed complex. 
 "# "$ %&1 %&2 %&3 %&4 %&5 %&6 %&7 %&8 "# 1.00 -0.59 -0.81 -0.88 -0.91 -0.88 -0.76 -0.48 -0.23 -0.11 "$ -0.59 1.00 0.82 0.79 0.76 0.71 0.61 0.39 0.19 0.08 %&1 -0.81 0.82 1.00 0.86 0.85 0.81 0.70 0.44 0.21 0.10 %&2 -0.88 0.79 0.86 1.00 0.90 0.85 0.74 0.47 0.22 0.10 %&3 -0.91 0.76 0.85 0.90 1.00 0.86 0.75 0.47 0.23 0.10 %&4 -0.88 0.71 0.81 0.85 0.86 1.00 0.71 0.45 0.22 0.10 %&5 -0.76 0.61 0.70 0.74 0.75 0.71 1.00 0.39 0.19 0.09 %&6 -0.48 0.39 0.44 0.47 0.47 0.45 0.39 1.00 0.12 0.05 %&7 -0.23 0.19 0.21 0.22 0.23 0.22 0.19 0.12 1.00 0.03 %&8 -0.11 0.08 0.10 0.10 0.10 0.10 0.09 0.05 0.03 1.00 
 
Table 9-2. Correlation matrix for the global fit model to aCRP – PAG formed complex. 
 "# "$ %&1 %&2 %&3 %&4 %&5 "# 1.00 -0.62 -0.84 -0.90 -0.88 -0.61 -0.20 "$ -0.62 1.00 0.85 0.82 0.73 0.50 0.16 %&1 -0.84 0.85 1.00 0.90 0.85 0.58 0.19 %&2 -0.90 0.82 0.90 1.00 0.88 0.60 0.20 %&3 -0.88 0.73 0.85 0.88 1.00 0.58 0.19 %&4 -0.61 0.50 0.58 0.60 0.58 1.00 0.13 %&5 -0.20 0.16 0.19 0.20 0.19 0.13 1.00 
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Table 9-3. Correlation matrix for the global fit model to the mixture (aBSA + aCRP) – PAG formed 
complex. 
 "# "$ %&1 %&2 %&3 %&4 %&5 %&6 %&7 %&8 "# 1.00 -0.58 -0.78 -0.88 -0.91 -0.89 -0.82 -0.63 -0.39 -0.17 "$ -0.58 1.00 0.81 0.79 0.75 0.72 0.64 0.49 0.31 0.13 %&1 -0.78 0.81 1.00 0.83 0.83 0.80 0.72 0.56 0.35 0.15 %&2 -0.88 0.79 0.83 1.00 0.89 0.87 0.79 0.61 0.38 0.17 %&3 -0.91 0.75 0.83 0.89 1.00 0.88 0.80 0.62 0.38 0.17 %&4 -0.89 0.72 0.80 0.87 0.88 1.00 0.78 0.60 0.37 0.16 %&5 -0.82 0.64 0.72 0.79 0.80 0.78 1.00 0.55 0.34 0.15 %&6 -0.63 0.49 0.56 0.61 0.62 0.60 0.55 1.00 0.26 0.11 %&7 -0.39 0.31 0.35 0.38 0.38 0.37 0.34 0.26 1.00 0.07 %&8 -0.17 0.13 0.15 0.17 0.17 0.16 0.15 0.11 0.07 1.00 
 
Table 9-4. Correlation matrix for the global fit model to the aBSA – BSA formed complex. 
 "# "$ %&1 %&2 %&3 %&4 %&5 %&6 "# 1.00 -0.70 -1.00 -1.00 -0.99 -0.98 -0.76 -0.09 "$ -0.70 1.00 0.73 0.73 0.72 0.71 0.55 0.06 %&1 -1.00 0.73 1.00 1.00 1.00 0.98 0.76 0.09 %&2 -1.00 0.73 1.00 1.00 0.99 0.98 0.76 0.09 %&3 -0.99 0.72 1.00 0.99 1.00 0.98 0.76 0.09 %&4 -0.98 0.71 0.98 0.98 0.98 1.00 0.74 0.08 %&5 -0.76 0.55 0.76 0.76 0.76 0.74 1.00 0.07 %&6 -0.09 0.06 0.09 0.09 0.09 0.08 0.07 1.00 
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Table 9-5. Correlation matrix for the global fit model to the aCRP – CRP formed complex. 
 "# "$ %&1 %&2 %&3 %&4 %&5 "# 1.00 -0.67 -0.97 -0.97 -0.96 -0.87 -0.36 "$ -0.67 1.00 0.80 0.79 0.76 0.69 0.30 %&1 -0.97 0.80 1.00 0.98 0.96 0.87 0.36 %&2 -0.97 0.79 0.98 1.00 0.96 0.87 0.36 %&3 -0.96 0.76 0.96 0.96 1.00 0.86 0.36 %&4 -0.87 0.69 0.87 0.87 0.86 1.00 0.32 %&5 -0.36 0.30 0.36 0.36 0.36 0.32 1.00 
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9.2 Appendix B 
Table 9-6. Correlation matrix for the global fit model to the mab7.3 – PAG formed complex 
 "# "$ %&1 %&2 %&3 %&4 "# 1.00 -0.57 -0.91 -0.94 -0.93 -0.88 "$ -0.57 1.00 0.78 0.74 0.70 0.65 %&1 -0.91 0.78 1.00 0.93 0.91 0.85 %&2 -0.94 0.74 0.93 1.00 0.92 0.87 %&3 -0.93 0.70 0.91 0.92 1.00 0.86 %&4 -0.88 0.65 0.85 0.87 0.86 1.00 
 
Table 9-7. Correlation matrix for the global fit model to the mab7.3 – LcrV formed complex 
 "# "$ %&1 %&2 %&3 "# 1.00 -0.43 -0.85 -0.94 -0.95 "$ -0.43 1.00 0.73 0.61 0.56 %&1 -0.85 0.73 1.00 0.89 0.88 %&2 -0.94 0.61 0.89 1.00 0.93 %&3 -0.95 0.56 0.88 0.93 1.00 
 
Table 9-8. Correlation matrix for the global fit model to the mab12.3 – PAG formed complex 
 "# "$ %&1 %&2 %&3 %&4 %&5 "# 1.00 -0.38 -0.89 -0.93 -0.90 -0.80 -0.47 "$ -0.38 1.00 0.66 0.55 0.48 0.42 0.24 %&1 -0.89 0.66 1.00 0.90 0.85 0.76 0.44 %&2 -0.93 0.55 0.90 1.00 0.87 0.77 0.45 %&3 -0.90 0.48 0.85 0.87 1.00 0.74 0.43 %&4 -0.80 0.42 0.76 0.77 0.74 1.00 0.38 %&5 -0.47 0.24 0.44 0.45 0.43 0.38 1.00 
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Table 9-9. Correlation matrix for the global fit model to the mab29.3 – PAG formed complex 
 "# "$ %&1 %&2 %&3 %&4 %&5 "# 1.00 -0.12 -0.95 -0.96 -0.95 -0.91 -0.74 "$ -0.12 1.00 0.21 0.15 0.09 0.07 0.06 %&1 -0.95 0.21 1.00 0.97 0.95 0.91 0.74 %&2 -0.96 0.15 0.97 1.00 0.96 0.92 0.75 %&3 -0.95 0.09 0.95 0.96 1.00 0.91 0.74 %&4 -0.91 0.07 0.91 0.92 0.91 1.00 0.72 
%&5 -0.74 0.06 0.74 0.75 0.74 0.72 1.00 
 
Table 9-10. Correlation matrix for the global fit model to the mab29.3 – LcrV formed complex 
 "# "$ %&1 %&2 %&3 %&4 "# 1.00 -0.04 -0.99 -0.99 -0.97 -0.88 "$ -0.04 1.00 0.06 0.05 0.04 0.03 %&1 -0.99 0.06 1.00 0.99 0.97 0.88 %&2 -0.99 0.05 0.99 1.00 0.97 0.88 
%&3 -0.97 0.04 0.97 0.97 1.00 0.86 %&4 -0.88 0.03 0.88 0.88 0.86 1.00 
 
Table 9-11. Correlation matrix for the global fit model to the mab46.3 – LcrV formed complex 
 "# "$ %&1 %&2 %&3 %&4 "# 1.00 -0.03 -0.99 -0.99 -0.99 -0.96 "$ -0.03 1.00 0.05 0.04 0.04 0.04 %&1 -0.99 0.05 1.00 0.99 0.99 0.96 %&2 -0.99 0.04 0.99 1.00 0.99 0.96 
%&3 -0.99 0.04 0.99 0.99 1.00 0.96 %&4 -0.96 0.04 0.96 0.96 0.96 1.00 
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Table 9-12. Correlation matrix for the global fit model to the mab46.3 – PAG formed complex 
 "# "$ %&1 %&2 %&3 %&4 %&5 "# 1.00 -0.08 -0.98 -0.98 -0.95 -0.88 -0.75 "$ -0.08 1.00 0.12 0.08 0.07 0.07 0.06 %&1 -0.98 0.12 1.00 0.98 0.96 0.89 0.75 %&2 -0.98 0.08 0.98 1.00 0.96 0.88 0.75 %&3 -0.95 0.07 0.96 0.96 1.00 0.86 0.73 %&4 -0.88 0.07 0.89 0.88 0.86 1.00 0.68 
%&5 -0.75 0.06 0.75 0.75 0.73 0.68 1.00 
 
Table 9-13. Correlation matrix for the global fit model to the mab36.3 – PAG formed complex 
 "# "$ %&1 %&2 %&3 %&4 "# 1.00 -0.08 -0.98 -0.97 -0.94 -0.77 "$ -0.08 1.00 0.13 0.08 0.06 0.05 %&1 -0.98 0.13 1.00 0.98 0.95 0.78 %&2 -0.97 0.08 0.98 1.00 0.95 0.78 
%&3 -0.94 0.06 0.95 0.95 1.00 0.76 %&4 -0.77 0.05 0.78 0.78 0.76 1.00 
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Table 9-14. Correlation matrix for the global fit model to the macaque serum sample MS325 – LcrV 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 %&6 "#1 1.00 -0.03 0.46 -0.29 0.18 -0.88 -0.89 -0.90 -0.89 -0.88 -0.78 "$1 -0.03 1.00 0.33 0.87 0.63 0.19 0.19 0.19 0.19 0.18 0.16 "#2 0.46 0.33 1.00 0.12 0.89 -0.69 -0.67 -0.67 -0.66 -0.65 -0.57 "$2 -0.29 0.87 0.12 1.00 0.40 0.48 0.48 0.48 0.47 0.46 0.41 γ 0.18 0.63 0.89 0.40 1.00 -0.38 -0.36 -0.35 -0.35 -0.34 -0.30 
%&1 -0.88 0.19 -0.69 0.48 -0.38 1.00 1.00 0.99 0.99 0.97 0.86 %&2 -0.89 0.19 -0.67 0.48 -0.36 1.00 1.00 1.00 0.99 0.97 0.86 %&3 -0.90 0.19 -0.67 0.48 -0.35 0.99 1.00 1.00 0.99 0.97 0.86 %&4 -0.89 0.19 -0.66 0.47 -0.35 0.99 0.99 0.99 1.00 0.96 0.85 %&5 -0.88 0.18 -0.65 0.46 -0.34 0.97 0.97 0.97 0.96 1.00 0.84 %&6 -0.78 0.16 -0.57 0.41 -0.30 0.86 0.86 0.86 0.85 0.84 1.00 
 
Table 9-15. Correlation matrix for the global fit model to the macaque serum sample MS325 – F1 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 %&6 "#1 1.00 0.30 0.71 0.10 0.36 -0.93 -0.93 -0.90 -0.86 -0.81 -0.78 "$1 0.30 1.00 0.60 0.41 0.90 0.02 0.01 0.03 0.03 0.00 -0.02 "#2 0.71 0.60 1.00 0.38 0.73 -0.54 -0.55 -0.54 -0.55 -0.57 -0.58 "$2 0.10 0.41 0.38 1.00 0.34 0.12 0.12 0.18 0.24 0.26 0.26 γ 0.36 0.90 0.73 0.34 1.00 -0.08 -0.08 -0.06 -0.08 -0.11 -0.14 
%&1 -0.93 0.02 -0.54 0.12 -0.08 1.00 0.98 0.97 0.93 0.88 0.84 %&2 -0.93 0.01 -0.55 0.12 -0.08 0.98 1.00 0.97 0.94 0.89 0.85 %&3 -0.90 0.03 -0.54 0.18 -0.06 0.97 0.97 1.00 0.94 0.90 0.86 %&4 -0.86 0.03 -0.55 0.24 -0.08 0.93 0.94 0.94 1.00 0.90 0.87 %&5 -0.81 0.00 -0.57 0.26 -0.11 0.88 0.89 0.90 0.90 1.00 0.86 %&6 -0.78 -0.02 -0.58 0.26 -0.14 0.84 0.85 0.86 0.87 0.86 1.00 
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Table 9-16. Correlation matrix for the global fit model to the macaque serum sample MS327 – F1 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 "#1 1.00 0.61 0.65 0.12 0.79 -0.89 -0.87 -0.80 -0.73 -0.51 "$1 0.61 1.00 0.57 -0.42 0.73 -0.36 -0.35 -0.32 -0.29 -0.21 "#2 0.65 0.57 1.00 0.23 0.84 -0.47 -0.46 -0.42 -0.39 -0.27 "$2 0.12 -0.42 0.23 1.00 0.26 0.01 0.01 0.01 0.01 0.00 γ 0.79 0.73 0.84 0.26 1.00 -0.48 -0.48 -0.44 -0.40 -0.28 
%&1 -0.89 -0.36 -0.47 0.01 -0.48 1.00 0.94 0.86 0.79 0.55 %&2 -0.87 -0.35 -0.46 0.01 -0.48 0.94 1.00 0.85 0.77 0.54 %&3 -0.80 -0.32 -0.42 0.01 -0.44 0.86 0.85 1.00 0.71 0.50 %&4 -0.73 -0.29 -0.39 0.01 -0.40 0.79 0.77 0.71 1.00 0.46 %&5 -0.51 -0.21 -0.27 0.00 -0.28 0.55 0.54 0.50 0.46 1.00 
 
Table 9-17. Correlation matrix for the global fit model to the macaque serum sample MS327 – LcrV 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 %&6 "#1 1.00 0.28 0.62 -0.04 0.28 -0.94 -0.94 -0.90 -0.82 -0.72 -0.62 "$1 0.28 1.00 0.62 0.55 0.91 0.03 0.02 0.04 0.03 0.00 -0.02 "#2 0.62 0.62 1.00 0.36 0.79 -0.47 -0.47 -0.49 -0.51 -0.50 -0.46 "$2 -0.04 0.55 0.36 1.00 0.55 0.29 0.31 0.37 0.38 0.34 0.29 γ 0.28 0.91 0.79 0.55 1.00 -0.02 -0.02 -0.02 -0.05 -0.09 -0.11 
%&1 -0.94 0.03 -0.47 0.29 -0.02 1.00 0.99 0.96 0.90 0.78 0.67 %&2 -0.94 0.02 -0.47 0.31 -0.02 0.99 1.00 0.97 0.90 0.79 0.68 %&3 -0.90 0.04 -0.49 0.37 -0.02 0.96 0.97 1.00 0.91 0.80 0.70 %&4 -0.82 0.03 -0.51 0.38 -0.05 0.90 0.90 0.91 1.00 0.78 0.68 %&5 -0.72 0.00 -0.50 0.34 -0.09 0.78 0.79 0.80 0.78 1.00 0.62 %&6 -0.62 -0.02 -0.46 0.29 -0.11 0.67 0.68 0.70 0.68 0.62 1.00 
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Table 9-18. Correlation matrix for the global fit model to the macaque serum sample MS330 – F1 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 "#1 1.00 0.39 0.60 0.11 0.35 -0.91 -0.89 -0.83 -0.71 -0.55 "$1 0.39 1.00 0.64 0.36 0.90 -0.04 -0.04 0.01 0.00 -0.05 "#2 0.60 0.64 1.00 0.30 0.76 -0.42 -0.41 -0.39 -0.44 -0.44 "$2 0.11 0.36 0.30 1.00 0.56 0.19 0.23 0.34 0.44 0.37 γ 0.35 0.90 0.76 0.56 1.00 -0.01 0.02 0.08 0.07 -0.01 
%&1 -0.91 -0.04 -0.42 0.19 -0.01 1.00 0.97 0.95 0.84 0.65 %&2 -0.89 -0.04 -0.41 0.23 0.02 0.97 1.00 0.95 0.86 0.67 %&3 -0.83 0.01 -0.39 0.34 0.08 0.95 0.95 1.00 0.89 0.70 %&4 -0.71 0.00 -0.44 0.44 0.07 0.84 0.86 0.89 1.00 0.72 %&5 -0.55 -0.05 -0.44 0.37 -0.01 0.65 0.67 0.70 0.72 1.00 
 
Table 9-19. Correlation matrix for the global fit model to the macaque serum sample MS330 – LcrV 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 "#1 1.00 0.42 0.64 0.63 -0.91 -0.62 -0.62 -0.62 -0.62 -0.60 "$1 0.42 1.00 -0.13 0.75 -0.49 0.33 0.31 0.31 0.31 0.29 "#2 0.64 -0.13 1.00 0.21 -0.49 -0.94 -0.95 -0.95 -0.93 -0.88 "$2 0.63 0.75 0.21 1.00 -0.83 -0.02 -0.04 -0.04 -0.04 -0.04 γ -0.91 -0.49 -0.49 -0.83 1.00 0.45 0.44 0.44 0.44 0.43 
%&1 -0.62 0.33 -0.94 -0.02 0.45 1.00 0.99 0.98 0.97 0.93 %&2 -0.62 0.31 -0.95 -0.04 0.44 0.99 1.00 0.98 0.97 0.93 %&3 -0.62 0.31 -0.95 -0.04 0.44 0.98 0.98 1.00 0.97 0.92 %&4 -0.62 0.31 -0.93 -0.04 0.44 0.97 0.97 0.97 1.00 0.91 %&5 -0.60 0.29 -0.88 -0.04 0.43 0.93 0.93 0.92 0.91 1.00 
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Table 9-20. Correlation matrix for the global fit model to the macaque serum sample MS331 – F1 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 %&6 "#1 1.00 0.13 0.43 0.21 -0.50 -0.96 -0.94 -0.92 -0.86 -0.76 -0.65 "$1 0.13 1.00 0.42 -0.01 0.62 0.10 0.11 0.12 0.14 0.11 0.03 "#2 0.43 0.42 1.00 0.07 0.19 -0.34 -0.34 -0.33 -0.35 -0.44 -0.53 "$2 0.21 -0.01 0.07 1.00 0.24 -0.09 -0.01 0.02 0.15 0.29 0.35 γ -0.50 0.62 0.19 0.24 1.00 0.69 0.73 0.73 0.76 0.70 0.57 
%&1 -0.96 0.10 -0.34 -0.09 0.69 1.00 0.99 0.97 0.93 0.84 0.72 %&2 -0.94 0.11 -0.34 -0.01 0.73 0.99 1.00 0.98 0.95 0.87 0.76 %&3 -0.92 0.12 -0.33 0.02 0.73 0.97 0.98 1.00 0.94 0.87 0.76 %&4 -0.86 0.14 -0.35 0.15 0.76 0.93 0.95 0.94 1.00 0.90 0.81 %&5 -0.76 0.11 -0.44 0.29 0.70 0.84 0.87 0.87 0.90 1.00 0.85 %&6 -0.65 0.03 -0.53 0.35 0.57 0.72 0.76 0.76 0.81 0.85 1.00 
 
Table 9-21. Correlation matrix for the global fit model to the macaque serum sample MS331 – LcrV 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 %&6 "#1 1.00 0.17 0.51 0.03 0.18 -0.79 -0.82 -0.71 -0.58 -0.50 -0.46 "$1 0.17 1.00 0.47 0.10 0.85 0.35 0.28 0.30 0.27 0.16 0.05 "#2 0.51 0.47 1.00 0.01 0.58 -0.29 -0.31 -0.30 -0.35 -0.46 -0.55 "$2 0.03 0.10 0.01 1.00 0.43 0.27 0.30 0.47 0.59 0.64 0.60 γ 0.18 0.85 0.58 0.43 1.00 0.32 0.30 0.39 0.40 0.29 0.17 
%&1 -0.79 0.35 -0.29 0.27 0.32 1.00 0.92 0.88 0.79 0.69 0.60 %&2 -0.82 0.28 -0.31 0.30 0.30 0.92 1.00 0.90 0.81 0.72 0.63 %&3 -0.71 0.30 -0.30 0.47 0.39 0.88 0.90 1.00 0.87 0.80 0.71 %&4 -0.58 0.27 -0.35 0.59 0.40 0.79 0.81 0.87 1.00 0.84 0.78 %&5 -0.50 0.16 -0.46 0.64 0.29 0.69 0.72 0.80 0.84 1.00 0.82 %&6 -0.46 0.05 -0.55 0.60 0.17 0.60 0.63 0.71 0.78 0.82 1.00 
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Table 9-22. Correlation matrix for the global fit model to the macaque serum sample MS336 – F1 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 %&6 "#1 1.00 0.34 0.62 -0.11 0.23 -0.91 -0.90 -0.83 -0.77 -0.68 -0.58 "$1 0.34 1.00 0.61 0.33 0.92 0.03 0.02 0.03 0.00 -0.05 -0.07 "#2 0.62 0.61 1.00 0.16 0.71 -0.46 -0.46 -0.49 -0.54 -0.56 -0.51 "$2 -0.11 0.33 0.16 1.00 0.39 0.38 0.41 0.50 0.53 0.50 0.42 γ 0.23 0.92 0.71 0.39 1.00 0.09 0.10 0.09 0.04 -0.03 -0.07 
%&1 -0.91 0.03 -0.46 0.38 0.09 1.00 0.97 0.93 0.88 0.77 0.65 %&2 -0.90 0.02 -0.46 0.41 0.10 0.97 1.00 0.94 0.89 0.79 0.67 %&3 -0.83 0.03 -0.49 0.50 0.09 0.93 0.94 1.00 0.91 0.82 0.70 %&4 -0.77 0.00 -0.54 0.53 0.04 0.88 0.89 0.91 1.00 0.84 0.72 %&5 -0.68 -0.05 -0.56 0.50 -0.03 0.77 0.79 0.82 0.84 1.00 0.68 %&6 -0.58 -0.07 -0.51 0.42 -0.07 0.65 0.67 0.70 0.72 0.68 1.00 
 
Table 9-23. Correlation matrix for the global fit model to the macaque serum sample MS336 – LcrV 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 %&6 "#1 1.00 0.50 0.72 0.20 0.36 -0.89 -0.89 -0.84 -0.81 -0.75 -0.64 "$1 0.50 1.00 0.73 0.68 0.94 -0.12 -0.12 -0.10 -0.10 -0.11 -0.11 "#2 0.72 0.73 1.00 0.45 0.78 -0.55 -0.55 -0.56 -0.57 -0.57 -0.50 "$2 0.20 0.68 0.45 1.00 0.70 0.19 0.21 0.26 0.28 0.27 0.23 γ 0.36 0.94 0.78 0.70 1.00 -0.02 -0.02 -0.01 -0.03 -0.05 -0.06 
%&1 -0.89 -0.12 -0.55 0.19 -0.02 1.00 0.98 0.96 0.94 0.87 0.74 %&2 -0.89 -0.12 -0.55 0.21 -0.02 0.98 1.00 0.97 0.94 0.88 0.75 %&3 -0.84 -0.10 -0.56 0.26 -0.01 0.96 0.97 1.00 0.95 0.89 0.76 %&4 -0.81 -0.10 -0.57 0.28 -0.03 0.94 0.94 0.95 1.00 0.89 0.76 %&5 -0.75 -0.11 -0.57 0.27 -0.05 0.87 0.88 0.89 0.89 1.00 0.73 %&6 -0.64 -0.11 -0.50 0.23 -0.06 0.74 0.75 0.76 0.76 0.73 1.00 
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Table 9-24. Correlation matrix for the global fit model to the macaque serum sample MS341 – F1 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 "#1 1.00 -0.01 0.40 -0.12 -0.07 -0.85 -0.88 -0.83 -0.65 -0.56 "$1 -0.01 1.00 0.35 0.48 0.89 0.45 0.40 0.43 0.42 0.33 "#2 0.40 0.35 1.00 0.14 0.47 -0.25 -0.26 -0.26 -0.32 -0.47 "$2 -0.12 0.48 0.14 1.00 0.61 0.44 0.43 0.50 0.56 0.55 γ -0.07 0.89 0.47 0.61 1.00 0.45 0.43 0.48 0.46 0.35 
%&1 -0.85 0.45 -0.25 0.44 0.45 1.00 0.95 0.94 0.79 0.70 %&2 -0.88 0.40 -0.26 0.43 0.43 0.95 1.00 0.94 0.80 0.70 %&3 -0.83 0.43 -0.26 0.50 0.48 0.94 0.94 1.00 0.82 0.74 %&4 -0.65 0.42 -0.32 0.56 0.46 0.79 0.80 0.82 1.00 0.74 %&5 -0.56 0.33 -0.47 0.55 0.35 0.70 0.70 0.74 0.74 1.00 
 
Table 9-25. Correlation matrix for the global fit model to the macaque serum sample MS341 – LcrV 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 "#1 1.00 0.01 0.63 -0.32 0.40 -0.83 -0.87 -0.88 -0.88 -0.86 "$1 0.01 1.00 0.26 0.77 0.60 0.12 0.12 0.12 0.11 0.11 "#2 0.63 0.26 1.00 0.00 0.88 -0.85 -0.83 -0.82 -0.81 -0.79 "$2 -0.32 0.77 0.00 1.00 0.24 0.47 0.47 0.47 0.46 0.45 γ 0.40 0.60 0.88 0.24 1.00 -0.62 -0.59 -0.58 -0.57 -0.55 
%&1 -0.83 0.12 -0.85 0.47 -0.62 1.00 0.99 0.99 0.97 0.95 %&2 -0.87 0.12 -0.83 0.47 -0.59 0.99 1.00 0.99 0.98 0.96 %&3 -0.88 0.12 -0.82 0.47 -0.58 0.99 0.99 1.00 0.98 0.96 %&4 -0.88 0.11 -0.81 0.46 -0.57 0.97 0.98 0.98 1.00 0.95 %&5 -0.86 0.11 -0.79 0.45 -0.55 0.95 0.96 0.96 0.95 1.00 
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Table 9-26. Correlation matrix for the global fit model to the macaque serum sample MacRef – F1 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 %&6 "#1 1.00 0.11 0.46 0.05 0.12 -0.81 -0.81 -0.71 -0.56 -0.45 -0.37 "$1 0.11 1.00 0.39 0.13 0.83 0.38 0.34 0.37 0.33 0.21 0.08 "#2 0.46 0.39 1.00 0.07 0.51 -0.26 -0.26 -0.26 -0.33 -0.46 -0.52 "$2 0.05 0.13 0.07 1.00 0.48 0.24 0.27 0.43 0.54 0.56 0.47 γ 0.12 0.83 0.51 0.48 1.00 0.36 0.36 0.46 0.45 0.33 0.17 
%&1 -0.81 0.38 -0.26 0.24 0.36 1.00 0.92 0.88 0.77 0.63 0.49 %&2 -0.81 0.34 -0.26 0.27 0.36 0.92 1.00 0.89 0.78 0.65 0.51 %&3 -0.71 0.37 -0.26 0.43 0.46 0.88 0.89 1.00 0.84 0.73 0.59 %&4 -0.56 0.33 -0.33 0.54 0.45 0.77 0.78 0.84 1.00 0.77 0.65 %&5 -0.45 0.21 -0.46 0.56 0.33 0.63 0.65 0.73 0.77 1.00 0.69 %&6 -0.37 0.08 -0.52 0.47 0.17 0.49 0.51 0.59 0.65 0.69 1.00 
 
Table 9-27. Correlation matrix for the global fit model to the macaque serum sample MacRef – LcrV 
formed complex 
 "#1 "$1 "#2 "$2 γ %&1 %&2 %&3 %&4 %&5 "#1 1.00 0.43 0.63 0.14 0.54 -0.79 -0.86 -0.85 -0.70 -0.76 "$1 0.43 1.00 0.76 0.76 0.95 0.03 -0.04 -0.04 -0.04 -0.06 "#2 0.63 0.76 1.00 0.59 0.89 -0.43 -0.46 -0.47 -0.42 -0.49 "$2 0.14 0.76 0.59 1.00 0.72 0.33 0.26 0.27 0.24 0.26 γ 0.54 0.95 0.89 0.72 1.00 -0.19 -0.24 -0.23 -0.21 -0.25 
%&1 -0.79 0.03 -0.43 0.33 -0.19 1.00 0.94 0.93 0.79 0.88 %&2 -0.86 -0.04 -0.46 0.26 -0.24 0.94 1.00 0.95 0.80 0.88 %&3 -0.85 -0.04 -0.47 0.27 -0.23 0.93 0.95 1.00 0.80 0.88 %&4 -0.70 -0.04 -0.42 0.24 -0.21 0.79 0.80 0.80 1.00 0.76 %&5 -0.76 -0.06 -0.49 0.26 -0.25 0.88 0.88 0.88 0.76 1.00 
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a b s t r a c t
The effect of human serum albumin (HSA) on an immunokinetic assay for an antibody to bovine serum
albumin has been determined in model serum solutions with HSA concentrations in the range 0 to
450 lM (0–30 mg mlÿ1). The assay is performed on two plasmon-based detection platforms: a continu-
ous gold surface and a nanoparticle-based array reader. The assay has a minimum detection concentra-
tion of 760 ± 160 pM (120 ± 25 ng mlÿ1) in phosphate-buffered saline, falling to 2.5 ± 0.7 nM
(380 ± 100 ng mlÿ1) in physiological HSA concentration. The concentration of HSA correlates with the
refractive index of the solution, and this may be used to calibrate assay response. The addition of the
charged chaotrope SCNÿ in 150 mM concentration improves the reproducibility and consistency of the
assay, with a minimum detection concentration of 2.9 ± 0.5 nM (440 ± 80 ng mlÿ1). The effect of high con-
centrations of HSA on the immunokinetic assay can be corrected with a measurement of bulk refractive
index in a reference channel.
Ó 2010 Elsevier Inc. All rights reserved.
Measurement of multiple biomarker concentrations in blood
serum or whole blood has an obvious benefit over single-bio-
marker studies, such as for prostate or ovarian cancer [1,2], result-
ing in consequent advantages for disease diagnosis. Biomarker
detection in serum requires low concentrations of a target protein
to be measured against the ‘‘background” of large concentrations of
other blood proteins [3]. In addition, the concentrations of these
background proteins change from patient to patient, with the level
of the most abundant protein in blood, human serum albumin
(HSA),1 varying in concentration over the range of 35 to 50 mg mlÿ1
[4], including healthy and diseased patients. Serum albumin levels
are also being investigated as a predictor of disease progression
and mortality in conjunction with other serum proteins [5–7]. How-
ever, detection of specific biomarkers must still be made against all
of the changes in the whole proteome during onset of disease, and in
many cases this proves to be rather challenging; for example, more
than 10 orders of magnitude separate HSA concentrations from
those of cytokine biomarkers [3].
Biomarker concentrations in complex fluids have been moni-
tored, label free, using a number of surface plasmon resonance
(SPR) platforms, but these are usually limited to one or two mark-
ers in each experiment [8–11]. Several SPR-based imaging technol-
ogies have been used to detect multiple biological analytes with
array format sensors [12,13], including nanoparticle scattering
immunoassay [14–16]. The latter relies on the change in the local-
ized plasmon properties of biofunctionalized nanoparticles on
antibody–antigen binding events. The real-time kinetic response
is related to the concentration of the biomarker in sample solu-
tions, producing an immunokinetic assay.
The nanoparticle localized plasmon field is only sensitive to a
change in refractive index (RI) of analyte solution in a small region
above the sensor surface. The penetration depth of the particle
plasmon field is typically of its radius, which may be compared
with the penetration depth of the propagating plasmon on a con-
tinuous gold surface of 200 to 300 nm [16,17]. The smaller sensing
depth results in better overlap, with an active biolayer that par-
tially compensates for the lower bulk RI sensitivity of the nanopar-
ticles as compared with continuous surface plasmon. This RI
contrast confers an advantage on particle-based immunokinetic
assays for the detection of antibodies in complex media such as
delipidized blood serum [16].
We have been exploiting the nanoparticle plasmon field advan-
tages for complex fluid analysis by developing a nanoparticle Array
Reader platform [14–16] where seed nanoparticles are printed in
an array format from solution using an inkjet printer. Nanoparti-
cles are grown from the seed particles to larger 130-nm truncated
polyhedra to provide bright scatter centers. The array spots are
illuminated in a total internal reflection configuration, and the
scattered light is monitored in real time. The temporal variation
of the immunofunctionalized spots leads to an immunokinetic
0003-2697/$ - see front matter Ó 2010 Elsevier Inc. All rights reserved.
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assay where the kinetic response of the assay is used to determine
the concentration of the target species. The multiplexed platform
allows the concentrations of many analytes to be determined
simultaneously, and although we have demonstrated the arrays
for 6000 spots, we have concentrated on understanding the assay
characteristics. A blind concentration trail has been performed
with four analytes for which the concentrations were determined
with an accuracy of 15%. The technological objective for the plat-
form is a point-of-care device for which no sample preparation is
important. Several proprietary buffers are used commercially
within the blood sample collection containers, including chao-
tropes, and we are investigating their effect on the immunokinetic
assay. However, the primary cause of variation in blood samples is
the effect of patient serum concentrations.
Variation in serum composition from patient to patient in a
clinical setting causes additional problems with the immunokinet-
ic assay. The bulk RI change causes initial sensor baseline offset,
followed by response to the nonspecific binding of HSA and other
proteins present in the sample in high concentration. Specific bind-
ing of the target protein to the assay is favored kinetically by a ra-
pid on-rate (ka) and, more important, a slow off-rate (kd). The
nonspecific binding association rate constant is typically
104 Mÿ1 sÿ1, which may be compared with the antibody associa-
tion rate constant of 106 Mÿ1 sÿ1; similarly, for the corresponding
dissociation rate constants, 10ÿ2 sÿ1 may be compared with
10ÿ4 sÿ1 [16]. For proteins with similar nonspecific association
rates, the additional displacement of lighter proteins by heavier
proteins, the Vroman effect, has been reported [18–21]. Both the
kinetic association and displacement factors affect the ultimate
sensitivity and accuracy of the immunokinetic assay.
Many techniques have been used for separation of the plasma
proteins for their characterization, including chromatography
[22–24] to membrane separation techniques that have potential
to be deployed on biosensor platforms [25]. There has been consid-
erable work on the use of ionic and nonionic surfactants in the sep-
aration of proteins with two possible complications: the proteins
may become denatured and surfactant micelles may form, so anal-
ysis above and below the critical micelle concentration and Krafft
temperature needs to be considered [26]. Chaotrope molecules
are often used in conjunction with surfactants to facilitate the sep-
aration of proteins on two-dimensional gels [27]. Similar chaotrope
protein separation techniques have been applied with success to
enzyme-linked immunosorbent assays (ELISAs) in solution [28]
specifically addressing the question of nonspecific binding compe-
tition with specific binding in the assay. The chaotrope molecule is
a small molecule such as the anion SCNÿ, which is thought to sur-
round the proteins with a highly charged layer changing the nature
of the surfaces involved in protein–protein interactions [29,30],
and this is expected to be beneficial for immunokinetic assays.
In this study, we addressed the problem of clinical variation of
HSA in patient serum samples by performing immunokinetic assay
for antibodies in model HSA-containing artificial sera solutions,
starting with the standard phosphate-buffered saline (PBS) and
systematically increasing the concentration of HSA in PBS. In addi-
tion, we further examined the effect of the chaotrope KSCN on the
antibody–antigen interactions and the immunokinetic assay.
Materials and methods
The label-free binding studies were performed on two plat-
forms: the commercially available continuous surface SensiQ Dis-
covery SPR instrument from ICX Nomadics and the biophotonic
particle plasmon Array Reader instrument developed in-house.
The Array Reader design has been discussed in detail elsewhere
[15,16], although the current configuration of the instrument uses
an LED light source (Thorlabs, 660 nm, 100 mW), replacing the la-
ser used previously. A schematic of the Array Reader, including the
injection system, is shown in Fig. 1A. The sensor arrays are manu-
factured by chemical growth of small (3 nm) gold nanoparticles.
These are spotted on glass substrates in a rectangular array format
and grown into larger particles of truncated polyhedra in shapes of
approximately 130 nm in size [16]. The developed array is then
functionalized with the target proteins according to the array key
(Fig. 1B). For kinetic assays, the sensor is equipped with a flow cell,
and the intensity changes of the light (scattered by the array of
nanoparticle-coated spots illuminated in the dark field configura-
tion) are monitored as a function of time to produce kinetic trace
for each individual spot of the sensor array.
After a stable baseline is obtained for 5 to 10 min, an antibody-
containing analyte is injected over the protein-functionalized sur-
face for 15 min at a flow rate of 25 ll minÿ1 (SensiQ) or
100 ll minÿ1 (Array Reader) to ensure concentration-limited
kinetics [15].
The absolute response from the Array Reader was calibrated for
each set of 24 spots functionalized with the same protein (Fig. 1B)
by measuring the response to the buffer change from PBS to double
concentrated PBS, corresponding to a change in bulk RI of
1.5  10ÿ3 refractive index units (RIU). (All data presented in the
subsequent figures are presented as the change in RI [DRI].) Similar
calibrations were performed for both channels of the SensiQ SPR
instrument where the sensitivity is typically 2  10ÿ6 RIU.
A
B
Fig. 1. (A) Schematic of the Array Reader instrument. (B) Array protein functional-
ization key.
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Chemicals
N-(3-Dimethylaminopropyl)-N0-ethylcarbodiimide hydrochlo-
ride (EDC), N-hydroxysuccinimide (NHS), 16-mercaptohexadeca-
noic acid (MHDA), potassium thiocyanate (99%), bovine serum
albumin (BSA, 98%), human fibrinogen (60% with 40% buffer salts;
the protein content is >80% clottable fibrinogen), HSA (>96%), and
transferrin (98%) were obtained from Sigma–Aldrich. Sheep poly-
clonal antibodies to BSA (aBSA, 23 mg/ml, immunoglobulin G
[IgG] fraction) were supplied by AbD Serotec UK. All solutions
where prepared in 18 MX deionized water, and protein solutions
were prepared in standard PBS (137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, and 1.5 mM KH2PO4, pH 7.3) unless otherwise
stated.
Sensor surface preparation
SensiQ SPR surface
Proteins were immobilized on the two sensor channels of the
SensiQ chip by peptide coupling between sensor surface carboxyl
groups and free amine groups of the proteins. The two-channel
gold surface of the SensiQ sensor chip surface for the SensiQ instru-
ment has a 50-nm-thick continuous gold surface that was first
cleaned with 10 mM HCl solution followed by incubation in
10 mM 16-MHDA in ethanol for 15 h, forming a carboxyl-function-
alized self-assembled monolayer (SAM) on the sensor surface. The
SAM carboxyl groups were activated with 0.05/0.25 M NHS/EDC
aqueous solution, forming amine-reactive succinimide ester
groups. Immediately after the activation step, 1-mg mlÿ1 solutions
of BSA and transferrin in 10 mM sodium acetate buffer (pH 4.9)
were injected into channels 1 and 2, respectively, at a flow rate
of 5 ll minÿ1 for 45 min. Following the protein immobilization
step, both surfaces were capped with 1 M ethanolamine, and after
a 10-mM HCl wash, the running buffer was then changed to PBS.
Array Reader particle plasmon surface
The array format sensors were functionalized with proteins by
spotting 1 mg mlÿ1 HSA, BSA, fibrinogen, and transferrin solutions
in PBS directly over the nanoparticle-containing array spots
according to the key in Fig. 1B. After 2 h of incubation, the slides
were washed with PBS and stored dry at 4 °C.
Results
Several series of experiments were performed to establish the
interference effects of the HSA concentration on the immunokinet-
ic assay accuracy for aBSA concentration measurements in model
sera. The effect of added chaotrope was also investigated in an at-
tempt to recover the accuracy of the assay. The experimental series
is summarized in Table 1.
The aBSA–BSA binding kinetics were measured in pure PBS buf-
fer acting as the control series. Further analyte solutions of 30 nM
aBSA (SensiQ) and 50 nM aBSA (Array Reader) with varying con-
centrations of HSA were prepared in PBS and injected over the
sensing surfaces of the SensiQ and Array Reader platforms. Each
injection lasted 15 min and was followed by a 5-min 10-mM HCl
regeneration step. Repeat injections were performed for each ser-
ies to establish reproducibility. The order of injection of the analyte
solutions of different HSA concentrations was randomized so as
not to perform the experiment from low to high concentrations.
The aBSA immunokinetic assay was repeated with a fixed physio-
logical concentration of HSA (450 lM). These experiments were
performed in three series (A–C):
A: aBSA–BSA assay in PBS; this is the reference series with vary-
ing aBSA concentrations (10–50 nM) (Figs. 2 and 3B).
B: aBSA–BSA assay with varying concentrations of HSA (0–
450 lM) (Figs. 2 and 4). and a fixed aBSA concentration of
30 nM (SensiQ) or 50 nM (Array Reader)
C: aBSA assay performed with a fixed HSA concentration
(450 lM) and varying concentrations of aBSA (10–50 nM)
(Figs. 3 and 5).
The effect of nonspecific binding was investigated by repeating
experimental series A to C with a fixed concentration of the chao-
trope, KSCN, at 150 mM [28] (series D–F):
D: aBSA–BSA assay in PBS with 150 mM chaotrope, analogous
to series A (Figs. 3 and 7).
E: aBSA–BSA assay with varying concentrations of HSA (0–
450 lM) and 150 mM KSCN, analogous to series B (Fig. 4).
F: aBSA assay performed with a fixed HSA concentration
(450 lM) and varying concentrations of aBSA (10–50 nM) and
150 mM KSCN, analogous to series C (Figs. 3 and 6).
The series A to F was performed on the Array Reader platform, with
B and E repeated on the SensiQ. Table 1 summarizes the conditions
of each experiment and the figures presenting the corresponding
data.
Discussion
The principal objective of this investigation was to perform an
immunokinetic assay for aBSA in the presence of varying concen-
trations of HSA to reflect the total serum protein content and its
variations in the clinical samples. The maximum used HSA concen-
tration of 450 lM roughly corresponds to the lower limit of clinical
albumin concentration range expected clinically (30–50 g Lÿ1) [4].
Potential applications of the Array Reader technology to the
measurement of blood protein concentrations require monitoring
of the background blood composition to understand the effects
that have been observed on the kinetic trace seen in Fig. 2. Ideally,
the concentration of HSA should be assayed simultaneously
with the target protein assays to ensure an accurate determination
of the target protein in the blood serum (aBSA in the current case).
In the arrays used in these experiments, we used a 24-spot aver-
aged fibrinogen control (Fig. 1B) to act as a nonspecific binding
channel that also responds to variations in light source intensity
and wavelength, both of which are noise sources that cause varia-
tion in the scattered light, the source of the signal for the kinetic
assay. Moreover, the normalization of the averaged signal from tar-
get spots against this fibrinogen control removes the effect of the
large bulk RI change. DRI, due to varying HSA concentrations in
Table 1
Summary of experiment series performed on the Array Reader and SensiQ platforms.
Series [aBSA] [HSA] [KSCN] Array
Reader
SensiQ Figure(s)
A Varied
10–50 nM
– ÿ + ÿ 2, 3
B Fixed 30
or 50 nM
Varied
100ÿ450 lM
ÿ + + 2, 4
C Varied
10–50 nM
Fixed
450 lM
ÿ + ÿ 3, 5
D Varied
10–50 nM
ÿ Fixed
150 mM
+ ÿ 3, 7
E Fixed 30
or 50 nM
Varied 100–
450 lM
Fixed
150 mM
+ + 4
F Varied
10–50 nM
Fixed
450 lM
Fixed
150 mM
+ ÿ 3
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PBS, is determined using the fibrinogen control and the absolute RI
shift calculated for each of the model serum solutions (plotted in
Fig. 8). Although the data appear to present a complex nonlinear
variation with concentration, a simple linear relation (r2 = 0.94)
satisfactorily describes a first measure (within experimental error)
of the bulk composition of the patient’s serum.
The response of the sensor surface to the coadsorption of the
HSA and aBSA during the immunokinetic assay has a clear effect
on the kinetics reflecting the complex set of competitive associa-
tion and surface displacement reactions, including the Vroman ef-
fect [20]. A detailed analysis of the competing process is beyond
the scope of this article; here we present an empirical analysis that
might form the basis for a simple interrogation algorithm for a
point-of-care instrument based on the Array Reader. The antibody
immunokinetic response is based on the Langmuir adsorption
equation [16]:
h ¼
#
#m
¼
ka½P
ka½P þ kd
ð1ÿ expðÿðka½P þ kdÞtÞÞ; ð1Þ
where h is the surface coverage (a fraction of the occupied binding
sites), [P] is the concentration of antibody in solution, and ka and kd
are the adsorption and desorption rate constants, respectively. Be-
cause the current data show that kd << ka[P] on the experimental
scale, the equation may be simplified to
#  #mð1ÿ expðÿka½PtÞÞ; ð2Þ
where # refers to the experimental observable, namely change in
scattering brightness, and #m corresponds to the maximum bright-
ness change when complete coverage of the available active sites on
the surface is achieved. Each recorded transient curve was fitted to
this single exponential expression.
The simple model contains the same assumptions as the Lang-
muir adsorption isotherm, notably the antibody interacting with
its antigen on the surface but neglecting the interactions between
antibodies at the surface or the interference from any other pro-
teins fouling the surface or the reduction in the rate of association
as a result of diffusion through a viscous medium. Taking these
into account, the derived ka and #m will not be perceived as true ki-
netic constants for aBSA–BSA interaction but rather will be per-
ceived as effective/empirical factors describing the complex
system of reactions in a most simple practical form. Moreover, a
significant degree of correlation between ka and #m may be re-
moved by forming a single #mka parameter [16] that is used to dis-
cuss the effects of nonspecific protein binding and the presence of
the chaotrope on specific response due to aBSA–BSA interaction.
Fig. 2. aBSA–BSA assay with varying concentrations of HSA: (a) 0 lM; (b) 100 lM;
(c) 200 lM; (d) 300 lM; (e) 450 lM.
Fig. 3. Variation of #mka versus antibody concentration for the immunokinetic
aBSA–BSA assays with different analyte buffer compositions: (a) KSCN- and HSA-
free PBS buffer (r2 = 0.93); (b) PBS and 150 mM KSCN (r2 = 0.95); (c) PBS and
450 lM HSA (r2 = 0.99); (d) PBS, 450 lM HSA, and 150 mM KSCN (r2 = 0.72).
Fig. 4. Dependence of #mka on concentrations of HSA in the analyte: (a) SensiQ,
30 nM aBSA; (b) SensiQ, 150 mM KSCN and 30 nM aBSA; (c) Array Reader, 50 nM
aBSA; (d) Array Reader, 150 mM KSCN and 50 nM aBSA.
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Using the #mka analysis, calibration curves for the concentration
may be derived for the SensiQ and Array Reader platforms (Fig. 4).
The curves show a significant difference between the particle and
continuous gold surfaces and the effect of the chaotrope on both
platforms. The limiting #mka value for the continuous surface is
40% smaller than that for the nanoparticle surface and with a smal-
ler dynamic range for the assay. The effect of the chaotrope is more
pronounced; on the SensiQ platform. the value of #mka is reduced
by one-third with the addition of the 150 mM chaotrope, further
reducing the dynamic range of the assay to 25% of the initial value
and, hence, reducing the sensitivity. However, with the nanoparti-
cle surface, the dynamic range of the assay is only reduced to 60%
of its original value. The variation in the performance of the Array
Reader platform depends in part on the variations during the print-
ing process that dominate the error in the signal.
The data from the reference channel presented in Fig. 8 can be
used to correct for the effect of high HSA concentration on the ob-
served aBSA–BSA association rates shown in Fig. 4. An empirical ra-
tional function efficiently describes the observed experimental
dependence of the #mka parameter on bulk RI change associated
with HSA concentration in the sample. The empirical functional
form is defined as
½P ¼
a #m
1stka
ÿ 
1ÿ bDbulk
þ c
½aBSA=M ¼
0:0135 #m
1stka
ÿ 
1ÿ 115DRIsample
ÿ 2:9 10ÿ9
ð3Þ
where a = 0.0135, b = 115, and c = ÿ2.9  10ÿ9 M are fitted parame-
ters and c is a small offset parameter within the accuracy of the
measurements (Fig. 9). Consequently, with this correction, the aBSA
concentration may be derived with an accuracy of 10 to 15% for all
samples containing HSA in the concentration range of 0 to 450 lM.
The a, b, and c parameters may be derived for a batch of slides pro-
duced and then used to calibrate each array slide, assuming consis-
tent printing integrity.
There is a cleardifference in theperformancesof the twoplasmon
platforms that may be explained in part by the differences in the
plasmon field penetration of the continuous and nanoparticle gold
surfaces. The plasmon field typically penetrates 300 nm from the
gold surface, of which only approximately 10 nm is occupied by
the antibody assay. The majority of the field plasmon field is sensi-
tive to large changes in the bulk RI, which is significant in the
presence of the large HSA concentration and the chaotrope. In the
two-channel SensiQ platform, the specific binding contributions to
Fig. 5. aBSA–BSA assay with [HSA] = 450 lM and varying [aBSA]: (a) 20 nM; (b)
30 nM; (c) 40 nM; (d) 50 nM.
Fig. 6. Effect of chaotrope on antibody binding from samples containing 50 nM
aBSA and 450 lM HSA: (a) without chaotrope; (b) with 150 mM KSCN.
Fig. 7. Immunokinetic aBSA–BSA assay in the presence of 150 mM KSCN antibody
concentrations: (a) 10 nM; (b) 20 nM; (c) 30 nM; (d) 40 nM; (e) 50 nM.
Fig. 8. Variation of bulk DRI determined from the fibrinogen control spot responses
to analyte samples containing 0 to 450 lM HSA (r2 = 0.98).
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the signal are derived from a subtraction of the large RI changes
associated with HSA and the chaotrope. The subtraction produces
the change associated with the binding, both specific and nonspe-
cific to the surface, an effect occurring in only 10% of the continuous
surface plasmonfield. This is based on the assumption that the assay
layer is approximately 20 nm thick, including all of the ligand
molecules and proteins, representing 10% of the surface plasmon
field penetration depth of 200 to 300 nm. However, the particle
platform performs the same subtraction over a number of control
spots on the array to observe the change assay in the volume that
occupies 50% of the plasmon field, where similar assumptions have
been made about the thickness of the assay layer and a particle
plasmon field penetration depth of 50 to 60 nm.
Calibration curves may be constructed for the Array Reader
platforms, from which variation of #mka against aBSA concentra-
tion may be seen in Fig. 3. There is a significant difference in
sensitivity of the assay in PBS, 84 ± 3 RIU sÿ1 Mÿ1, compared with
the 23 ± 2 RIU sÿ1 Mÿ1 for the physiological HSA concentration.
The detection limit for aBSA in PBS is 760 ± 160 pM (120 ± 25 ng
mlÿ1), whereas in physiological HSA it is 2.5 ± 0.7 nM (380 ± 100
ng mlÿ1). The challenge for the measurement of antibodies in real
serum samples with varying HSA concentrations is to provide a ro-
bust estimate of the effect of the HSA to enable the concentration
to be observed.
The effect of the chaotrope is also clear from the original trace in
Fig. 6 and the calibration curve in Fig. 3 with a sensitivity of
66 ± 3 RIU sÿ1 nMÿ1 in 150 mM KSCN and PBS. The kinetic trace
in Fig. 6 is slower in rate when the chaotrope is present and does
not reach the same #m during the course of the experiment; how-
ever, the quality of the exponential curve is better, resulting in a
better fit to the data. There is also a large increase in the RI of
the sample with the added chaotrope, and this causes a number
of subtraction artifacts in the traces, notably in the SPR surface
but not as much in the particle plasmon surfaces. The chaotrope
does, however, improve the accuracy of the aBSA assay in the pres-
ence of 450 lM HSA. The detection limits for both assays are
2.5 ± 0.7 nM (380 ± 100 ng mlÿ1) in PBS and 2.9 ± 0.5 nM
(440 ± 80 ng mlÿ1) in the chaotrope-augmented PBS.
The KSCN behaves like a chaotrope by surrounding the proteins
in the solution with a small-molecule charged layer to each of the
proteins in the solution, causing a change in the protein–protein
interactions but not so as to denature them. There are both ionic
and nonionic chaotropes, such as KSCN and urea, respectively, as
well as kosmotropes, such as CO2ÿ3 , that affect the interactions
between proteins and their solubility in solution [31]. The current
mechanism of action [31] suggests polarization of the salvation
shell around large molecules such as proteins as well as hydropho-
bic, surface tension, and direct binding mechanisms.
Conclusion
We have demonstrated the albumin interference effect on the
immunokinetic assay for aBSA in analytes with varying concentra-
tions of HSA. The total RI can be used as a simple measure of the
HSA concentration, thereby allowing an empirical correction to
immunokinetic assay for aBSA under varying HSA conditions.
While testing complex analytes with large HSA content, there is
a clear particle plasmon detection advantage on the Array Reader
platform compared with the continuous gold surface, and the addi-
tion of the KSCN chaotrope somewhat improves the integrity and
accuracy of the assay, although there is a slight reduction in the
detection limit. Because albumin interference with assays in blood
serum is well known and there are proprietary reagents that have
been added to serum solutions to improve the integrity of a num-
ber of assays [32,33], a novel set of reagents with some of the
advantageous characteristics of KSCN will need to be developed
specifically for the immunokinetic assays based on continuous sur-
face and particle-based SPR techniques.
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Measurement of the localised plasmon penetration
depth for gold nanoparticles using a non-invasive
bio-stacking method†
Thomas Read, Rouslan V. Olkhov and Andrew M. Shaw*
We have used the formation of a bio-probe stack with up to 24 steps on gold nanoparticle and
continuous gold surfaces to characterize the penetration depth of the plasmon field in a non-invasive
manner by only involving biomolecules from standard bio-assays. An alternating anti-goat rabbit IgG
and anti-rabbit IgG bio-probe stack is polymerized on protein A/G functionalized gold surfaces. The
change in plasmon excitation angle or light scattering decreases exponentially with each stacking step
although the bio-integrity of the antibody epitope is maintained. The exponential decay in the derived
kinetic parameters is attributed to the change in the penetration depth and the step size is calibrated
using a commercial continuous gold surface plasmon resonance surface to be 17.5  0.8 nm, consistent
with the expected dimension of the antibody. The penetration depth of the gold spherical nanoparticles
of diameter 90  13 nm is determined to be 93  10 nm.
Introduction
Biomolecules binding to a gold plasmon resonance sensor
surface formally change the refractive index (RI) of the medium
above the surface explored by the plasmon field. A biosensing
event is measured as a change in a parameter such as the
resonance angle of a propagating plasmon excitation on a
continuous gold layer for surface plasmon resonance (SPR)
instruments, or the optical extinction for localized surface
plasmon resonance (LSPR) based instruments.1,2 The inter-
action with the plasmon field, through the polarizability of
the adsorbing species, correlates directly with the mass and
composition. However, the plasmon field penetrates signifi-
cantly into the medium above a continuous gold surface,
decaying exponentially with a penetration depth, ld (Fig. 1).
The radiation intensity is the square of the electric field
strength and therefore it decays with height z above the metal
surface as exp(ÿ2z/ld). The average probed refractive index hZi
can be calculated with the depth integral as:
hZi ¼ 2=ldð Þ
Z1
0
ZðzÞ exp ÿ2z=ldð Þdz (1)
where Z(z) is the RI at height z.3 The integration of eqn (1),
assuming Z(z) = Zanalyte within a layer of analyte and Z(z) = Zbulk
above it, gives the plasmonic sensor response,3 R:
R ¼ mDZ 1ÿ exp ÿ2d=ldð Þð Þ (2)
where m is sensor sensitivity (DI/DRIU) to changes in the bulk
refractive index, DZ is the difference of bulk and analyte
refractive indexes, Zanalyte ÿ Zbulk, and d is the thickness of
the adsorbed layer. When the analyte layer is composed of a
Fig. 1 The fundamentals of SPR vs. LSPR. The decay of the plasmon field is
greater on the LSPR (array reader) platform leading to a faster decrease in the
observed sensor response.
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number of individual sub-layers d = n  di, where n is the
number of adsorbed sub-layers of characteristic thickness di.
From eqn (2) it follows that bio-assays of complex media on
continuous surfaces, where ld c d, are vulnerable to bio-noise
within the plasmon field above the 10 nm associated with the
surface-bound assay. By contrast, gold nanoparticles have a
smaller ld, comparable with d, so the sensing volume overlaps
the bio-assay more precisely. Consequently, LSPR methods
have a significant advantage in the analysis of complex fluids
such as whole blood.4 The ld parameter is dependent on the
nanoparticle composition, shape and size,5 although the
spatial plasmon field can be theoretically calculated, the pene-
tration depth is routinely discussed as a fitted or measured
parameter characterizing the average decay of the electric field
in LSPR measurements.4,6,7 The fundamental importance of ld
for LSPR studies has prompted many attempts to measure
it experimentally by depositing various material layers
(aluminium oxide, alkanethiols, polyelectrolytes) onto the
nanoparticles while monitoring the sensor response.7–9 There
are many uncertainties in these methods including the effect of
the choice of coating material perturbing and independent
measures of the layer thickness. The penetration depth
depends on the polarizability of the material in the plasmon
field and optimization for biosensor suggests ld should be
measured with a biomaterial. Further, methods producing a
permanent coating on the surface do not allow the surface to be
regenerated for subsequent or repeated measurements.
Here, we present a method to determine the penetration
depth of the plasmon field directly from a biological immuno-
assay. Two mutually specific antibodies are involved in stepwise
polymerization process to produce a multilayer surface with
controlled, repeating step size and thickness: a sequence of
goat-anti-rabbit-IgG and rabbit-anti-goat-IgG allows alternating
layers of the antibodies to form a bio-stack on top of a protein
A/G functionalized surface. The biological integrity and step
size is assured as the 3D-epitopes for each of the antibodies are
preserved giving rise to specific binding. The numbers of
antibodies attaching in each layer of the bio-stack remains
constant, controlled by the packing fractions (epitope density)
and the vertical spacing determined by the dimensions of the
antibody. The decrease in the observed sensor response is
therefore attributed to the variation of plasmon field with
distance from the surface characterized by the penetration
depth, ld (Fig. 1). Importantly, only biomolecules normally
involved in standard bio-assays are utilized in the measure-
ments, no special coating techniques or materials are required
ensuring ld is a good measure of the penetration depth for the
bio-assay.
Experimental section
A series of immuno-kinetic binding studies were performed
to measure the penetration depth of the plasmon field on
two platforms: the commercially available dual-channel conti-
nuous gold surface SensiQ Discovery SPR instrument (SensiQ)
from ICX Nomadics and the gold nanoparticle based light
scattering array reader instrument (AR) developed in-house.
The AR design can be seen in Fig. 2, it has been discussed
previously in detail elsewhere10,11 and will be described only
briefly below.
The gold nanoparticle surface was functionalised with
dithiobis-(succinimidyl propionate) (DSP) to allow subsequent
peptide coupling of proteins. The SensiQ chip surface was
activated with N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide
hydrochloride (EDC), N-hydroxysuccinimide (NHS) for similar
protein functionalisation, all purchased from Sigma-Aldrich.
Bovine serum albumin (BSA, 98%), and human fibrinogen
(60% with 40% buffer salts; the protein content is >80%
clottable fibrinogen) were obtained from Sigma-Aldrich; recom-
binant protein A/G was supplied from Pierce. Rabbit polyclonal
antibody to goat IgG-H&L-HRP (rabbit-anti-goat-IgG), and goat
polyclonal antibody to rabbit IgG-H&L-HRP (goat-anti-rabbit-
IgG) were supplied by Abcam and used without modification.
All solutions where prepared in 18 MO cm deionised water,
and protein solutions were prepared in standard phosphate
buffered saline (PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, and 1.5 mM KH2PO4, pH 7.3) unless otherwise
stated.
The experiments on both platforms followed a standard
procedure and injection sequence: PBS buffer is passed over
the sensor surface until a stable baseline is obtained; the first
injected antibody is captured by protein A/G resulting in
a primary response; the subsequent n number of analyte
injections alternating between rabbit-anti-goat-IgG and goat-
anti-rabbit-IgG result in the growth of a [IgG]n polymer chain
stacking away from the surface (n = 9 for the AR and n = 25
for the SensiQ). The analytes were injected over the sensor
surfaces for 10 min at a flow rate of 25 mL minÿ1 with a
concentration of 100 nM (SensiQ), or 20 min at 100 mL minÿ1
with a concentration of 50 nM (AR), to ensure concentration-
limited kinetics.10 The intermittent PBS wash steps allowed
only specific, high-affinity binding of the antibodies to their
respective epitopes maintaining the 3D-integrity of the bio-
stack. After the binding experiment was complete the surface
Fig. 2 Schematic illustration of the array reader design, with the SEM image of
the gold nanoparticles on the glass substrate.
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was regenerated with a 4 min long injection of 10 mM hydro-
chloric acid (HCl).
The sensor responses for each of the array elements (AR) or
channels (SensiQ) were calibrated with a bulk refractive index
switch between PBS and double-concentrated PBS solutions
which corresponds to a DRI of 1.53 10ÿ3 refractive index units
(RIU), independently measured by a refractometer. The choice
of PBS as the system buffer allowed binding of the antibody
to immobilized antigen at near saturated coverage, reached in
20 min (AR) and 10 min (SensiQ), with negligible dissociation
on the time scale of the experiment.
Array reader particle plasmon surface
The arrays are printed on glass substrates with small seed
nanoparticles into the 96-spot format using an Arrayjet inkjet
printer. The seed particles are then chemically grown to pro-
duce a population of nanoparticle shapes and sizes on each
array spot: three distinct shapes including spherical nano-
particles (85%), rod shaped nanoparticles (10%) and flatter
disc shaped nanoparticles (5%). An example of one of the SEM
images of the sensor surface used from which the nanoparticle
mean size and standard deviation were derived (mean  SD)
can be seen in Fig. 2. The spherical particles diameter was
90  13 nm, with the disc particles having a diameter of
147  17 nm. The rod-shaped particles are characterized by
the length  width of 250  60 nm  65  15 nm. The
nanoparticle density was calculated at 1 np per 220  60 nm2.
The grown gold particle arrays are then coated with DSP and
returned to the inkjet printer for functionalisation by printing
protein A/G (48 assay spots), BSA (8 control spots) and fibrinogen
(40 control spots) solutions at a concentration of 2 mg mLÿ1.
After 2 hours of incubation, the slides were washed with PBS and
stored dry at 4 1C. In the AR the arrays are illuminated in a total-
internal-reflection configuration and scattered light normal to
the surface is interrogated using a video camera to derive the IgG
binding response in the immuno-kinetic assay.
SensiQ propagating plasmon surface
The proteins were immobilized on the two sensor channels of
the SensiQ chip by peptide coupling between sensor surface
carboxyl groups and free amine groups of the proteins. The
SensiQ chips used were carboxylated COOH1 biosensors sup-
plied by Labtech. Once installed, the sensor surface was first
cleaned with 10 mM HCl solution for 10 min at 10 mL minÿ1.
The carboxyl groups were activated with 5/25 mM NHS/EDC
aqueous solution, injected for 4 min at a rate of 50 mL minÿ1,
forming amine-reactive succinimide ester groups. Immediately
after the activation step, 2 mg mLÿ1 solutions of recombinant
protein A/G and fibrinogen in 10 mM sodium acetate buffer
(pH 4.9) were injected into channels 1 and 2, respectively, at a
flow rate of 5 mL minÿ1 for 50 min. Following the protein
immobilization step, both surfaces were capped with 1 M
ethanolamine, and after a 10 mM HCl wash, the running buffer
was changed to PBS. The plasmon excitation wavelength of the
chip is 860 nm and the measured range of the reflected angles
is 62–74 degrees.
Results and discussion
The change in the scattered light intensity from the array-spot
nanoparticles is shown in Fig. 3a with specific binding of the
goat-anti-rabbit-IgG to protein A/G via its Fc-region specific
binding sites.12 The first and subsequent stacking steps show
the expected antibody–antigen binding kinetics with an asso-
ciation rate constant of (2.0  0.4)  105 sÿ1 Mÿ1 and dissocia-
tion constant typically (10ÿ4 sÿ1) consistent with high-affinity
antibody–antigen binding, with the preservation of the
3D-epitope integrity.13 The changes in sensor response per
binding step of the same IgG appear to decrease with increased
step number. The same stacking step sequence is shown in
Fig. 3b for the continuous gold surface on the SensiQ platform.
The change in DRI on the SensiQ for the primary binding step
to protein A/G is B2.4 mRIU compared to B0.7 mRIU on the
array reader indicating different surface protein A/G densities.
The surface regeneration step on both instruments removes the
entire antibody population to recover the initial protein A/G
layer. Reproducibility of the AR signal after regeneration has an
error of o4% from the parameter Wm (eqn (3)) and has a
Fig. 3 Response of the immuno-kinetic sensors to the sequence of alternating
analyte injections of rabbit-anti-goat-IgG and goat-anti-rabbit-IgG on a protein
A/G surface: panel (a), AR platform, averaged over 48 spots; panel (b), SensiQ
platform. The stacking sequence involved n number of analyte injection steps:
n = 9 for the AR and n = 25 for the SensiQ. Sensor regeneration steps are
indicated by an asterisk (*). The shaded area in panel A represents the ab
association phase, with the unshaded representing the dissociation phase; the
period when only PBS is flowed over the surface. The insert refer to the first
binding step on the AR platform for the assay and control spots.
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detection limit of B2  0.5 nM (200  50 ng mLÿ1). Fig. S1
(ESI†) highlights this reproducibility with repeated injections of
the same analyte solution after regeneration. The control
channels have not been discussed as protein A/G has a better
defined step size and is therefore more suited for determining
the penetration depth.
Each of the epitope-stable binding steps can then be inter-
preted using the conventional Langmuir adsorption isotherm
(eqn (3)) which does not take account of the lateral interactions
in the protein biofilm layer as it is formed:2
y ¼
W
Wm
¼
ka½P
ka½P þ kd
1ÿ expÿ ka½Pþkdð Þt
 
(3)
where y is the surface coverage, W refers to the experimental
observable, in this case change in scattered brightness, and Wm
corresponds to the maximum brightness change when com-
plete coverage of the available active sites on the surface is
achieved, [P] is the concentration of antibody in analyte
solution, and ka and kd are the adsorption and desorption rate
constants, respectively.
The [IgG]n chain growth in the present case is determined by
polyclonal antibody interactions, where more than one specific
epitope on the analyte combined with two antibody binding
sites, presumably result in highly branched and cross-linked
polymer structure rather than orderly linear chains. Such a
structure is expected to be much more stable than a simple 1 : 1
interaction antibody–antigen complex and therefore character-
ized by a rather small kd. Indeed, the data collected in this
investigation show that kd { ka[P]; with kd B 10
ÿ4 sÿ1, there-
fore no dissociation is evident over the experimental time scale.
For this reason the equation can be simplified to give eqn (4):
W E Wm(1 ÿ exp(ÿka[P]t)) (4)
The initial binding rate is characterized by the combined
parameter Wmka, shown in Fig. 4, it is better defined in the
fitting process than the single parameters Wm or ka. The alter-
nating intensity in each step is consistent with a small difference
in the properties of the rabbit and goat polyclonal antibodies.
The length of the antibody in the stack and the number of
epitopes available on each antibody determines the thickness of
each of the stacking steps and includes the antibody orientation
and water content. The use of polyclonal antibodies allows for
increased epitope presentation on the surface ensuring the bio-
stack is built successfully at each step. If monoclonal antibodies
had been used than theymay not have bound to the forming bio-
stack if the epitope was obscured.
After the primary binding step it is the goat-anti-rabbit-IgG
that displays the bigger value for Wmka (Fig. 4), the main
contributing factor is likely to be a greater epitope density on
the rabbit-anti-goat-IgG. Leading to a greater number of epitopes
available on the surface of the rabbit-anti-goat-IgG that are not
sterically hindered by neighboring immunoglobulin’s allowing a
larger number of goat-anti-rabbit-IgG to attach on top.
There may also be some variation in antibody size between
the rabbit and goat species due to different glycosylation
patterns,14 mechanical flexibility of the antibody structure,
or slight differences in molecular weight,15 although this effect
is considered to be small.
Common to the observations on both the nanoparticle and
continuous gold surface, is the approximate exponential decay
in the sensor response for each successive bio-stack step, Fig. 4.
Fitting the exponential decay of the parameter Wmka, observed
for both the continuous gold surface (SensiQ data) and the
nanoparticles based surface array data gives a characteristic
decay length of 13.6  0.6 steps for continuous and 5.3  0.3
steps for the nanoparticle surfaces, Fig. 5.
The propagating plasmon field penetration depth may be
written:
ld ¼
l0
2p
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
em þ Z
2
Z4


s
(5)
where l0 is the wavelength of the excitation radiation, em is the
real part of the relative permittivity of the metal film and Z is
the RI of the medium.16 The RI for IgG has been estimated at
1.41.17 The penetration depth, ld, for a continuous gold surface
for the protein layer is calculated from eqn (5) (l0 = 860 nm
(SensiQ specifications), em = 10.0,
18 Z = 1.4117), to be 238 nm
indicating a step length of 17.5  0.8 nm. From this stacking
step calibration, the plasmon field penetration of the nanoparticle
Fig. 4 Calculated values of Wmka plotted against stack step number for the
protein A/G surface. Panel (a), AR platform, averaged over 48 spots; panel (b),
SensiQ platform.
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surface is 93  10 nm which is comparable to the particle
diameter measured by electron microscopy. The derived step
length of 17.5 nm is consistent with IgG protein dimensions
derived from neutron scattering data in the solution phase.19
The long-axis dimension of IgG was determined to be in the
range 16–18 nm in solution, depending on the species in which
it was raised. The step length determined here points to the
integrity of the IgG molecule on the sensor surface.
The derived penetration depth 93  10 nm is very close to
the measured diameter of the spherical nanoparticles of
90  13 nm which make up the majority of the gold nano-
particles present,B85% (Fig. 2). The penetration depth may be
compared with the sensing depth reported for some other
LSPR-based sensors. There is no consistency in the literature
values, with 12 nm diameter spherical particles reported as
having a sensing depth of 24 nm, 15 nm diameter particles have
a reported sensing depth of 20–25 nm and 39 nm particles have
a reported sensing depth of 40 nm;6,20,21 all sensing depth
determinations appear to be within 1–2 particle diameters.
A further measure of the plasmon field penetration depth is
the plasmon interaction range which has been estimated to be
the order of the particle diameter for 10, 20, 150 nm diameter
particles.8 The effect of shape is also not clear: flat nanoprisms
with a side width of B100 nm and a height of 50 nm display
saturation of the LSPR response when coated with multi-layer
alkanethiols of 30–50 nm thick.7,22 In some plasmonic systems
an extreme long-range sensing is reported, 70 nm discs and
nanoholes arrays exhibit plasmon sensing at >300 nm.23 The
field extension range can also be indirectly inferred from a
study of interacting nanoparticle pairs, for 50 nm diameter
discs the interaction is insignificant at a distance of 60 nm or
1.2 particle diameters.24 The interaction range may be compared
with our particle surface density of 1 np per 220  60 nm2,
indicating the penetration depth measurement results predomi-
nantly from non-interacting particles.25
Future optimization of an LSPR sensor may include tuning
of the particle plasmon field penetration depth in order to
maximize the contribution from the surface adsorbed analyte
to the instrument response. The bio-stacking measurement of
ld using IgG, a potential bio-assay species, provides a conveni-
ent method of measuring ld, indicating an exponential decay in
the plasmon field, and confirms the antibody integrity at the
gold surface, both important parameters in the sensor optimi-
zation process. Conversely, once the penetration depth has been
calibrated, it can be used as a ruler to measure the solution
dimensions of protein biolayers: a significantly simpler measure-
ment than neutron scattering.
Conclusions
The aim of this experiment was to develop a simple method for
determining the overall ld of an LSPR plasmon field, which could
subsequently be used to optimize the performance of a biosensor.
Current techniques routinely used to measure layer thickness
include atomic force microscopy and layer-by-layer polyelectrolyte
deposition,26,27 and are invasive or produce measurements that
do not reflect the subsequent biosensor penetration depth. By
contrast our technique offers a very simple approach to measur-
ing the overall penetration depth of the nanoparticle surface,
taking into account any particle variation and potential scattering
hot spots. Therefore, whatever the range of particle shapes and/or
sizes that are present, or how disperse the particle size distribu-
tion, an effective penetration depth for the biosensor can be
calculated. Additionally, once characterized the surface may be
regenerated to complete the assay optimization. This process of
using only biomolecules to measure the penetration depth has
not previously been achieved.
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